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Introduction
1.1 Mental Retardation
Definition
Mental retardation is a highly diverse disorder in terms of both cognitive and non-cognitive 
functions. A non-verbal adult in an institution who is fully dependent on support in his/her 
activities and a child with Down syndrome in a regular elementary school are just two extremes 
of the wide clinical manifestation of mental retardation. Mental retardation has many faces and 
worldwide it is defined in various different ways. The most widely used definition is provided 
by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), published by the 
American Psychiatric Association.1 Other well-known definitions have been formulated by the 
American Association on Intellectual and Developmental Disabilities (AAIDD), formerly the 
American Association on Mental Retardation (AAMR),2 and in the World Health Organization’s 
International Classification of Diseases (ICD-10).3
The diagnostic criteria for mental retardation according to the DSM-IV-TR include: (i) significant 
sub-average intellectual functioning, (ii) concurrent deficits or impairments in present adaptive 
functioning, and (iii) the onset before the age 18 years.1 Similarly, in the definition of the AAIDD 
mental retardation or intellectual disability is defined as a disorder characterized by significant 
limitations both in intellectual functioning and in adaptive behavior as expressed in conceptual, 
social and practical adaptive skills, originating before the age of 18 years.2 The ICD-10 defines 
mental retardation as a ’condition of arrested or incomplete development of the mind, which is 
especially characterized by impairment of skills manifested during the developmental period’, 
skills which contribute to the overall level of intelligence, i.e., cognitive, language, motor and 
social abilities.3
With regard to the intellectual criterion for the diagnosis of mental retardation, intelligence 
is generally defined by an Intelligent Quotient (IQ) test score of approximately 70 or below. 
However, both the DSM-IV-TR and the AAIDD take into account a five-point measurement 
error inherent to the more commonly used intelligence tests and, therefore, individuals with 
IQ scores between 70 and 75 can also be diagnosed as having mental retardation if they 
exhibit significant deficits in adaptive functioning.1,2 In children younger than 5 years of age 
standardized IQ testing is not reliable and, therefore, the term global developmental delay is 
usually reserved for these cases, whereas the term mental retardation or intellectual disability 
is applied to older children. Global developmental delay is defined as a significant delay in two 
or more domains, including gross or fine motor development, speech/language, cognition, 
social/personal development and activities of daily living, and it is thought to predict the 
future manifestation of mental retardation.4
Adaptive skills are the conceptual, social, and practical skills that people have learned to function 
in their everyday lives, e.g. communication, self-care, home living, social/ interpersonal skills, 
use of community resources, self-direction, functional academic skills, work, leisure, health and 
safety.2 In both the DSM-IV-TR and the AAIDD definition, adaptive behavior should be limited 
in at least two of these areas.1,2
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The commonly used definitions discussed above are inclusive and tend to capture limitations 
in different aspects, emphasizing the vast impact on everyday functioning for people with 
mental retardation and their families. In addition to the impairments in intellectual and adaptive 
functioning, a large proportion of mentally retarded children is delayed in reaching motor 
or speech developmental milestones, such as rolling over, sitting up, standing and walking, 
and suffer from a wide range of associated disabilities such as epilepsy, motor impairment, 
sensory (vision and/or hearing) impairment and behavioral and/or psychiatric disorders, such 
as aggression, self-injury and mood disorders.5 
Additionally, mental retardation is also frequently associated with congenital malformations 
and dysmorphisms (syndromic mental retardation). Congenital malformations can be defined as 
developmental abnormalities resulting from an intrinsically abnormal developmental process,6 
e.g. malformation of the limbs, heart and nervous system. The latter may include neural tube 
defects, polymicrogyria, holoprosencephaly and agenesis of the corpus callosum, and may be 
directly related to the mental retardation. Dysmorphisms are defined as deviations of outward 
body form,7 such as hypertelorism and clinodactyly. Specific combinations of congenital 
malformations and/or dysmorphic features may direct a clinician towards a syndrome, i.e., a 
particular set of developmental anomalies occurring together in a recognizable and consistent 
pattern that is known (or assumed) to be the result of a single cause.6
Classification and prevalence
The severity of mental retardation is often classified based on ranges in IQ score. The DSM-IV-
TR and ICD-10 classify four different degrees of mental retardation: mild, moderate, severe and 
profound (Table 1.1), although individuals with severe and profound mental retardation are 
often grouped together in a single category. According to DSM-IV-TR, the segments of mental 
retardation are distributed from a high proportion of mild mental retardation (85%) to a low 
proportion of profound mental retardation (1-2%).1 Also a binary classification of severity is 
often used, with mild mental retardation defined by an IQ score of 50-70 and severe mental 
retardation by an IQ score below 50.
Table 1.1: Levels of mental retardation as classified by DSM-IV-TR and ICD-10 based on IQ scores
 DSM-IV-TR classification ICD-10 classification
Level of MR code IQ level code IQ level
Mild 317 50-55 to 70 F70 50-69
Moderate 318.0 35-40 to 50-55 F71 35-49
Severe 318.1 20-25 to 35-40 F72 20-34
Profound 318.2 <20-25 F73 <20
Note.The DSM-IV-TR takes into account a measurement error of approximately five-points, inherent in the 
more commonly used intelligence tests.1
In contrast, the AAIDD classification system focuses on the intensity of the support required, 
thus stressing the overall impact of mental retardation on everyday life. Accordingly, the level 
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of mental retardation is classified in four groups: intermittent, limited, extensive and pervasive 
support. To some extent, the DSM-IV-TR and the ICD-10 classification levels also reflect 
the four AAIDD classification levels. However, the AAIDD system is more comprehensive, 
requiring interdisciplinary teams to determine the types of support required across multiple 
dimensions.
The prevalence of mental retardation shows considerable variation in different studies. 
Leonard and Wen incorporated data on the rate of severe (IQ <50) and mild (IQ 50-70) mental 
retardation, adapted from a review by Roeleveld et al.8 and data from prevalence studies 
reported between 1997 and 2002.9 The prevalence of severe mental retardation was relatively 
constant and suggested to be 3-4 per 1,000 children, with a range of 1 to 7 per 1,000.9 The 
prevalence of mild mental retardation showed even more variation (2-85 per 1,000), with an 
average prevalence of approximately 33 per 1,000.9 It should be noted that the wide range 
of rates of mental retardation reported in the literature may be attributable to differences in 
definition, classification and methods of identifying persons with mental retardation, rather 
than true differences in prevalence.8
Etiology of mental retardation
Mental retardation may be caused by a wide range of factors that, together, contribute to its 
pathogenesis. In different studies on the etiology of mental retardation the diagnostic yield 
appeared to be highly variable (reviewed by Curry et al.,10 Leonard and Wen,9 and Moog11). This 
variation is likely attributable to differences in methodology, classification and particularly the 
use of the term diagnosis, thus hampering comparisons of clinical studies on the etiology of 
mental retardation.11
In 2003, a comprehensive study on the etiology of mental retardation was performed by 
Stevenson et al.12 The study was based on a cohort drawn from a service delivery population, 
including 10,997 individuals with mental retardation. Although not perfect, this study provides 
a general idea on the frequencies of the main causative categories (Figure 1.1). A specific cause 
for mental retardation was found in 44% of the individuals in the cohort, which is in line with 
previous reports indicating that even after extensive investigation about half of the individuals 
with mental retardation remain without a diagnosis.9-11,13-15
Environmental factors were implicated in approximately 16% of the cohort, similar to the 
percentage of exogenous causes reported in a meta-analysis by Curry et al.10 In some other 
studies, e.g. Rauch et al., mental retardation was assigned to environmental factors in a much 
lower percentage.14 This may be due to an underrepresentation of this category among 
individuals referred to specialized clinical genetic centers. Environmental factors may include 
prenatal causes, such as excess maternal alcohol consumption, drug abuse and cigarette 
smoking during pregnancy, but also numerous other prenatal and perinatal conditions that 
can cause brain damage, such as prematurity and maternal infections, including rubella, 
toxoplasmosis and cytomegalovirus. In addition, postnatal emotional deprivation, malnutrition 
and infectious diseases, such as meningitis and encephalitis, may cause mental retardation.
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Genetic factors represent another important causative category in mental retardation. 
Stevenson et al. reported that genetic conditions may account for up to 28% of the causes.12 
The Online Mendelian Inheritance in Man (OMIM) database for genetic conditions (http://www.
ncbi.nlm.nih.gov/omim/) contains 1,498 entries in which mental retardation is reported (June 
2008). Similarly, the Winter-Baraitser Dysmorphology Database contains information on over 
1,680 syndromes associated with mental retardation and/or developmental delay, including 
single gene disorders, sporadic conditions and syndromes caused by environmental agents. 
Overall, genetic disorders can be divided into multifactorial disorders, single-gene disorders 
and chromosomal disorders. Multifactorial disorders result from the action of one or multiple 
genes in combination with environmental factors. Numerous birth defects that cause 
deformities of the central nervous system leading to mental retardation, such as neural tube 
defects, hydrocephalus, agenesis of the corpus callosum and Dandy–Walker malformation, can 
be assigned to the multifactorial category. 
For the total of 1,498 mental retardation entries in OMIM, 300 genes are currently recorded. 
Chelly et al. proposed a ‘synapse-based’ hypothesis for the pathogenesis of mental retardation.16 
In this hypothesis, mental retardation results from defects in synaptic structure and/or function, 
and neuronal connectivity, caused by dysfunction of proteins encoded by genes involved in 
a large spectrum of specific pathways and cellular processes.16 Examples of distinct functional 
subclasses of proteins encoded by mental retardation-related genes include transcription 
(TCF4, SOX3) and chromatin-remodeling factors (CBP, MECP2, ATRX), transmembrane proteins 
(TM4SF2, IL1RAPL), microtubule- and actin-associated proteins (DCX, SHROOM4) and regulators 
and/or effectors of RhoGTPase pathways (OPHN1, FGD1, PAK3, ARHGEF6) (reviewed by 
Nokelainen and Flint,17 Chiurazzi et al.,18 Raymond and Tarpey,19 and Chelly et al.16) 
The most common single gene disorder associated with mental retardation is the fragile X 
syndrome (MIM #300624). The fragile X syndrome is caused by trinucleotide repeat expansions 
within the Fragile X Mental Retardation 1 (FMR1) gene and is the most prevalent cause of 
heritable mental retardation with a frequency of approximately 1 in 6,000 males.13,20 Single 
genes that affect cognitive functions have predominantly been found on the X chromosome. 
At present, more than 80 genes on the X chromosome are known to be involved in mental 
retardation (http://xlmr.interfree.it/home.htm).18 This may be due to the gene richness of the 
Unknown
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Figure 1.1: Causes of mental retardation. Adapted from Stevenson et al.12
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X chromosome, but also to the ease to identify families with X-linked inheritance patterns of 
mental retardation.21 Therefore, it is likely that the majority of autosomal mental retardation 
genes still await identification. The identification of autosomal dominant genes, however, is 
complicated by the fact that autosomal dominant disorders manifest themselves mostly in 
isolated cases. Moreover, the genetic heterogeneity of mental retardation and the scarcity of 
large pedigrees hamper the identification of autosomal recessive mental retardation genes. 
So far, only five genes, PRSS12 on 4q26 (MIM #249500),22 CRBN on 3p26 (MIM #607417),23 
CC2D1A on 19p13.12 (MIM #608443),24 GRIK2 on 6q16.3 (MIM #611092)25 and CC2D2A on 
4p15.33-p15.226 have been reported to cause autosomal recessive mental retardation without 
additional abnormalities (non-syndromic mental retardation).
Genetic disorders most commonly found in individuals with mental retardation are chromosome 
aberrations.12 With an estimated incidence of 1 per 800 births, trisomy 21, which causes Down 
syndrome (MIM #190685), is the most common mental retardation-associated chromosome 
abnormality.27-29 Besides trisomies and other changes in overall copy number (aneuploidies), 
chromosome aberrations can be grouped into those encompassing changes in copy number 
over specific regions (segmental aneuploidies) and those encompassing balanced structural 
rearrangements.
1.2 Identification of chromosome aberrations in mental retardation
The detection of chromosome aberrations in patients with mental retardation started with the 
determination of the human diploid chromosome number as 46 in 1956.30-32 This discovery 
enabled the identification of numerical chromosome aberrations in individuals with mental 
retardation and/or congenital malformations such as trisomy 21 in Down syndrome (MIM 
#190685),33 45,X in Turner syndrome,34 47,XXY in Klinefelter syndrome,35 trisomy 13 in Patau 
syndrome36 and trisomy 18 in Edwards syndrome.37 The subsequent implementation of 
chromosome banding techniques and the improvement of cell culture methods from the 
1970s on resulted in an enormous increase in the detection of both segmental aneupoidies 
and structural rearrangements, causally related to mental retardation and/or malformation 
syndromes.38 Since the 1970s, G-banding has been the main tool for the detection of 
microscopically visible chromosome aberrations  (>5-10 Mb) and, based on this technology, 
numerous mental retardation-related unbalanced chromosome aberrations such as deletions, 
duplications, translocations and inversions have been reported and categorized.39
Through the application of high-resolution chromosome banding techniques the level of 
resolution of chromosome analysis was increased to <5 Mb.40 The method includes the 
fixation of cells at an early stage of mitosis (prometaphase) when the chromosomes are not 
fully contracted yet.41 The subsequent recognition of genome alterations in the 104 to 106 bp 
range was enabled by the introduction of restriction fragment length polymorphism (RFLP) 
analysis,42 pulsed-field gel electrophoresis (PFGE),43 and fluorescence in situ hybridization 
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(FISH).44 For FISH analyses, large fragments of DNA such as those cloned into bacterial artificial 
chromosomes (BACs; ~40,000 to 200,000 bp) are labeled with a fluorescent dye and hybridized 
to either metaphase spreads or interphase nuclei. Subsequently, fluorescence microscopy can 
be used to assess if and where the fluorescent probe has bound to the chromosome, thus 
allowing the detection and localization of specific DNA fragments. FISH can be used to dissect 
in detail (sub)microscopic chromosomal aberrations. However, large-scale FISH studies are 
time consuming, since they often require separate hybridizations and extensive microscopic 
analyses. In the early 1990s comparative genomic hybridization (CGH) was developed.45 In 
this application, equal amounts of patient DNA and normal reference DNA are fluorescently 
labeled with different colors and hybridized to normal human metaphase chromosomes. 
The DNA copy-number is proportional to the test/reference fluorescence ratio. However, the 
detection of small, cryptic aberrations is limited, because metaphase chromosomes are used 
as the hybridization target.45
Several quantitative polymerase chain reaction (Q-PCR)-based technologies have also been 
developed for the identification of submicroscopic chromosome aberrations, including 
multiplex amplifiable probe hybridization (MAPH),46 quantitative fluorescent PCR (QF-PCR),47 
and multiplex ligationdependent probe amplification (MLPA).48 However, similar to the FISH 
technique mentioned above, these quantitative PCR-based approaches are targeted and, as 
such, only allow the screening of a limited number of loci in a single experiment. More recently 
developed FISH-based techniques using multiple fluorescence dyes, such as multiplex-FISH 
(M-FISH)49 and spectral karyotyping (SKY),50 enabled the simultaneous visualization of all 
chromosomes, thus allowing the identification of (complex) chromosome rearrangements 
without prior knowledge of the regions involved (‘chromosome painting’). Still, however, these 
techniques are labor intensive, have a limited resolution and are difficult to automate.
The introduction of molecular cytogenetic tools, mainly DNA microarrays,51,52 enabled 
the bridging of the technical divide between molecular genetics and cytogenetics. DNA 
microarrays allow the detection of submicroscopic genomic variation at a resolution far below 
5 Mb. Submicroscopic genomic variants that alter chromosomal structure are often referred 
to as structural variation.53 Structural variation includes inversions and translocations, but also 
changes that alter DNA copy number, i.e. deletions, insertions and duplications, which are 
collectively termedcopy number variations (CNVs).53 By definition, the minimum size of 
structural variation is 1kb and, although no maximum size is determined, structural variation 
and CNV are commonly used in the context of submicroscopic aberrations (Figure 1.2).53
The high-throughput genome-wide detection of submicroscopic interstitial structural variation 
associated with mental retardation became feasible with the introduction of array-based 
comparative genomic hybridization (array CGH),51,52 also referred to as ‘molecular karyotyping’. 
Molecular karyotyping refers to all technologies that allow a genome-wide detection of 
chromosome aberrations at the submicroscopic level.55,56 The initial array CGH platforms were 
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clone-based platforms that used genomic fragments from large insert clones such as cosmids, 
P1 clones, phage artificial chromosome (PAC) clones52 and bacterial artificial chromosome 
(BAC) clones,51 as probes. The development of these clone-based microarrays was mediated 
by (i) the generation of genome-wide clone resources integrated into the finished human 
genome sequence, (ii) the development of high throughput microarray-based platforms, and 
(iii) the optimization of CGH protocols and data analysis systems.57 The main principle of array 
CGH is outlined in Figure 1.3.
Figure 1.2: From chromosome to DNA level. The genome manifests a size continuum of genomic variants from 
single base deletions or duplications to whole chromosomal aneuploidies.54 Structural variation includes vari-
ants that alter chromosomal structure, both balanced changes and variants that alter DNA copy number [copy 
number variation (CNV)]. Different genomic technologies are required to interrogate genomic variants at dif-
ferent levels, from single basepair changes using DNA sequencing to the identification of microscopically visible 
chromosomal aberrations through conventional karyotyping. 
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Figure 1.3: The principle of array CGH. Equal amounts of isolated and fragmented genomic test DNA and re-
ference DNA are differentially labeled using fluorescent dyes. Subsequently, test (patient DNA; left panel) and 
reference samples (reference DNA; right panel) are mixed with Cot-1 DNA, co-precipitated, and resuspended 
in a hybridization solution. After denaturation the DNA mix is hybridized to the DNA on the array. After several 
washing steps, images of the fluorescent signals are captured and the ratio of test over reference signals is quan-
tified computationally and plotted for each probe on the array.  For color figure see page 190.
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1.3 Clinical consequences of submicroscopic copy number variation
Subtelomeric copy number variation
Chromosome rearrangements of the telomeres are one of the most commonly observed 
structural abnormalities detected by conventional chromosome analyses in individuals with 
mental retardation. In 1963, Lejeune et al. described deletions of the short arm of chromosome 
5 (5p-) in patients with similar phenotypic features, thus defining the Cri-du-Chat syndrome 
(MIM #123450).58,59 Later terminal deletions of 4p were identified in patients with Wolf-
Hirschhorn syndrome (MIM #194190)60,61 and terminal deletions of 17p in patients with Miller-
Dieker syndrome (MIM #247200).62-64 
Since the descriptions of the Cri-du-Chat, Wolf–Hirschhorn and Miller–Dieker syndromes, 
clinical disorders caused by terminal microscopically visible deletions have been reported for 
numerous human chromosomes.39 Moreover, in 1995, Flint et al. reported the identification 
of cryptic, submicroscopic structural rearrangements involving subtelomeric regions in 
individuals with mental retardation.65
Subtelomeres are defined as genomic regions adjacent to the telomeres. The telomeres 
themselves are complex regions harboring repetitive DNA sequences consisting of long 
(TTAGGG)n. repeats.
66 The subtelomeres are divided by interstitial degenerate (TTAGGG)n repeats 
into distal and proximal sequences that are repeated near the ends of multiple chromosomes 
(Figure 1.4).67 The complex structure of the subtelomeres is a potential source of phenotypic 
diversity and may have a role in the reconstitution of telomeres in the absence of telomerase. 
However, it may also mediate rearrangements of the ends of the chromosomes.68 These latter 
rearrangements are likely to have clinical consequences as the highest gene densities in the 
human genome are encountered in the regions just adjacent to telomeres.69
Figure 1.4: Structure of the subtelomeric region. Subtelomeres are the genomic regions just adjacent to the te-
lomeres and are subdivided by interstitial degenerate (TTAGGG)n repeats into distal and proximal subtelomeric 
sequences that are repeated near the end of multiple chromosomes.67 
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After the first report of submicroscopic CNVs in the subtelomeres of individuals with unexplained 
mental retardation,65 technological improvements in cytogenetics, such as the development 
of a 12-color FISH assay, termed M-TEL,70 and the introduction of the MultiprobeTM slide,71 
soon allowed the interrogation of all subtelomeres into a routine procedure. The first survey 
of a large cohort of 466 children with idiopathic mental retardation and a normal G-banded 
karyotype revealed subtelomeric CNVs in 5% of them, of which almost 50% was inherited 
from a balanced carrier.72 Since then, numerous studies have been performed showing 
that subtelomeric rearrangements contribute significantly to idiopathic mental retardation 
(reviewed by Biesecker,73 de Vries et al.,74 Flint and Knight,75 and Rooms et al.76) In the majority 
of these studies FISH was used to identify subtelomeric rearrangements, but also other 
techniques were employed such as microsatellite marker analysis,77,78 MAPH,46 MLPA (Chapter 
2.1),79,80 and array CGH.81,82 In total, subtelomeric rearrangements were identified in 5-6% of 
~3,800 individuals with unexplained mental retardation.76 As most of these initial reports 
represent proof-of-principle studies, the patient cohorts may have been preselected. In 2006, 
FISH analyses among a large cohort of 11,668 individuals with unexplained mental retardation 
revealed clinically significant telomere aberrations in ~2.5% of the cases, of which 60% was 
inherited from a normal parent carrying a balanced translocation.83 A similar diagnostic yield 
was obtained from nearly 7,000 consecutive clinical cases analyzed by targeted array CGH.84 
Taken together, these latter two studies encompass the results of almost 19,000 subtelomere 
tests. The most common submicroscopic subtelomeric CNVs identified in these studies, are 
discussed below.
1p
One of the best-studied subtelomeric regions is 1p36. The 1p36 microdeletion syndrome 
(MIM #607872) is the most frequently observed subtelomeric deletion and, with an incidence 
of one in 5,000 births, one of the most commonly occurring mental retardation syndrome 
in humans.85-87 Clinical features characteristic for the 1p36 microdeletion syndrome include 
developmental delay/mental retardation, epilepsy, hypotonia, hearing loss, microcephaly, 
Figure 1.5: Clinical photographs of patients with subtelomere deletions. (a) 1pter deletion (b) 4pter deletion 
(c) 9qter deletion (d) 22qter deletion. Informed consent was obtained for publication of photographs. For color 
figure see page 191.
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brachycephaly and facial dysmorphisms including straight eyebrows, deep-set eyes, a flat 
nasal bridge, a flat nose, asymmetric ears and a pointed chin (Figure 1.5a). In addition, cardiac 
defects and cleft lip/palate are common features.86,88,89 Molecular cytogenetic analyses revealed 
that terminal 1p36 deletion sizes vary widely from ~1 Mb to more than 10 Mb and that the 
deletions comprise terminal deletions, derivative chromosomes, complex rearrangements and 
interstitial deletions.85,89,90
2q
Isolated, primarily subtelomeric deletions with breakpoint at or within chromosome 2q37 
have been reported in almost 100 individuals.91 Individuals with subtelomeric 2q37 deletions 
commonly present with mild-moderate mental retardation, epilepsy, autistic features and facial 
characteristics, including prominent forehead, thin, highly arched eyebrows, a depressed nasal 
bridge, full cheeks, hypoplastic alae nasi, prominent columella, a thin upper lip and various 
minor anomalies of the pinnae.91 Brachymetaphalangism is reported in ~50% of the cases.92 In 
addition, central nervous system anomalies and ocular-, cardiac-, gastrointestinal-, renal- and 
other genitourinary malformations have been noted in nearly one-third of the patients. There is 
an extensive phenotypic variability, and a clear genotype-phenotype correlation has not been 
observed. Patients with the most distal deletion present with mental retardation, short stature, 
obesity and bracymetaphalangia. These features, resembling the physical anomalies found in 
Albright hereditary osteodystrophy (MIM #103580), have been designated Albright hereditary 
osteodystrophy (AHO)-like syndrome or brachydactyly-mental retardation syndrome (MIM 
%600430). The minimal deleted region in patients with AHO-like brachymetaphalangism has 
been narrowed down to ~3 Mb.92
4p
Subtelomeric deletions of 4p result in a clinically well recognizable characteristic phenotype 
known as the Wolf-Hirschhorn syndrome (WHS, MIM #194190).60,61 WHS occurs in approximately 
one in 50,000 births.93 The major features are low birth weight, postnatal failure to thrive, 
microcephaly and mental retardation, hypertelorism, prominent glabella (Greek warrior 
helmet), a broad nasal tip, a bilateral cleft lip and a short philtrum (Figure 1.5b).94 The WHS 
critical region (WHSCR) is located in 4p16.3 and in approximately 25% of the patients the 
deletion comprising this region is not detectable using conventional chromosome analysis.74 
The shortest region of overlap of the deletions observed in WHS patients has been confined 
to a stretch of 165 kb, including the WHSC1 and WHSC2 genes.95 Moreover, a second critical 
interval of 300 to 600 kb on 4p16.3 (WHSCR2), contiguous distally with the WHSCR, was defined 
by Zollino et al. in patients with a mild phenotype.96
7q
Common clinical features in children with cryptic 7q36 deletions include developmental 
delay, holoprosencephaly, microcephaly, facial dysmorphisms and heart anomalies. 
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Holoprosencephaly associated with the subtelomeric 7q36 genomic segment is caused by 
loss of the Sonic Hedgehog gene (SHH).97 SHH encodes the human sonic hedgehog homolog, 
a protein that is instrumental in patterning the early embryo and has been implicated in 
normal development of a variety of organ systems, including the brain and spinal cord, the 
eye, craniofacial structures and the limbs (reviewed by Ming et al.98) Haploinsufficiency of 
another gene included in this region, the HLXB9 homeobox gene, causes Currarino syndrome 
(MIM #176450), which is characterized by the triad sacral dysgenesis, anorectal atresia and a 
presacral mass.99,100 Holoprosencephaly and Curranino syndrome exhibit remarkable clinical 
variability and the expression of features of the holoprosencephaly spectrum and of the 
Currarino syndrome due to deletions of 7q36 can be minimal.101
8p
Distal 8p23.1 deletions are associated with a mild phenotype that can extend into the normal 
range.102 Deletions of 8p23.1pter were first identified in a boy with mental slowness, behavioral 
problems and seizures, in his sister and father who had minimal phenotypic abnormalities 
with borderline to normal intelligence and, prenatally, in a fetus and its phenotypically normal 
father.103,104 Subsequently, a de novo terminal deletion of 8p23.1pter was ascertained in a girl 
with initial motor and language delays, but average cognitive development and intellectual 
ability after close monitoring over a period of 5 years.105 De Vries et al. reported two mildly 
retarded, non-dysmorphic cousins with behavioral problems including inappropriate sexual 
behavior and pyromania and a submicroscopic 8pter deletion caused by a familial t(8;20)
(p23;p13).106 In addition, several patients with a microscopically visible 8p23.1pter deletion 
and normal IQ scores have been reported.103-105
Interstitial deletion of 8p23.1, mediated by clusters of olfactory receptor/ defensin repeats, 
is a genomic disorder characterized by developmental delay, behavioral problems, including 
hyperactivity and impulsiveness, congenital heart disease, diaphragmatic hernia and a 
Fryns syndrome-like condition.107-110 Some of these deletions are larger than the common 
rearrangement and may even extend to include the 8p subtelomeric region.110 The congenital 
heart disease characteristic for this deletion is attributable to haploinsufficiency of the GATA4 
gene.111
9q
Common features seen in the 9q34 deletion syndrome are severe mental retardation, 
hypotonia, brachycephaly, a flat face with hypertelorism, synophrys, anteverted nares, a cupid 
bow or a tented upper lip, an everted lower lip, prognathism, macroglossia, conotruncal heart 
defects and behavioral problems (Figure 1.5c).112,113 Comprehensive mutation analysis of the 
EHMT1 gene in patients with clinical presentations reminiscent of the 9q subtelomeric deletion 
syndrome revealed two de novo mutations, indicating that haploinsufficiency of EHMT1 is 
causative for the 9q subtelomeric deletion syndrome.112
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16p
Deletions of the 16p13.3 region give rise to α-thalassemia-mental retardation linked to the 
chromosome 16 syndrome (ATR-16; MIM #141750).114 In addition to the α-thalassaemia, the most 
consistent physical findings in pure 16pter monosomy are mild mental retardation, hypotonia, 
a high forehead, hypertelorism, a broad or prominent nasal bridge and talipes equinovarus 
(clubfoot).115 Genital abnormalities are also seen, particularly undescended testes in males. 
Also nonspecific difficulties in the perinatal period are relatively common, possibly due to 
neuromuscular hypotonia.115 A similar disorder, the X-linked α-thalassemia-mental retardation 
syndrome (ATR-X, MIM #301040), is caused by mutations in the ATRX gene.116 Familial ATR-
16 has been described resulting from an inherited cryptic subtelomeric translocation, t(3;16)
(q29;p13.3), inherited in a seemingly autosomal dominant fashion with reduced penetrance.117 
Haploinsufficiency of the α-1 (HBA1) and α-2 (HBA2) globin genes is thought to cause the 
α-thalassaemia, whereas haploinsufficiency of the transcriptional regulator SOX8 has been 
suggested to contribute to the mental retardation in ATR-16.118 
22q
One of the first syndromes caused by a submicroscopic subtelomeric CNV identified among 
unselected individuals with idiopathic mental retardation was the subtelomeric 22q13.3 
microdeletion syndrome (MIM #606232).119 Subtelomeric 22q13.3 deletions range in size from 
130 kb to 9.0 Mb, but comparison of clinical features to deletion sizes showed few correlations 
(Chapter 2.2).120,121 The 22q13.3 deletion syndrome is characterized by neonatal hypotonia, 
global developmental delay, normal to accelerated growth, minor dysmorphic features 
(Figure 1.5d), absent to severely delayed speech development and autistic behavior.122-124 
It has been suggested that haploinsufficiency of SHANK3/ProSAP2, encoding the synaptic 
scaffolding protein SHANK3, is responsible for the clinical disorder.125 Moreover, it has been 
shown that mutations in SHANK3 and CNVs encompassing SHANK, are also associated with 
autism spectrum disorder.123,125-127 
1.3.2. Interstitial copy number variation
Elucidation of the underlying cause of known syndromes
The introduction of novel techniques such as high resolution prometaphase chromosome 
banding, RFLP, PFGE and FISH allowed the detection of genomic aberrations that could not be 
detected by conventional chromosome analyses (Chapter 1.2). Using these techniques, cryptic 
CNVs were found to be the cause of several previously described malformation syndromes, 
such as deletion of 15q11q13 in Prader-Willi syndrome (PWS, MIM #176270) and Angelman 
syndrome (AS, MIM #105830), deletion of 8q24.11q24.13 in trichorhinophalangeal syndrome 
type II (TRPS2, MIM #150230), deletion of 11p13 in the Wilms tumor aniridia genitourinary-
anomalies mental retardation syndrome (WAGR, MIM #194072) and deletion of 22q11.2 in 
DiGeorge/velocardiofacial syndrome (DGS/VCFS, MIM, #188400/#192430) (Table 1.2).
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The latter recurrent microdeletions share a common etiologic mechanism, i.e., non-allelic 
homologous recombination (NAHR) between low-copy repeats (LCRs) that flank the rearranged 
unique genomic segment.136,137 NAHR is based on mispairing between non-allelic homologous 
LCRs and subsequent crossing over between DNA strands during meiosis, resulting in 
duplication or deletion of the intervening sequence that may range in size from a few kb to 
several Mb.136,137 Clinical human disorders that are caused by rearrangements predisposed 
by structural characteristics of the genome are referred to as ‘genomic disorders’.136 The 
rearrangements associated with these genomic disorders include deletions, duplications and 
inversions and lead to the complete loss or gain of a gene(s) sensitive to a dosage effect or, 
alternatively, to disruption of its structural integrity.84,136-138 Next to NAHR, other molecular 
mechanisms might underlie these rearrangements, such as non-homologous end joining 
(NHEJ)139 and replication Fork Stalling and Template Switching (FoSTeS).140 
Identification of new interstitial CNVs in mental retardation
From the identification of microdeletions in clinical syndromes and the detection of cryptic 
subtelomeric aberrations using FISH and PCR-based analyses, it could be expected that 
submicroscopic chromosome aberrations should also be present at various other sites within 
the human genome, in particular in patients with mental retardation. The first probe collections 
for the measurement of chromosome anomalies across the human genome were assembled in 
2001.141 The subsequently developed microarrays contained approximately 3,400 BAC clones 
covering the entire genome with an average spacing of one clone per Mb.142
Several pilot studies showed the diagnostic value of the genome-wide 1 Mb resolution 
microarrays in mental retardation.142-144 In these studies de novo submicroscopic genome 
Table 1.2: Mental retardation syndromes commonly caused by submicroscopic CNVs: their chromosomal 
location and genes involved
Syndrom CNV Chromosomal Common Gene(s) MIM
  location Size (Mb) involved
Williams-Beuren del 7q11.23 1.5 ELN6 194050
TRPS2 del 8q23.3q24.1 – TRPS1, 150230
    EXT1c
WAGR del 11p13 – PAX6, 194072
    WT1d
Prader-Willi/Angelman del 15ql1.2ql3a 5 UBE3Ac 176270/105830
Smith-Magenis del 17pl1.2 3.7 RA11 182290
DiGeorge/velocardiofacial del 22ql1.2 3 TBX1f 188400/192430
Pelizaeus-Merzbacher dup/del Xp22 – PLP1 312080
a Paternal in origin in PWS; maternal in origin in AS.128
b ELN mutations cause supravalvular aortic stenosis.129
c Mutations in TRPS1 and EXT1 cause TRPS1 and multiple exostoses type I, respectively.130,131
d PAX6 mutations cause aniridia type II; loss of WT1 results in genitourinary anomalies and increased risk for 
Wilms’ tumor.132,133
e In approximately 25% AS is caused by mutations in the ubiquitin-protein ligase E3A gene (UBE3A).134 
f TBX1 mutations result in five major components of the 22q11.2 microdeletion syndrome.135
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imbalances were identified in approximately 10-15% of individuals with mental retardation.142-144 
The clinical usefulness of genome profiling was underscored in larger cohorts of patients with 
unexplained mental retardation using similar microarrays, tiling-resolution BAC microarrays 
and, subsequently, 100k SNP microarrays.121,145-151
In genome-wide studies among unselected individuals with unexplained mental retardation, the 
diagnostic yield of clinically relevant CNVs was approximately 11% (Table 1.3).121,142-157 Obviously, 
the diagnostic yield of genome-wide diagnostic approaches largely depends on the previous 
cytogenetic studies performed, patient selection and the microarray platforms used.158
The exact clinical interpretation of the CNVs observed, however, is challenging and many 
questions remain (Chapter 3.1). One of the major difficulties is caused by the fact that genomes 
from normal individuals show extensive benign genomic copy number variation.159-161 It is 
generally assumed now that CNV is the most prevalent type of structural variation in the human 
genome and that it contributes significantly to genetic heterogeneity.162 A first-generation map 
of CNVs in healthy individuals showed that up to approximately 12% of the human genome 
involves CNVs.160 In genome-wide approaches for the diagnosis of mental retardation, these 
CNVs challenge the interpretation of the test results and the translation into clinical phenotypes. 
Since as yet little is known about the clinical consequences of these submicroscopic CNVs, they 
severely hamper the genetic counseling in families. Targeted genomic microarrays designed to 
interrogate regions of known clinical significance can be used in order to facilitate the clinical 
interpretation of submicroscopic CNVs in a diagnostic setting.163,164 However, in contrast to 
Table 1.3: Diagnostic yield of genome-wide microarray studies in mental retardation using different platforms
Study Reference Number Platform Diagnostic yield (%)
1 Vissers (2003) 20 1 Mb BAC array 10
2 Shaw-Smith (2004) 50 1 Mb BAC array 14
3 De Vries (2005) 100 32K BAC array 10
4 Schoumans (2005) 41 1 Mb BAC array 9.1
5 Tyson (2005) 22 1 and 3 Mb BAC array 9.8
6 Menten (2006) 140 1 Mb BAC array 16.7
7 Miyake (2006) 30 1,5Mb BAC array 13.6
8 Friedmann (2006) 100 100K oligo array 13.6
9 Krepischi-Santos (2006) 95 1 Mb BAC array 10
10 Rosenberg (2006) 81 1 Mb BAC array 13.7
11 Engels (2007) 60 500 kb BAC array 6.7
12 Hoyer (2007) 104 100K oligo array 12.0
13 Fan (2007) 100 44K oligo array 8.7
14 Aradhya (2007) 20 44K oligo array,  40
   1 Mb BAC array
15 Wagenstaller (2007) 67 100K oligo array 14.9
16 Thuresson 92007) 48 1 Mb BAC array 4.2
17 Koolen (in press)a 386 32K BAC array 9.1
 Total 1,364  11.2
a The results of de Vries et al.121 are included. 
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genome-wide microarrays, targeted approaches fail to detect sporadic CNVs related to mental 
retardation, as the corresponding probes are not present on these microarrays (Chapter 3.2).
Delineation of new interstitial mental retardation syndromes
The implementation of novel cytogenetic and molecular techniques resulted in the 
identification of recurrent disease-associated CNVs. Often, these recurrent rearrangements 
result from local structural characteristics of the genome (see above). The first recurrent 
rearrangement that was shown to result from such genomic architectural features was a 1.5-
Mb DNA duplication of the 17p12p11.2 region associated with Charcot-Marie-Tooth disease 
type 1A (CMT1A, MIM #118220).165,166 The duplication results from NAHR mediated by flanking 
LCRs, leading to a gene dosage effect of the PMP22 gene.167-169 Point mutations in the same 
gene can lead to the same phenotype.170-172 Reciprocal deletions were identified in patients 
with a milder phenotype, i.e., hereditary neuropathy with liability to pressure palsies (HNPP, 
MIM #162500).173 Similarly, reciprocal duplications of known genomic disorders associated with 
mental retardation are predicted to occur. The Potocki-Lupski syndrome (PLS, MIM #610883), 
resulting from homologous recombination reciprocal of the Smith-Magenis syndrome-
associated microdeletion 17p11.2, was the first predicted mental retardation microduplication 
syndrome described.174,175 Similarly, reciprocal duplications of the WBS critical region at 7q11.23 
and the DGS/VCFS region at 22q11.2 have been associated with mental retardation.176-179
High resolution cytogenetic analyses and/or additional molecular/cytogenetic analyses also 
revealed mental retardation syndromes such as the Potocki-Shaffer syndrome (PSS, MIM 
#601224), caused by an interstitial deletion of 11p11.2p12 and recurrent 10q22q23 deletions, 
associated with cognitive and behavioral abnormalities.180,181
The implementation of microarray technologies resulted in the identification of numerous 
overlapping submicroscopic CNVs in individuals with mental retardation. In retrospect, 
common clinical features could be determined and, subsequently, a clinical syndromes 
associated with mental retardation could be defined. This ‘genotype-first’ approach,182 or 
‘reverse phenotypics’, by which individuals with unexplained mental retardation are 
characterized by a similar genomic aberration before a common clinical presentation is defined, 
has proven to be successful considering the constantly increasing list of newly detected 
microdeletion/microduplication syndromes (Table 1.4). Various interstitial microdeletion/
microduplication syndromes associated with mental retardation that were recently recognized 
are briefly discussed below.
opmaak koolen.indd   26 10-09-2008   10:11:41
27
Introduction
Ta
bl
e 
1.
4:
 N
ew
ly
 re
co
gn
iz
ed
 in
te
rs
tit
ia
l m
ic
ro
de
le
tio
n/
du
pl
ic
at
io
n 
sy
nd
ro
m
es
 a
ss
oc
ia
te
d 
w
ith
 m
en
ta
l r
et
ar
da
tio
n.
N
am
e 
Si
ze
 (M
b)
a  
LC
R 
M
IM
 
Cl
in
ic
al
 fe
at
ur
es
1q
41
q4
2 
m
ic
ro
de
le
tio
n 
1.
2 
- 
- 
M
R,
 s
ei
zu
re
s, 
va
rio
us
 d
ys
m
or
ph
is
m
s, 
cl
ef
t p
al
at
e,
 d
ia
ph
ra
gm
at
ic
 h
er
ni
a
2p
15
16
.1
 m
ic
ro
de
le
tio
n 
 
3.
9 
- 
- 
 M
R,
 M
C,
 re
ce
di
ng
 fo
re
he
ad
, p
to
si
s, 
te
le
ca
nt
hu
s, 
sh
or
t p
al
pe
br
al
 fi
ss
ur
es
, d
ow
ns
la
nt
in
g 
pa
lp
eb
ra
l 
fis
su
re
s, 
br
oa
d/
hi
gh
 n
as
al
 b
rid
ge
, l
on
g/
st
ra
ig
ht
 e
ye
la
sh
es
, s
m
oo
th
 a
nd
 lo
ng
 p
hi
ltr
um
, s
m
oo
th
 
up
pe
r 
ve
rm
ill
io
n 
bo
rd
er
, e
ve
rt
ed
 l
ow
er
 l
ip
, h
ig
h 
na
rr
ow
 p
al
at
e,
 h
yd
ro
ne
ph
ro
si
s, 
op
tic
 n
er
ve
 
hy
po
pl
as
ia
 
3q
29
 m
ic
ro
de
le
tio
n 
 
1.
6 
+ 
60
94
25
 
M
R,
 m
ild
 F
D
, i
nc
lu
di
ng
 h
ig
h 
na
sa
l b
rid
ge
 a
nd
 s
ho
rt
 p
hi
ltr
um
3q
29
 m
ic
ro
du
pl
ic
at
io
n 
 
1.
6 
+ 
61
19
36
 
M
ild
/m
od
er
at
e 
M
R,
 M
C,
 o
be
si
ty
7q
11
.2
3 
du
pl
ic
at
io
n 
 
1.
5 
+ 
60
97
57
 
M
R,
 s
pe
ec
h 
an
d 
la
ng
ua
ge
 d
el
ay
, a
ut
is
m
 s
pe
ct
ru
m
 d
is
or
de
rs
, m
ild
 F
D
9q
22
.3
 m
ic
ro
de
le
tio
n 
6.
5 
- 
- 
M
R,
 h
yp
er
ac
tiv
ity
, o
ve
rg
ro
w
th
, t
rig
on
oc
ep
ha
ly
, m
ac
ro
ce
ph
al
y,
 F
D
12
q1
4 
m
ic
ro
de
le
tio
n 
 
3.
4 
- 
- 
M
ild
 M
R,
 fa
ilu
re
 to
 th
riv
e,
 p
ro
po
rt
io
na
te
 s
ho
rt
 s
ta
tu
re
 a
nd
 o
st
eo
po
ik
ilo
si
s
14
q1
2 
m
ic
ro
de
le
tio
n 
 
0.
4 
- 
- 
 M
R,
 w
id
el
y 
sp
ac
ed
 e
ye
s, 
sh
or
t 
no
se
 w
ith
 fl
at
 n
as
al
 b
rid
ge
, l
on
g 
ph
ilt
ru
m
, C
up
id
’s 
bo
w
 o
f 
th
e 
up
pe
r l
ip
, f
ul
l l
ow
er
 li
p,
 a
ur
ic
ul
ar
 a
no
m
al
ie
s
15
q1
3.
3 
m
ic
ro
de
le
tio
n 
 
1.
5 
+ 
61
20
01
 
M
R,
 e
pi
le
ps
y,
 F
D
, d
ig
ita
l d
ys
m
or
ph
is
m
s 
15
q2
4 
m
ic
ro
de
le
tio
n 
 
1.
7 
+ 
- 
 M
R,
 g
ro
w
th
 r
et
ar
da
tio
n,
 M
C,
 d
ig
ita
l 
ab
no
rm
al
iti
es
, g
en
ita
l 
ab
no
rm
al
iti
es
, h
yp
os
pa
di
as
, l
oo
se
 
co
nn
ec
tiv
e 
tis
su
e,
 h
ig
h 
fr
on
ta
l h
ai
rli
ne
, b
ro
ad
 m
ed
ia
l e
ye
br
ow
s, 
do
w
ns
la
nt
ed
 p
al
pe
br
al
 fi
ss
ur
es
, 
lo
ng
 p
hi
ltr
um
16
p1
1.
2p
12
.2
 m
ic
ro
de
le
tio
n 
 
7.
1 
+ 
- 
 M
R,
 fl
at
 f
ac
ie
s, 
do
w
ns
la
nt
in
g 
pa
lp
eb
ra
l fi
ss
ur
es
, l
ow
-s
et
 a
nd
 m
al
fo
rm
ed
 e
ar
s, 
ey
e 
an
om
al
ie
s, 
or
of
ac
ia
l 
cl
ef
tin
g,
 h
ea
rt
 d
ef
ec
ts
, f
re
qu
en
t 
ea
r 
in
fe
ct
io
ns
, s
ho
rt
 s
ta
tu
re
, m
in
or
 h
an
d 
an
d 
fo
ot
 
an
om
al
ie
s, 
fe
ed
in
g 
di
ffi
cu
lti
es
, h
yp
ot
on
ia
17
p1
1.
2 
m
ic
ro
du
pl
ic
at
io
nb
 
3.
7 
+ 
61
08
83
 
M
R,
 
in
fa
nt
ile
 
hy
po
to
ni
a,
 
fa
ilu
re
 
to
 
th
riv
e,
 
au
tis
tic
 
fe
at
ur
es
, 
sl
ee
p 
ap
ne
a,
 
an
d 
st
ru
ct
ur
al
 
ca
rd
io
va
sc
ul
ar
 a
no
m
al
ie
s
17
q2
1.
31
 m
ic
ro
de
le
tio
n 
 
0.
5 
+ 
61
04
43
 
 M
R,
 h
yp
ot
on
ia
, l
on
g 
hy
po
to
ni
c 
fa
ce
 w
ith
 p
to
si
s, 
la
rg
e 
an
d 
lo
w
-s
et
 e
ar
s, 
tu
bu
la
r o
r p
ea
r-
sh
ap
ed
 
no
se
 w
ith
 b
ul
bo
us
 n
as
al
 ti
p,
 lo
ng
 c
ol
um
el
la
 w
ith
 h
yp
op
la
st
ic
 a
la
e 
na
si
, b
ro
ad
 c
hi
n
22
q1
1.
2 
m
ic
ro
du
pl
ic
at
io
n 
 
3.
7 
+ 
60
83
63
 
 H
ig
hl
y 
va
ria
bl
e.
 
M
R,
 
FD
, 
e.
g.
 
w
id
el
y 
sp
ac
ed
 
ey
es
 
an
d 
do
w
ns
la
nt
in
g 
pa
lp
eb
ra
l 
fis
su
re
s, 
ve
lo
ph
ar
yn
ge
al
 in
su
ffi
ci
en
cy
, c
on
ot
ru
nc
al
 h
ea
rt
 d
is
ea
se
22
q1
1.
2 
di
st
al
 m
ic
ro
de
le
tio
n 
 
1.
4 
- 2
.1
 
+ 
61
18
67
 
 M
R,
 p
re
m
at
ur
ity
, p
re
na
ta
l/p
os
tn
at
al
 g
ro
w
th
 d
el
ay
, m
ild
 sk
el
et
al
 a
bn
or
m
al
iti
es
, a
rc
he
d 
ey
eb
ro
w
s, 
de
ep
-s
et
 e
ye
s, 
sm
oo
th
 p
hi
ltr
um
, t
hi
n 
up
pe
r l
ip
, h
yp
op
la
st
ic
 a
la
e 
na
si
, s
m
al
l p
oi
nt
ed
 c
hi
n
Xq
28
 m
ic
ro
du
pl
ic
at
io
n 
0.
4 
- 0
.8
 
- 
- 
M
R,
 s
ev
er
e 
hy
po
to
ni
a,
 p
ro
gr
es
si
ve
 lo
w
er
-li
m
b 
sp
as
tic
ity
, a
bs
en
t o
r v
er
y 
lim
ite
d 
sp
ee
ch
N
ot
e.
 
Th
e 
8p
23
.1
 s
yn
dr
om
e 
is
 d
es
cr
ib
ed
 in
 C
ha
pt
er
 1
.3
.1
, a
s 
so
m
e 
de
le
tio
ns
 e
xt
en
d 
to
 in
cl
ud
e 
th
e 
8p
 te
lo
m
er
e.
 M
R,
 m
en
ta
l r
et
ar
da
tio
n;
 M
C,
 m
ic
ro
ce
ph
al
y;
 F
D
, f
ac
ia
l 
dy
sm
or
ph
is
m
s
a  C
om
m
on
 re
gi
on
b  P
ot
oc
ki
-L
up
sk
i s
yn
dr
om
e 
opmaak koolen.indd   27 10-09-2008   10:11:41
28
Chapter 1
1q41q42 microdeletion
Using a targeted microarray covering regions commonly rearranged in chromosome 
abnormalities and genes involved in important developmental pathways, Shaffer et al. 
identified seven recurrent de novo deletions of 1q41q42 that include the DISP1 gene, which 
is involved in the sonic hedgehog pathway (SHH; see above 7q36 deletion syndrome).182 The 
deletions range in size from 2.7 – 9.1 Mb with a smallest region of overlap of 1.2 Mb. Although 
none of these patients showed frank holoprosencephaly, many exhibited other midline defects 
(cleft palate, diaphragmatic hernia), developmental delay or mental retardation, seizures and 
dysmorphic features. 
2p15p16.1 microdeletion
Through whole genome array CGH screening of subjects with idiopathic intellectual disability, 
Rajcan-Separovic et al. identified two unrelated individuals with an overlapping de novo 
interstitial microdeletion at 2p15-2p16.1 with respective sizes of 4.5 and 5.7 Mb.183 De Leeuw 
et al. reported a similar patient with a corresponding 3.9 Mb deletion at 2p15-2p16.1.184 
These individuals shared a number of malformations and rather specific dysmorphic features, 
including microcephaly, facial dysmorphisms (bitemporal narrowing, a receding short 
forehead, ptosis, telecanthus, short palpebral fissures, downslanting palpebral fissures, a 
broad/high nasal bridge, long, straight eyelashes, a smooth and long philtrum, a smooth upper 
vermillion border, an everted lower lip, a high narrow palate) (Figure 1.6a), hydronephrosis 
and optic nerve hypoplasia, as well as moderate to severe mental retardation, indicating that 
they share a newly recognized microdeletion syndrome. Chabchoub et al. identified a 570-kb 
de novo microdeletion at 2p15 in a patient with mild intellectual disability, a heart defect, an 
ectomorphic habitus and similar facial dysmorphic features, but without the microcephaly, 
kidney anomalies, autistic disorder, or optic nerve hypoplasia.185 
Figure 1.6: Patients with newly recognized interstitial microdeletion syndromes. (a) 2p15p16.1 microdeletion, 
(b) 3q29 microdeletion (c) 17q21.31 microdeletion (d) distal 22q11 microdeletion. Informed consent was ob-
tained for publication of photographs. For color figure see page 191.
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3q29 microdeletion
Subtelomere screening using FISH and MLPA revealed the presence of a terminal deletion of 
3q29 in six individuals with mild to moderate mental retardation, a long and narrow face, a 
short philtrum and a high nasal bridge (Figure 1.6b).186 Further delineation of the deletions 
using FISH revealed that they were interstitial, as the most distally located ~700 kb was 
retained in all cases. In addition, the deletions were almost identical in size, and the presence 
of two highly homolgous LCRs on either side of the deletion breakpoint suggested that NAHR 
is the likely mechanism underlying this syndrome. Ballif et al. identified 14 individuals with 
microdeletions of 3q29, including a family with a mildly affected mother and two affected 
children, among 14,698 individuals with idiopathic mental retardation that were analyzed by 
array CGH.187 Eleven individuals had typical 1.6 Mb deletions and three individuals had deletions 
that flank, span, or partially overlap the commonly deleted region. The clinical presentations 
of individuals with microdeletions of 3q29 varied widely, with mild to moderate mental 
retardation/developmental delay, microcephaly, and mild dysmorphic features (including a 
high nasal bridge and a short philtrum) the only features common to the majority.187
3q29 microduplication
A reciprocal duplication of the recurrent 3q29 microdeletion was identified in a three-
generation family in which five members exhibited mild to moderate mental retardation and 
minor dysmorphic features.188 Ballif et al. identified five reciprocal duplication products of the 
3q29 microdeletion.187 Like that of the 3q29 microdeletion, the phenotypes of the reciprocal 
microduplication varied considerably, with mental retardation, microcephaly and obesity 
being the only common features.187
9q22.32q22.33 microdeletion
In a genome-wide array CGH-based screening of patients with unexplained overgrowth 
syndromes Redon et al. identified two children with nearly identical 6.5 Mb long de novo 
interstitial deletions at 9q22.32q22.33.189 Although the deletion boundaries were different 
in the two patients, they suggested that microdeletions of 9q22.32q22.33 represent a 
recognizable syndrome, as both affected individuals presented with similar clinical features, 
including psychomotor delay, hyperactivity, overgrowth, trigonocephaly, macrocephaly and 
distinctive facial features.189
15q13.3 microdeletion
Through whole-genome array CGH-based screening of 757 individuals with mental retardation 
and/or congenital anomalies Sharp et al. identified two identical de novo 1.5 Mb deletions in 
15q13.3.190 Subsequently, they screened 1,040 individuals with mental retardation of unknown 
etiology using quantitative PCR (Q-PCR) assays targeted to the 15q13.3 region. By doing so, 
they identified nine affected individuals, including six probands: two with de novo deletions, 
two who inherited the deletion from an affected parent and two with an unknown mode 
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of inheritance. The patients had mental retardation, epilepsy and variable facial and digital 
dysmorphisms in common. The proximal breakpoint of the largest deletion is contiguous with 
breakpoint 3 (BP3) of the PWS and AS region, extending 3.95 Mb distally to BP5. A smaller 
1.5 Mb deletion had a proximal breakpoint within the larger deletion (BP4) and shared the 
same distal breakpoint (BP5). This recurrent 1.5 Mb deletion encompasses six genes, including 
a candidate gene for epilepsy (CHRNA7).
15q24 microdeletion
De Vries et al. reported a 15q24 deletion identified in a boy with mental retardation121 and, 
subsequently, Sharp et al. identified another patient with a de novo microdeletion of 15q24 
among a cohort of 290 children with idiopathic mental retardation.191 After this, two more 
patients with submicroscopic deletions of this region were identified and all four individuals 
shared several clinical features, including mental retardation, growth retardation, microcepahly, 
digital abnormalities, genital abnormalities, hypospadias and loose connective tissue. In 
addition, similar facial dysmorphisms were noted, including high frontal hairline, broad 
medial eyebrows, downslanted palpebral fissures and a long philtrum, indicating that the 
15q24 deletions represent a clinical syndrome.192 A further 15q24 microdeletion case showed 
similar phenotypic features, although microcephaly and growth deficiency were absent.193 
The deletion in the patients varied from 1.7 to 3.9 Mb in size. The breakpoints were located in 
nearly identical segmental duplications, which turned NAHR into the most likely underlying 
mechanism
16p11.2p12.2 microdeletion
Ballif et al. screened the pericentromeric regions of the genome and identified recurrent de 
novo interstitial deletions of 16p11.2p12.2 in four patients.194 The common clinical features 
included distinct facial features, i.e., flat facies, downslanting palpebral fissures, low-set and 
malformed ears and eye anomalies. Other features were orofacial clefting, heart defects, 
frequent ear infections with potential hearing loss, a short stature, minor hand and foot 
anomalies, feeding difficulties, hypotonia and cognitive and developmental delays.194 The 
deletions, ranging from 7.1 to 8.7 Mb in size, shared a common distal breakpoint, but varied 
in their proximal breakpoints. The complex structure of the 16p11.2p12.2 region, including 
LCRs that flank some of the deletion breakpoints, suggest that NAHR may be the mechanism 
underlying these deletions.
17q21.31 microdeletion
Three groups simultaneously described the identification of a microdeletion syndrome 
encompassing 17q21.31. Recurrent overlapping de novo microdeletions in 17q21.31 were 
identified in patients with mental retardation using array CGH and MLPA (Chapter 3.3).191,195,196 
Clinical comparison of these patients revealed marked phenotypic similarities, i.e., mental 
retardation, hypotonia and characteristic facial features, including a long hypotonic face with 
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ptosis, large and low-set ears, a tubular or pear-shaped nose with a bulbous nasal tip, long 
columella with hypoplastic alae nasi and a broad chin (Figure 1.6c).195 The identification of 
more patients with the same aberration showed that the 17q21.31 microdeletion syndrome 
(MIM *610443) is a frequent cause of mental retardation and allowed the detailed clinical and 
molecular delineation this syndrome (Chapter 3.4).197
22q11.2 distal micodeletion
Using array CGH analysis, Ben-Shachar et al. defined a recurrent genomic disorder at 22q11.2, 
distinct from the DGS/VCFS critical region.198 They detected six de novo deletions within 
22q11.2, located distal to the approximately 3 Mb common 22q11.2 deletion region. The 
rearrangements shared clustered breakpoints and either a ~1.4 Mb or a ~2.1 Mb recurrent 
deletion flanked by LCRs. The patients presented with prematurity, prenatal and postnatal 
growth delay, developmental delay and mild skeletal abnormalities, and characteristic facial 
dysmorphic features, including arched eyebrows, deep-set eyes, a smooth philtrum, a thin 
upper lip, hypoplastic alae nasi and a small, pointed chin (Figure 1.6d). Two patients had a 
cardiovascular malformation and one patient had a cleft palate. Although there is some clinical 
overlap with DGS/VCFS, the distal chromosome 22q11.2 deletion syndrome (MIM #611867) 
represents a novel genomic disorder.
Xq28 duplication
By array CGH, van Esch et al. identified a small duplication at Xq28 in a large family with a severe 
form of mental retardation associated with progressive spasticity.199 Subsequently, Q-PCR 
analysis among patients with similar clinical features revealed three additional duplications at 
Xq28. The duplications varied in size from 0.4 to 0.8 Mb encompassing the LICAM and MECP2 
genes. No consistent flanking centromeric or telomeric breakpoints could be identified.199 
Individuals with a Xq28 duplication encompassing MECP2 frequently present with severe 
mental retardation, severe hypotonia and in the majority of patients a progressive lower-
limb spasticity and absence or very limited speech.199,200 In addition, seizures and recurrent 
severe infections are common.199,200 Loss-of-function mutations of MECP2 are associated with 
Rett syndrome (MIM #312750) in females and increased gene dosage of MECP2 is the most 
likely explanation for the severe mental retardation in patients with submicroscopic Xp28 
duplications.199
The above-mentioned syndromes emphasize the great potential of the development of 
novel technologies and show that the detection of submicroscopic CNVs might result in the 
identification of numerous novel disorders associated with mental retardation. Apart from 
these syndromes, several other novel genomic disorders have been identified, such as a 
microdeletion syndrome on 12q14, associated with osteopikilosis, short stature and mental 
retardation201 and recurrent deletions of 14q11.2.202 Moreover, reciprocal 16p13.1 duplications 
and deletions predisposing to autism and/or mental retardation have been described, similar 
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to the association between autism and microdeletion or microduplication at 16p11.2.203,204 
Additionally, recurrent interstitial CNVs in the subtelomeric region of the long arm of 
chromosome 1 have been described.205-207 The identification of these interstitial CNVs close 
to the telomere, but also e.g., the complex nature of many subtelomeric 1p36 deletions85,89,90 
illustrates that the discrimination between subtelomeric- and interstitial submicroscopic CNVs 
is in fact artificial and mainly reflects the historical context in which the respective CNVs have 
been identified. 
1.4 Outline of the thesis
At the onset of the work described in this thesis, the genetic diagnosis of mental retardation 
remained unknown in about 50% of the patients. Next to a number of gross chromosomal 
anomalies detected by conventional cytogenetic analysis, also several submicroscopic 
chromosomal anomalies (smaller than ~5-10 Mb) had already been identified in several well-
defined clinical syndromes using FISH and/or PCR-based techniques. Among these anomalies, 
subtelomeric rearrangements were found to represent an important cause of mental 
retardation. In addition, several pilot-studies indicated that also interstitial submicroscopic 
chromosome aberrations might significantly contribute to the etiology of mental retardation. 
Subsequently, genomic microarrays found their way into the clinical workup of individuals 
with mental retardation, and they further emphasized the importance of structural genomic 
variation mainly CNVs in mental retardation. The identification of these causes of mental 
retardation is of major importance for the patients and their families, as an explanation of the 
disease may provide insight in its occurrence and the clinical features associated with it. This, in 
turn, may lead to better genetic counseling within families and a better clinical management 
of the patients.
The general goal of this thesis was to obtain a better understanding of the genetic basis of 
mental retardation and congenital malformations by aiming at the following objectives:
I. Determination of the frequency of submicroscopic CNVs in mental retardation.
Using MLPA, we determined the frequency of submicroscopic CNVs at the subtelomeres 
among a cohort of individuals with unexplained mental retardation (n=210) (Chapter 2.1). In 
order to establish the frequency of interstitial CNVs in mental retardation we studied affected 
individuals (n=386) using whole-genome tiling resolution BAC arrays (Chapter 3.1). The 
frequency of CNVs associated with mental retardation was tested by MLPA analysis targeting 
to candidate regions for mental retardation among a large European patient cohort (Chapter 
3.2).
II. Identification and characterization of mental retardation syndromes.
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The identification of overlapping submicroscopic deletions and duplications in individuals 
with mental retardation and similar clinical features, allows the definition of new mental 
retardation syndromes. Implementation of subtelomeric DNA copy number analysis in the 
diagnostic workup of patients with mental retardation resulted in the recognition of several 
distinct clinical entities, such as the 22q13 microdeletion syndrome (MIM #606232). We studied 
the size and nature of 22q13 deletions using high-resolution chromosome specific array CGH 
and investigated the relationships between clinical features and deletion sizes (Chapter 2.2).
We identified three overlapping interstitial submicroscopic deletions on 17q21.31 in patients 
with unexplained mental retardation (Chapter 3.3). Clinical comparison of the patients 
revealed marked phenotypic similarities, indicating that this microdeletion underlies a clinical 
syndrome. Subsequently, we studied a cohort of individuals with the 17q21.31 microdeletion 
syndrome (n=22), allowing a delineation of the critical region (Chapter 3.4). Based on detailed 
clinical information of all deletion carriers, the clinical phenotype of the syndrome could be 
established and an estimate of the prevalence of the 17q21.31 microdeletion syndrome could 
be obtained.
In Chapter 4 the implications of this work are discussed and an outline of future avenues 
towards the detection of additional mental retardation-associated syndromes and its clinical 
diagnostic application are provided.
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Abstract
Background: Subtelomeric rearrangements contribute to idiopathic mental retardation and 
human malformations, sometimes as distinct mental retardation syndromes. However, for 
most subtelomeric defects a characteristic clinical phenotype remains to be elucidated. 
Objective: To screen for submicroscopic subtelomeric aberrations using multiplex ligation 
dependent probe amplification (MLPA).
Methods: 210 individuals with unexplained mental retardation were studied. A new set of 
subtelomeric probes, the SALSA P036 human telomere test kit, was used.
Results: A subtelomeric aberration was identified in 14 patients (6.7%) (10 deletions and four 
duplications). Five deletions were de novo; four were inherited from phenotypically normal 
parents, suggesting that these were polymorphisms. For one deletion, DNA samples of the 
parents were not available. Two de novo submicroscopic duplications were detected (dup 
5qter, dup 12pter), while the other duplications (dup 18qter and dup 22qter) were inherited 
from phenotypically similarly affected parents. All clinically relevant aberrations (de novo 
or inherited from similarly affected parents) occurred in patients with a clinical score of >3 
using an established checklist for subtelomeric rearrangements. Testing of patients with a 
clinical score of >3 increased the diagnostic yield twofold to 12.4%. Abnormalities with clinical 
relevance occurred in 6.3%, 5.1%, and 1.7% of mildly, moderately, and severely retarded 
patients, respectively, indicating that testing for subtelomeric aberrations among mildly 
retarded individuals is necessary.
Conclusions: The value of MLPA is confirmed. Subtelomeric screening can be offered to 
all mentally retarded patients, although clinical preselection increases the percentage of 
chromosomal aberrations detected. Duplications may be a more common cause of mental 
retardation than has been appreciated.
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Introduction
Chromosomal rearrangements involving subtelomeric regions are a common cause of 
idiopathic mental retardation (reviewed by Knight and Flint1 and De Vries et al..2) Subtelomeric 
rearrangements have been reported to occur in approximately 5% of patients with unexplained 
mental retardation.2 Some subtelomeric submicroscopic deletions result in well defined mental 
retardation syndromes, such as monosomy 1p36, Wolf–Hirschhorn syndrome (4p-), and cri-du-
chat syndrome (5p-), but for most subtelomeric defects a characteristic phenotype remains to be 
defined.2 For this reason, screening of all subtelomeres is a valuable diagnostic tool. Multiprobe 
FISH (fluorescence in situ hybridization), using telomeric probes on metaphase chromosomes 
is commonly used for detecting subtelomeric abnormalities.3-5 This reliable method, however, 
remains labor intensive and therefore expensive for routine diagnostic testing. New techniques, 
such as multiplex amplifiable probe hybridization (MAPH) and array based comparative genomic 
hybridization (array CGH), are proven to be suitable for the detection of subtelomeric chromosome 
aberrations.6,7 However, MAPH, requires immobilization of sample nucleic acids8 and array CGH 
is labor intensive and requires expensive equipment. Recently, multiplex ligation dependent 
probe amplification (MLPA) was applied to detect subtelomeric defects in 75 patients with mental 
retardation of unknown cause.9 In the current study MLPA was used with a new set of subtelomeric 
probes designed by Schouten et al.8 for the detection of submicroscopic aberrations in a larger 
sample of clinically well defined patients with idiopathic mental retardation. We show that MLPA 
is a reliable technique to detect submicroscopic telomeric copy number changes, rendering it 
suitable for routine diagnostic screening in mentally retarded patients.
Methods
Patients
The diagnostic capacity of MLPA for detecting subtelomeric chromosome aberrations was tested 
by screening 210 patients with unexplained mental retardation. The patients were all referred 
to the department of human genetics, University Medical Centre Nijmegen for subtelomeric 
analysis. A total of 137 patients had been evaluated by one of the clinical geneticists at our 
centre. The remaining patients were referred by other medical specialists, mainly pediatricians. 
All patients had a normal G banded karyotype at a 550 band level using standard procedures, 
and no clinical syndrome had been recognized. The level of mental retardation (mild, IQ 50 to 
70; moderate, IQ 30 to 50; severe, IQ <30) and the score on the checklist for submicroscopic 
subtelomeric rearrangements developed by de Vries et al.10,11 were obtained retrospectively 
from notes by the referring specialist. The incidence of subtelomeric aberrations was assessed 
for the level of mental retardation and for the subtelomeric aberration checklist score. In case 
of a subtelomeric aberration, DNA samples of the parents were requested for further testing. 
The MLPA kit was first validated using 15 DNA samples from patients with 16 known (sub)
microscopic defects involving the subtelomeric region. 
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Multiplex ligation dependent probe amplification
MLPA probes
A specifically designed set of probes for testing for subtelomeric chromosomal imbalances, 
SALSA P036 human telomere test kit (MRC-Holland, Amsterdam, Netherlands; http://www.
mrc-holland.com) was used for subtelomere screening. Probe preparation has been described 
previously.8 The MLPA mix contained probes for each subtelomeric region (Table 2.1.1) except 
for the short arms of the acrocentric chromosomes. For the latter, probe recognition sequences 
on the q arm, in one of the first genes following the repeated sequences of the centromere, were 
used. Because these probes were not subtelomeric, they were not included in our analysis.
MLPA analysis 
Genomic DNA of each patient was isolated using standard procedures.14 MLPA analysis was 
carried out as described by Schouten et al.,8 with slight modifications. Briefly, 200 to 400 ng 
Table 2.1.1: Subtelomeric MLPA probes and their distance to the telomere
 Salsa P036 MLPA subtelomere probes of Salsa P036 MLPA subtelomere probes of 
 the p arms the q arms
Telomere Length (nt) Gene detected Distance to Length (nt) Gene detected Distance to
   telomere (Mb)   telomere (Mb)
 1 130 CAB45  1.07 306 KIAA1720 0.20
 2 137 ACP1  0.25 314 CAPN10 1.76
 3 144 CHL1  0.34 322 BDH 0.74
 4 151 FLJ20265  0.50 330 FAT 3.41a
 5 158 PDCD6  0.37 338 MGC16175 0.24
 6 165 IRF4  0.34 346 PSMB1 0.21
 7 172 CENTA1  0.70 354 VIPR2 0.23
 8 179 FBXO25  0.40 362 KIAA0150 1.58
 9 186 DMRT1  0.84 370 MRPL41 0.71
10 194 KIAA0934  0.44 378 CYP2E1 0.22
11 202 MUC2  1.09 386 KIAA0056 0.85
12 210 SLC6A12  0.17 394 KIAA1545 0.68
13 218 PSPC1 18.14 402 F7 1.32
14 226 HEI10 18.78 410 KIAA0284 1.99
15 234 CYFIP1 20.52 418 ALDH1A3 1.07
16 242 POLR3K  0.04 426 TUBB4 0.30
17 250 RPH3AL  0.21 434 TBCD 0.32
18 258 USP14  0.19 442 FLJ21172 0.22
19 266 CDC34  0.49 450 LOC125905 0.18
20 274 SOX12  0.30 458 EEF1A2 0.89
21 282 RBM11 14.51 466 S100B 0.10
22 290 BID 16.60 474 RABL2B 0.06
X/Y 298 SHOX  0.54 482 SYBL1 0.13
The SALSA P036 human telomere test kit was used. The unique length of the amplification product of each probe 
(in nucleotide [nt]) and the gene detected are shown. The distance to the telomere for each probe recognition 
sequence was determined using the UCSC Human Genome Browser and Blat Search, July 2003 Freeze. 
a Proximal to the D4Z4 repeat associated with FSHD.12,13
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of DNA sample was diluted with milliQ to 8 ml and heated at 98˚C for five minutes (GeneAmp 
PCR System 9700, Applied Biosystems, Foster City, California, USA). After addition of the 
probe mix (1.5 ml per sample), which was mixed 1:1 with a salt solution (1.5 M KCl; 300 mM 
Tris-HCl, pH 8.5; 1 mM EDTA), samples were heated for one minute at 95˚C and incubated 
overnight at 60˚C. Next the Ligation-65 mix (following the supplier’s instructions) was added 
and incubated for 15 minutes at 54˚C. Ligase-65 was inactivated by heating at 98˚C for one 
minute. The ligation products were amplified by polymerase chain reaction (PCR) using the 
common primer set with the 6-FAM label distributed by the supplier. Amplification products 
were identified and quantified by capillary electrophoresis on an ABI 3100 genetic analyzer, 
using Genescan analysis software (version 3.7) and Genotyper software, all from Applied 
Biosystems. Subtelomeric screening of 48 samples using MLPA took approximately 1.5 days, 
including four hours of hands-on time. Each subtelomeric rearrangement was detected by at 
least one additional MLPA analysis. 
Statistical analysis/data processing 
The signal strength of the PCR products was determined by Genotyper software (Applied 
Biosystems). A spreadsheet was developed in MicrosoftTM Excel in order to process the sample 
data efficiently. First, the data were normalized by dividing each probe’s signal strength by 
the average signal strength of the sample. This normalized peak pattern was divided by the 
average peak pattern of all the samples in the same experiment. The resulting values were 
approximately 1.0 for every wild type peak, 0.5 for heterozygous deletions, and 1.5 for 
heterozygous duplications. As a quality check for the probes, we computed the coefficient of 
variation (cv) of the normalized signal strength over the controls. If a particular probe had a cv 
of more than 10% over all samples tested, the results of the analysis for that particular probe 
were discarded. However, this was never the case with the Salsa P036 probe set. The analysis 
for a particular sample was repeated if the cv over all probes was more than 15% (~18% of 
all tests). Twenty control samples (40 alleles) were run to exclude the presence of common 
polymorphisms and to test the feasibility of the statistical analysis. 
Confirmation experiments 
FISH analysis using first and second generation sets of telomere specific clones5,15 and 
Vysis probes (Vysis, Downes Grove, Illinois, USA) was carried out to confirm the aberrations 
identified by MLPA. Copy number changes were checked for de novo occurrence by MLPA 
and FISH analyses in both parents. In case the aberration could not be detected by FISH, DNA 
samples from the parents were only tested by MLPA. FISH analyses were done using routine 
methods. Fixed chromosome suspensions were prepared from cultured peripheral blood 
lymphocytes obtained from patients and parents. Labeling of the probes, slide preparation, 
and hybridization were carried out using a standard protocol. A Leica DMRA fluorescence 
microscope, equipped with appropriate filters, was used for visual examination of the slides. 
The images were captured by a cooled CCD camera (SenSys) coupled to a Leica computer and 
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analyzed by a CW4000 software package. Inverted DAPI staining and a chromosome specific 
centromere probe were used for chromosome identification. 
Results
In this study MLPA was used to detect subtelomeric aberrations in a group of 210 patients with 
unexplained mental retardation. An improved set of subtelomeric probes—the SALSA P036 
human telomere test kit—was applied. The sensitivity of the probe set was first determined by 
testing DNA samples from patients with a known chromosomal defect. These known defects 
were either cytogenetically visible or detected by FISH. Positive controls were available for 
1pter, 1qter, 2qter, 3pter, 4pter, 7pter, 9pter, 10qter, 16qter, 18qter, 19qter, 22qter, and for 
the probes in the pseudoautosomal regions of Xpter, Ypter, Xqter, and Yqter. In all cases the 
genomic defect was confirmed by MLPA (data not shown). 
The initial subtelomeric screening in patients with idiopathic mental retardation showed a 
subtelomeric rearrangement in 19 patients. Remarkably, a duplication of the 10qter MLPA 
probe was detected in five patients. These duplications could not be confirmed by FISH analysis. 
Parental analysis of two of the cases by the same technique revealed an identical duplication in a 
phenotypically normal father and mother in different families. In addition, the patients showed 
no clinical resemblance. For these reasons the 10qter duplication was considered most likely to 
be a polymorphism and was therefore not included in further analyses. Thus 14 patients (6.7%) 
with a subtelomeric rearrangement remained: 10 deletions and four duplications. Four MLPA 
profiles of subtelomeric aberrations are shown in Figure 2.1.1. Five deletions were de novo (1p 
(twice), 3q, 4p, 10q) and all could be confirmed by FISH. Four deletions (2p, 11p, 12p, 16q) were 
also present in phenotypically normal parents and these deletions could not be confirmed 
by FISH. In case 10 with a 22qter deletion, the parents were not available for testing. Two de 
novo subtelomeric duplications (5q, 12p) were detected. The other duplications identified by 
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Figure 2.1.1: Detection of subtelomeric 
aberrations by multiplex ligation de-
pendent probe amplification (MLPA). In 
each figure the profile of the patient is 
shown in line 1. The profiles of the father 
and mother are depicted in lines 2 and 3, 
respectively. The rectangle indicates the 
position of the aberrant MLPA probe. (a) 
De novo 1pter deletion (case 1). (b) Ma-
ternal inherited 11pter deletion (case 7). 
(c) De novo 12pter duplication (case 12). 
(d) 18qter duplication inherited from the 
mother (case 13).
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MLPA (18q, 22q) were inherited from phenotypically similarly affected parents. For the 22qter 
duplication, FISH analysis showed that this was the result of a submicroscopic unbalanced 
translocation (t(21;22)), whereas the other direct duplications identified by MLPA could not be 
confirmed by FISH. Table 2.1.2 shows overviews of the respective submicroscopic deletions 
and duplications identified by MLPA.
Table 2.1.2: Submicroscopic deletions and duplications identified by multiplex ligation dependent 
probe amplification (MLPA)
Case MLPA result FISH confirmation Parents Clinical featuresa Scoreb
Submicroscopic  deletions
1 del 1pter Yes de novo Moderate MR; facial dysmorphisms;  6
    ventricular septal defect;
    hearing loss
2 del 1pter Yes de novo Severe MR; facial dysmorphisms ;  3
    vesico-ureteric reflux; urachus cyst
3 del 3qter Yes de novo Mild MR; scaphocephaly; facial  4
    dysmorphisms; pectus carinatum
4 del 4pter Yes de novo Moderate MR; short stature;  4
    microcephaly; plagiocephaly; facial
    dysmorphisms; hydronephrosis;  
    hypospadias
5 del 10qter Yes de novo Mild MR; facial dysmorphisms; 5 
    vesico-ureteric reflux; hearing loss
6 del 2pter No Inherited  Moderate MR; behavior problems; 4
   Paternal microcephaly; facial dysmorphisms
7 del 11pter No Inherited  Moderate MR; brachycephaly; facial 2
   Maternal dysmorphisms
8 del 12pter No Inherited  Severe MR; hypotonia; 4
   Paternal microcephaly; holoprosencephaly; 
    corpus callosum dysgenesis
9 del 16qter No Inherited  Moderate MR; facial dysmorphisms 3
   Paternal
10 del 22qter Yes Not  Severe MR ; no clinical information
   available available
Submicroscopic  duplications
11 dup 5qterc No de novo Mild MR; facial dysmorphisms;  3
    hearing loss; epilepsy;
    brachycephaly; hydrocephalus
12 dup 12pterc No de novo Moderate MR; short stature; facial  6
    dysmorphisms; hypermobility;
    pectus excavatum
13 dup 18qterc No Inherited  Mild MR; short stature 3
   Maternal 
14 dup 22qter Yes, der(21) Inherited 
  t(21;22) Paternald Moderate MR; short stature; facial  3
    dysmorphisms; seizures; behavior 
    disorders; micro- and trigonocephaly
a For more details, see results section.
b Subtelomeric clinical checklist score.10
c Submicroscopic aberration not reported before.
d Inherited from phenotypically similarly affected parents.
FISH, fluorescence in situ hybridization; MLPA, multiplex ligation dependent probe amplification; MR, mental 
retardation.
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The degree of mental retardation in the study group was mild in 31% of the cases (63/201), 
moderate in 39% (78/ 201), and severe in 30% (60/ 201). In nine cases the level of mental 
retardation was unspecified. Clinically relevant aberrations (de novo or inherited from a 
phenotypically similarly affected parent) occurred in 6.3%, 5.1%, and 1.7% of the mildly, 
moderately, and severely retarded patients, respectively. Figure 2.1.2 shows the clinical 
score on the checklist for subtelomeric rearrangements reported by de Vries et al.10 and the 
subtelomeric anomalies per group. All aberrations with clinical relevance were identified in 
patients with a clinical score of >3. Clinical information was insufficient for determining a 
score in 10 cases. A brief clinical description of the cases in which a chromosomal imbalance 
was identified is given below. If any phenotypic or chromosomal abnormality was present in 
either parent, this is included in the case description. For case 10 (del 22qter), a 14 year old 
boy, additional clinical features were not available, nor were the parents available for further 
testing. 
De novo submicroscopic subtelomeric deletions identified by MLPA 
Case 1 (del 1pter) was a moderately mentally retarded 18 month old girl (born at 40 weeks’ 
gestation; birth weight 3,060 g, 15th centile). She presented with psychomotor delay and 
growth failure. She had a perimembranous ventricular septal defect, hearing loss, and several 
dysmorphic features including a large anterior fontanelle, prominent broad forehead, flat 
midface, deep set eyes, strabismus, downslant of the palpebral fissures, slight hypertelorism, 
small low set posteriorly rotated ears, small nose, and flat nasal bridge. In addition she had a 
flat palate with wide alveolar ridges, downturned corners of the mouth, pointed chin, a short 
neck, and small broad hands with abnormal implant of the thumbs. At the age of 11.5 months 
her height was 70 cm (5th centile) and her occipitofrontal head circumference (OFC) was 44.5 
cm (16th centile). 
Case 2 (del 1pter) was a severely mentally retarded five year old girl (born at 37 weeks’ gestation; 
birth weight 2,765 g, 30th centile) who presented with delayed psychomotor development. 
Her dysmorphic features included almond shaped eyes, upward slant of the palpebral fissures, 
flat nasal bridge, bifid uvula, a small U shaped curve in the hard palate, bilateral epicanthic 
folds, downturned corners of the mouth, mild retrognathia, and a short perineum. She also 
had a urachus cyst which was corrected surgically and vesicoureteric reflux for which she was 
treated with prophylactic antibiotics. At four years and three months her height was 109.5 cm 
(75th centile), her weight was 28.6 kg (+4 SD), and her OFC was 49.9 cm (50th centile). 
Case 3 (del 3qter) was a mildly mentally retarded six year old girl (born at 40 weeks’ gestation; 
birth weight 2,930 g, 10th centile). She presented with hearing loss and psychomotor delay. She 
had scaphocephaly. Computed tomography of the cerebrum revealed a normal brain structure. 
At six years and two months her height was 1.17 cm (30th centile) and her OFC was 51 cm 
(50th centile). Besides the scaphocephaly, other dysmorphic features included frontal bossing, 
slightly downslanting palpebral fissures, low set posteriorly rotated ears, broad nostrils, smooth 
philtrum, everted lower lip, high palate, pectus carinatum, clinodactyly of the fifth fingers, long 
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tapering fingers, and clinodactyly of toes three to five. Case 4 (del 4pter) was a moderately 
mentally retarded five year old boy (born at 37+6 weeks’ gestation; birth weight 2,105 g, -2.5 
SD) who presented with psychomotor delay, growth failure, and severe feeding difficulties 
which required percutaneous endoscopic gastrostomy. He had unilateral hydronephrosis, 
astigmatism, and exotropia of the left eye. At the age of four years and 10 months his height was 
97 cm (-3 SD) and his OFC was 46.2 cm (-3 SD). Dysmorphic features included plagiocephaly, 
frontal bossing, proptosis, epicanthus, hypertelorism, prominent glabella, wide nasal bridge, 
short philtrum, high palate, short neck, and hypospadias. In retrospect, the Wolf–Hirschhorn 
Figure 2.1.2: Distribution of subtelomeric aberrations using the subtelomeric clinical checklist score developed 
by de Vries et al.10
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syndrome was the likely clinical diagnosis, although his psychomotor development was better 
than in previously reported cases and epilepsy was not present. 
Case 5 (del 10qter) was a mildly mentally retarded two year old girl (born at 40+ weeks’ 
gestation; birth weight 2,335 g, -2.5 SD). Delay in psychomotor development was noticed. At 
the age of 15 months her height was 70 cm (-3 SD) and her OFC was 44.5 cm (10th centile). 
Dysmorphic features included bilateral epicanthic folds, strabismus convergens (which was 
surgically corrected), posteriorly rotated left ear, and a small right ear with prominent helix. 
She underwent unilateral ureteric reimplantation because of left sided grade IV vesico-ureteric 
reflux with decreased function of the kidney. In addition she had a mild conductive hearing 
loss (40 dB) of the right ear. 
Familial submicroscopic subtelomeric deletions identified by MLPA 
Case 6 (del 2pter) was a moderately mentally retarded six year old boy (born at 40 weeks’ 
gestation; birth weight 3,220 g, 20th centile). He presented with mild developmental delay, 
hyperactivity, and aggressive behavior. Dysmorphic features included microcephaly, midface 
hypoplasia, bilateral epicanthic folds, small nose, smooth philtrum with a thin upper lip, short 
fifth fingers, and camptodactyly of the third left toe. Because of severe prenatal maternal 
alcohol abuse, fetal alcohol syndrome was suggested. At the age of five years and 10 months 
his height was 123 cm (85th centile) and his OFC was 48.5 cm (2nd centile). 
Case 7 (del 11pter) was a moderately mentally retarded two year old girl born at full term (birth 
weight 2,940 g, 30th centile). She presented with psychomotor delay and feeding difficulties. 
She had a triangular face, brachycephaly, deep set eyes, strabismus alternans, slight upslanting 
of the palpebral fissures, straight eyebrows, dysplastic helices, clinodactyly of the fifth digits of 
the hands, and hypoplastic nails of the second toes. 
Case 8 (del 12pter) was a severely mentally retarded 10 month old boy (born at 35+6 weeks’ 
gestation; birth weight 2,835 g, 50th centile). He was kept in hospital after delivery because 
of respiratory insufficiency and maternal fever during labor. He had microcephaly (-2.5 SD) 
and generalized hypotonia. Magnetic resonance imaging (MRI) of the cerebrum revealed 
semilobar holoprosencephaly with fusion of the frontal lobes and corpus callosum dysgenesis. 
Apart from a high palate no dysmorphic features were noted. 
Case 9 (del 16qter) was a moderately mentally retarded nine year old boy born a term 
(birth weight 3,800 g, 75th centile). He presented with psychomotor retardation with 
prominent speech delay. He had a triangular face, broad forehead, flat midface, slightly 
upslanting palpebral fissures, telecanthus, broad nasal bridge, large posteriorly rotated ears, 
and a prominent chin. He was admitted once to hospital because of haematuria of unknown 
cause. At nine years and two months his height was 132 cm (10th centile) and his OFC was 55 
cm (86th centile). 
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De novo submicroscopic subtelomeric duplications identified by MLPA 
Case 11 (dup 5qter) was a mildly mentally retarded three year old girl (41+4 weeks’ gestation) 
with bilateral mixed hearing loss (60 dB), epilepsy, a left sided choroidal defect, and a lateral 
neck fistula/dimple at the lower jaw. Psychomotor development was delayed, with initial 
walking at 26 months. MRI of the cerebrum showed enlargement of the intra- and extracerebral 
spaces. At the age of two years and 11 months her height was 95 cm (50th centile) and her 
OFC was 51 cm (85th centile). Dysmorphic features included brachycephaly, frontal bossing, 
midfacial dysplasia, narrow palate, small nose, small mouth, slight retrognathia, and small 
posteriorly rotated ears. Case 12 (dup 12pter) was a moderately mentally retarded 12 year old 
girl (born at 37+4 weeks’ gestation; birth weight 2,580 g, 30th centile) who presented with 
growth failure and hypermobility of the joints. She had feeding difficulties and constipation. 
At 12 years and four months of age her height was 141 cm (-2.5 SD) and her OFC was 51 cm 
(3rd centile). Dysmorphic features included high broad forehead, upslanting palpebral fissures, 
telecanthus, broad nasal bridge, short philtrum with a smooth upper lip, small maxilla, high 
palate, hypermobility of the wrists and the finger joints, and thin slightly hyperelastic skin. 
She had broad fingertips and bilateral clinodactyly of the fifth finger. In addition she had mild 
pectus excavatum and a strikingly furrowed tongue.
Familial submicroscopic subtelomeric duplications identified by MLPA
Case 13 (dup 18qter) was a mildly mentally retarded eight year old boy (39+5 weeks’ gestation; 
birth weight 2,500 g, -2.5 SD). He was referred because of growth failure and mild mental 
retardation. At 7.5 years his height was 112.7 cm (-3.5 SD). Microcephaly was noted, with an 
OFC of 48 cm (-2.5 SD). His mother had a similar 18qter duplication and she had attended 
a special school for learning difficulties. Her adult height was 153 cm (-2.5 SD) with striking 
microcephaly (-4 SD). 
Case 14 (dup 22qter) was a moderately mentally retarded five year old boy, born at term (birth 
weight 2,330 g, 3rd centile) to unrelated parents. The first year of life was complicated by 
feeding problems, failure to thrive and frequent attacks of syncope. He presented at two years 
with delayed psychomotor development, seizures, hyperactivity, and dysmorphic features, 
including micro- and trigonocephaly, deep set eyes, flat midface, depressed nasal bridge, 
prominent upper lip, and downturned corners of the mouth. At the age of three years and 11 
months his height and OFC were 93 cm (-3 SD) and 45.5 cm (-3.5 SD), respectively. MRI of the 
brain revealed post-haemorrhagic ventricular dilatation. Analysis of the father, who had similar 
clinical features (microcephaly, sparse hair, hypertelorism, and prominent upper lip), showed 
the same unbalanced submicroscopic translocation, der(21)t(21;22)(p10;q13.3), as was present 
in the boy. 
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Discussion
In this study we present the results of the subtelomeric screening by MLPA in a group ofs 210 
patients with unexplained mental retardation. A duplication of 10qter was identified in five of 
these patients on initial testing. This aberration was also present in two phenotypically normal 
parents and was regarded as a polymorphism and excluded from further analyses. Apart 
from the 10qter duplication, aberrations were identified in 6.7% of the patients screened: 10 
deletions and four duplications. Clinically relevant submicroscopic aberrations were identified 
in nine patients (4.3%): seven de novo aberrations (five deletions and two duplications) and 
two duplications inherited from similarly affected parents. In the group of patients with mild, 
moderate, and severe mental retardation, clinically relevant anomalies occurred in 6.3%, 5.1%, 
and 1.7% of the cases, respectively. 
It is of note that the greatest frequency of abnormalities was detected among mildly mentally 
retarded patients, in contrast to previous findings by Knight et al., who reported abnormalities 
in 7.4% among moderately or severely retarded individuals, and only in 0.5% among mildly 
retarded individuals.4 This might be explained by the increased detection of smaller aberrations 
and by the identification of submicroscopic duplications that cause less severe phenotypes in 
general. Our data support testing for subtelomeric aberrations in individuals with mild mental 
retardation. 
In addition, rearrangements with clinical relevance were all found in patients with a clinical 
score of O3 using the checklist for subtelomeric rearrangements composed by de Vries et al.10 
This 0–10 checklist was developed to help preselection of cases for subtelomeric testing and 
consists of five items: family history of mental retardation, prenatal onset of growth retardation, 
postnatal growth abnormalities, two or more facial dysmorphic features, and one or more non-
facial dysmorphic features or congenital abnormalities. Testing of patients with a clinical score 
of >3 increased the diagnostic yield twofold to 12.4% (12/97). 
The results of the current study show that clinical preselection of cases for subtelomeric 
screening is beneficial. The frequency of abnormalities in this study is comparable to previous 
studies, in which subtelomeric defects were identified in approximately 5% of the patients,2,16 
although direct telomeric duplications were not included in the previous studies. A novel 
finding in our study is that subtelomeric direct duplications are a relatively frequent cause of 
isolated as well as familial mental retardation. Previous studies using FISH strategies were largely 
insensitive to such duplications, except those associated with an unbalanced translocation. We 
believe that subtelomeric direct duplications may have been underdiagnosed. We identified 
five de novo submicroscopic subtelomeric deletions in this study. Del 1pter (case 1–2), del 4pter 
(case 4), and del 10qter (case 5) have often been reported before and resembled the previous 
reports.2 The patient with a de novo 3qter deletion (case 3) had scaphocephaly, which was 
also seen in her mother (OFC 60 cm; +2.5 SD), grandfather, two of uncles, and a cousin. A de 
novo submicroscopic 3qter deletion has only been reported once.17 In microscopically visible 
terminal deletions of 3q, similar abnormal skull shapes (dolichocephaly and trichonocephaly) 
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have also been reported.18 However, the abnormal skull shape seemed to be familial and 
therefore not to be related to the de novo 3qter deletion in our case. 
Two de novo submicroscopic subtelomeric duplications were identified. The three year old 
mildly mentally retarded girl with a duplication 5qter (case 11) had to our knowledge the first 
reported submicroscopic duplication of this region. In addition to facial dysmorphisms, she 
had hearing loss and epilepsy. Patients with microscopically visible 5qter duplications and 
unbalanced 5qter duplications with additional deletions of other chromosome ends have 
been described.19,20 In addition to mental retardation, growth retardation, seizures, and some 
overlapping facial characteristics were present, making it likely to be a pathogenic cause in 
this patient. The 12pter duplication is also the first submicroscopic duplication of this region 
to be reported. Some of the dysmorphisms found in microscopically visible cases of 12pter 
duplications21 could also be observed in our case. 
Four subtelomeric deletions were inherited from phenotypically normal parents. The 
phenotypes described in these cases—del 2pter (case 6), del 11pter (case 7), del 12pter (case 
8), and del 16qter (case 9)—were quite different from previously reported cases with deletions 
in a similar region.17,22-25 Therefore it is likely that these aberrations are polymorphisms without 
clinical implications. 
Both familial duplications detected in this study were inherited from similarly affected parents. 
In case 13, a maternal duplication of probe 18qter was identified in a mildly retarded boy 
presenting with growth failure, and the same features were observed in his mother. She 
was microcephalic (-4 SD) and had a height of -2.5 SD and learning difficulties. Intrauterine 
growth retardation and microcephaly have been reported in microscopically visible 18qter 
duplications,26 strengthening the impression that the duplication in the 18qter chromosomal 
segment caused the phenotype in our patient. The duplication in our patient was significantly 
smaller than those previously reported, which might explain the milder phenotype in our case. 
In case 14, MLPA analysis showed a duplication of the 22qter probe. FISH analysis confirmed 
the duplication and revealed an unbalanced submicroscopic translocation—der(21)t(21;22) 
(p10;q13.3)—in the proband and his father. The father was mildly mentally retarded and 
showed similar minor facial anomalies. Duplications including the telomere region of the long 
arm of chromosome 22 have been described, with some clinical resemblance to the proband, 
such as intrauterine growth retardation, microcephaly, and hypertelorism.26 
All de novo deletions could be confirmed by FISH analysis. However, the inherited deletions 
(del 2pter, del 11pter, del 12pter, and del 16qter) could not be confirmed. The MLPA probes 
were positioned in or close to (~50 kb) the telomere specific FISH clones of the same telomere, 
except for the 11pter MLPA probe which was mapped more to the centromere (UCSC Genome 
Browser, July 2003 Freeze).5 It is most likely that these familial aberrations represent small 
genomic polymorphisms missed by a FISH probe encompassing the same region. Three 
duplications (dup 5qter, dup 12pter, and dup 18qter) could not be confirmed by FISH. The 
duplicated regions were probably too close together on the genome to be detectable by 
routine FISH. In the current study a single new set of subtelomeric probes was used—the 
opmaak koolen.indd   59 10-09-2008   10:11:53
60
Chapter 2
SALSA P036 human telomere test kit. In general the MLPA probes were either located in the 
region covered by the telomere specific FISH clone or were closely proximal to this region. For 
the latter probes, it is possible that terminal aberrations detectable by FISH may be missed 
by MLPA. In a recent paper, a group of 75 mentally retarded patients was analyzed using two 
complementary MLPA probe sets, SALSA P019 and P020.9 When validating these probe sets on 
our panel with known chromosomal aberrations, we found that several probes in the P019 and 
P020 kit were too far from the telomere to detect small terminal deletions. The main problem 
is that the probe on 1p missed small deletions that are relatively common.27 Furthermore, in 
addition to the probe on 21q,9 the probes for 2q, 6p, and 15q in the P019 and P020 kit were 
polymorphic (data not shown). Thus the P036 kit not only has the advantage that only one kit is 
needed for all subtelomeric regions, but the individual probes in this kit are also more reliable. 
A fusion of the three kits with additional subtelomeric probes might eventually offer the best 
solution for routine diagnostic screening of subtelomeric aberrations, because it will allow 
more accurate identification and delineation of the subtelomeric copy number changes. 
Conclusions 
We have confirmed that MLPA is a reliable method for detecting subtelomeric rearrangements. 
Screening for subtelomeric anomalies by MLPA can be offered to all mentally retarded 
patients, although clinical preselection increases the percentage of anomalies detected. To 
exclude polymorphisms, interpretation of the results should always include parental testing 
and comparison with clinical features of previously reported patients with similar subtelomeric 
rearrangements. In addition, we found that MLPA detects pure subtelomeric duplications that 
can easily be missed by routine FISH analysis. 
Note added in proof 
The duplication 5qter in case 11 could not be confirmed by later MLPA testing when repeated 
on a new DNA sample and therefore we cannot exclude the possibility that the duplication was 
the result of a technical artefact. Since the acceptance of this paper, we have found several other 
duplications in the same subtelomeric region—for example on 15qter and 9pter—confirming 
that duplications may be more common than previously thought. 
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Abstract
The 22q13 deletion syndrome is associated with global developmental delay, absent or delayed 
speech, and generalized hypotonia. In this study, the size and nature of 22q13 deletions (n=9) 
were studied in detail by high-resolution chromosome specific array-based comparative 
genomic hybridization (array CGH). The deletion sizes varied considerably between the 
different patients, that is, the largest deletion spanning 8.4 Mb with the breakpoint mapping to 
22q13.2 and the smallest deletion spanning 3.3 Mb with the breakpoint mapping to 22q13.31. 
In one case, a unique subtelomeric 3.9 Mb deletion associated with a 2.0 Mb duplication 
of 22q13 was observed, adding to a growing number of similar cases identified for other 
chromosome ends. Remarkably, this patient had signs suggestive of retinitis pigmentosa, 
which has never been reported before in the 22q13 deletion syndrome. The identification of 
two pairs of recurrent proximal breakpoints on 22q13 suggests that these specific regions may 
be prone to recombination, due to yet unknown genome architectural features. In addition 
to the copy number changes on 22q13, a duplication of ~330 kb on 22q11.1 was observed 
and shown to be a genetic large-scale copy number variation without clinical consequences. 
The current study failed to reveal relationships between the clinical features and the deletion 
sizes. Global developmental delay and absent or severely delayed speech were observed in 
all patients, whereas hypotonia was present in 89% of the cases (8/9). This study underscores 
the utility of array CGH for characterizing the size and nature of subtelomeric deletions, such 
as monosomy 22q13, and underlines the considerable variability in deletion size in the 22q13 
deletion syndrome regardless of the clinical phenotype.
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Introduction
Subtelomeric deletions are a common cause of mental retardation.1,2 In recent years, screening 
of subtelomeres for copy number changes in mentally retarded patients has resulted in the 
recognition of new distinct clinical entities, based on monosomy 1q, 2q, 9q, 14q, and 22q 
(reviewed in Vries et al.1) The latter entity is also referred to as the 22q13 deletion syndrome, 
of which to date at least 100 cases have been reported.3–6 Common features associated with 
this syndrome are mild-to-severe global developmental delay, absent or delayed speech, 
generalized hypotonia, and minor anomalies including dolichocephaly, ptosis, abnormal ears, 
relatively large hands, and dysplastic toenails.5 
Here we describe a series of nine patients with monosomy 22q13 in which the size and the 
nature of the chromosome 22 deletions were studied in detail by high-resolution chromosome-
specific array-based comparative genomic hybridization (array CGH).7 
Materials and methods
Patients and DNA samples
In total, nine patients with subtelomeric deletions of 22q13 were included in this study. Three 
cases were previously published (case 2,8 case 79 and case 910). DNA samples of the patients 
were derived from different clinical centers in France, Ireland, the United Kingdom, and the 
Netherlands (Nijmegen). Clinical information on the patients was obtained from the referring 
physician. DNA samples of all patients were analyzed using array CGH. In one patient (case 
3), the 22qter deletion was initially identified by routine chromosome analysis at a 550-band 
level and confirmed by fluorescence in situ hybridization (FISH) [46, XY, del(22)(q13.2).ish 
del(22)(TUPLE+, ARSA-)]. Another deletion (case 4) resulted from a de novo translocation [46, 
XY, der(22)t(14;22)(q32.33;q13.31)pat. ish der(22)(N85A3-)], whereas the remaining cases were 
initially identified by FISH, using the following probes: N85A3 (cases 1–2, 5), ARSA (cases 6–8), 
D22S163 (case 8), or STS WI-941 and D22S39 (case 9).  
Array-based comparative genomic hybridization 
High-resolution chromosome 22 array CGH was performed. The microarray consisted of 350 
positionally selected chromosome 22 BAC clones (BACPAC Resources), together with 1532 
control clones located on other chromosomes. The chromosome 22-specific clones covered 
the long arm of chromosome 22 (35.1 Mb) with an average spacing of one clone per 100 kb. 
However, the actual resolution may be less in repeat dense regions. The average clone-insert 
size was 168 kb, resulting in a 1.7-fold coverage of the long arm of chromosome 22. DOP-
PCR products of the BAC clones were spotted in six-fold onto CMT-GAPS-coated glass slides 
(Ultragaps, Corning) using an OmniGrid 100 arrayer (Genomic Solutions). All steps in the 
labeling, hybridization, and data-analysis procedure were performed as described previously.11 
In brief, equal amounts of patient and reference genomic DNAs were labeled by random 
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priming with Cy3-dUTP or Cy5-dUTP (Amersham Biosciences). Labeled test- and reference 
DNAs were mixed with Cot-1 DNA (Roche), co precipitated and resuspended in a hybridization 
solution. After denaturation of probe and target DNA, hybridization and post-hybridization 
washing procedures were performed using a GeneTac Hybridization Station (Genomic 
Solutions), according to the instructions of the manufacturer. Fluorescence intensity images 
were acquired using an Affymetrix 428 scanner (Affymetrix), and analyzed by Genepix Pro 5.1 
(Axon Instruments).  
Statistical data analysis
Data normalization was performed by applying Lowess curve fitting with a smoothing factor 
of 0.3 as described by Vissers et al.11 Copy number alterations were identified by using a Hidden 
Markov Model algorithm. Three hidden states represent normal, loss, and gain conditions. The 
probability to observe a log ratio given its hidden state is modeled by a Gaussian with SD 
0.25 and mean 0, -0.4 and 0.4, respectively. The hidden state of adjacent clones is correlated 
with respect to their distance. The thresholded marginal probability of a clone’s hidden state 
determines if it is normal, a loss or gain. In order to discriminate between causative aberrations 
and large-scale copy number variations (LCV) we used a data set of 72 normal individuals. The 
control population was tested by a genome-wide 32,477 clone BAC array which included the 
same clones as used for the chromosome 22 array.
Results
Seven patients with a submicroscopic 22qter deletion, one patient with an unbalanced 
translocation and one patient with a microscopically visible 22qter deletion were studied. In 
Table 2.2.1, the main characteristics of the patients are summarized. In addition, minor facial 
dysmorphisms were noted (Figure 2.2.1). High-resolution chromosome 22-specific array CGH 
confirmed the known copy number changes in all cases and delineated the specific aberrations 
in detail. Figure 2.2.2 shows two examples of chromosome 22 array CGH profiles. All deletions 
analyzed included the most telomeric clones. Interstitial deletions in the subtelomeric region 
of the long arm of chromosome 22 were not observed. The deletion sizes identified in this 
study varied considerably between the different patients, that is, the largest deletion spanning 
8.4 Mb with breakpoint mapping to 22q13.2qter (68 clones, case 1) and the smallest deletion 
spanning 3.3 Mb with breakpoints mapping to 22q13.31qter (27 clones, case 9) (Figure 2.2.3). 
Identical proximal breakpoints were localized in cases 2 and 3 (between RP11-786O06 and 
RP11-236I15) and cases 5 and 6 (between RP11-766K21 and RP11-49A20), resulting in deletion 
sizes of 7.7 and 5.9 Mb, respectively. In case 3, a del(22)(q13.2qter) was originally identified 
by routine chromosome analysis. Array CGH analysis confirmed the karyotypic analysis and 
established the deletion size to 7.7 Mb. Case 4 carried a translocation between chromosomes 
14 and 22 [46,XY,der(22)t(14;22)(q32.33;q13.31)]. Array CGH analysis revealed a 6.6 Mb deletion 
at 22q13.31qter. In case 7, a deletion of 5.0 Mb was identified, whereas in case 8 the deletion 
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spanned 3.9 Mb. The latter 22q13 deletion was associated with a duplication of 2.0 Mb, 
including 13 clones adjacent to the deleted region (Figure 2.2.2b). 
In addition to these subtelomeric copy number alterations, a duplication of ~330 kb on 22q11.1 
was detected in the same patient. Duplications in the same region next to the centromere 
were identified in two other cases in this series (cases 4 and 7). In the control panel of 72 normal 
Table 2.2.1: Main characteristics of 22q13 deletion cases presented in this study
Patients 1 28 3 4a 5 6 79 8 910
Deletion size (Mb) 8.4 7.7 7.7 6.6 5.9 5.9 5.0 3.9 3.3
Duplication size (Mb) – – – – – – – 2.0 –
Clinical characteristics
 Sex F M M M F F M F F
 Global developmental delay + + + + + + + + +
 Normal to accelerated growth + + + + + + + – +
 Absent/severely delayed speech + + + + + + + + +
 Hypotonia + + + + + + + – +
 Chewing behavior + – – – – – + – –
 Dolichocepahaly – – – – – – – – –
 Ptosis – – – – – – – – –
 Prominent/dysplastic ears + + + + + + + + –
 Prominent/pointed chin + – – + + + + - –
 Relatively large, fleshy hands + – – – + + + + –
 Abnormal toenail growth + + + – + – + – –
F, female; M, male; +, feature present; -, feature absent.
a 46,XY,der(22)t(14;22).
Figure 2.2.1: Patients with 22q13 deletion syndrome. Note the known facial features of the 22q13 deletion 
syndrome, prominent dysplastic ears (visible in cases 1, 2, 4 and 5), and a prominent/ pointed chin (cases 1 and 
4– 7). For color figure see page 192.
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individuals tested by a tiling resolution genome-wide BAC array, copy number gain of the same 
region was observed in five individuals, whereas loss of the chromosomal segment was seen in 
21 controls (de Vries, submitted). 
Discussion
For detailed analyses of patients with known 22q13 deletions, a tiling resolution array was 
constructed with a 1.7-fold coverage of the long arm of chromosome 22. Buckley et al.12 
demonstrated the utility of such a comprehensive chromosome 22 array by profiling acral 
melanoma, dermatofibrosarcoma, DiGeorge syndrome, and neurofibromatosis 2. The 
chromosome 22 tiling resolution array had an average clone spacing of 100 kb, resulting in 
a resolution that is 30 times higher than high-resolution karyotyping. The array did not cover 
Figure 2.2.2: Examples of chromosome- 22 profiles obtained by array CGH. Arrays contained 350 cloned chro-
mosome- 22 genomic DNA targets (indicated by small circles representing the mean log2-transformed and 
Lowess-normalized T/R intensity ratios), ordered from q11.1 to qter on the basis of physical mapping positions 
obtained from the May 2004 freeze of the UCSC Genome Browser. The centromere is indicated by a hatched 
area. (a), case 1: del(22)(q13.2); (b), case 8: del(22)(q13.31). Note the duplication of 2.0 Mb on 22q13.31 and the 
duplication on 22q11.1. 
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the most telomeric 635 kb of the chromosome, which includes the gene SHANK3/ProSAP2. 
Haploinsufficiency of this gene has been proposed to be responsible for the major neurological 
features of the 22q13 deletion syndrome.6,13,14 However, FISH analysis using subtelomeric 
clones, confirmed the extension of all deletions found till the subtelomeric region. 
In the present study, a considerable difference in deletion sizes was noted, which is in accordance 
with the results of Luciani et al.3 which showed an extremely variable 22qter deletion size, 
extending from 160 kb to 9 Mb. Interestingly, a complex chromosome 22 rearrangement 
was observed in case 8, with a unique combination of a deletion and a duplication of 
22q13. The detection of the deletion-duplication in this patient adds to a growing number 
of similar cases identified for other chromosomes, including deletion-duplications in 1p, 2q, 
4p, and 8p.15–18 Giglio et al. demonstrated that the formation of the inverted duplications of 
8p associated with a terminal deletion is caused by nonallelic homologous recombination 
(NAHR) between two olfactory receptor-gene clusters.19 In addition, Ballif et al. described two 
terminal deletions of 1p36 associated with cryptic interrupted inverted duplications.18 This 
type of chromosome rearrangement may be more common than previously thought. The 
detection of cryptic duplication associated with terminal deletions is greatly improved by high-
resolution copy number screening using array CGH. Further studies are needed to determine 
the mechanisms underlying these rearrangements. Ballif et al.18 proposed a premeiotic 
model in which a terminally deleted chromosome is generated in the germ line and passes 
through at least one breakage–fusion–bridge cycle in which uncapped sister chromatids are 
fused by nonhomologous end joining (NHEJ), resulting in gametes with terminal deletions 
associated with cryptic interrupted inverted duplications. The identification of recurrent 
proximal breakpoints in cases 2 and 3 (between RP11- 786O06 and RP11-236I15) and cases 5 
and 6 (between RP11-564B15 and RP11-673D06), suggests that these regions may be prone to 
recombination, due to the presence of yet unknown genome architectural features. Segmental 
duplications were present at or close to the recurrent breakpoints and also to the other, non-
recurrent breakpoints in our series. To a large extent, chromosome rearrangement breakpoints 
are located in intervals containing complex genomic architecture, such as AT-rich palindromes 
or low copy repeats (LCRs).20 Through the process of NAHR, LCRs can lead to translocations, 
inversions, duplications and interstitial deletions.21 However, the mechanisms for generating 
and/or stabilizing terminally deleted chromosomes are poorly understood. NEHJ, possibly 
stimulated by LCRs or other repetitive sequences, may be one of the causative mechanisms for 
the terminal 22q13 deletions in our series. 
In addition to the known 22qter deletions, a submicroscopic duplication on 22q11.1 next to 
the centromere was identified in three cases (cases 4, 7 and 8). In the control population of 72 
normal individuals, copy number gains in the same region were identified in five individuals, 
whereas losses were observed in 21 controls (de Vries; submitted), indicating that this anomaly 
represents a LCV. This LCV at 22q11.1 was previously reported by Sebat et al.22 (http://projects.
tcag.ca/variation/) and stresses the variation of the human genome and the importance of 
parental and control analysis in case a submicroscopic alteration is identified.
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Figure 2.2.3: Overview of the array CGH results for the nine patients with monosomy 22qter. Arrays contained 
350 chromosome-22 DNA BAC clones, ordered from q11.1 to qter on the basis of physical mapping positions ob-
tained from the May 2004 freeze of the UCSC Genome Browser. The distal 9 Mb of the long arm of chromosome 
22 is depicted in the figure. Copy number alterations were identified, using a Hidden Markov Model algorithm. 
Three hidden states represent normal (empty), loss (LOSS) and gain (GAIN) conditions. Individual clones that did 
not pass quality control criteria were excluded (EXCL).
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In the current study, no relation between clinical features and deletion size could be observed. 
The clinical features observed were consistent with the common clinical phenotype associated 
with the 22q13 deletion syndrome,5 although dolichocephaly and ptosis were not found in 
the current study. Global developmental delay and absent or severely delayed speech were 
observed in all patients. Hypotonia was present in 89% of the cases (8/9). A pointed chin was 
present in cases 1 and 4–7. Wilson et al.6 previously suggested a candidate gene for this feature 
in the proximal region of 22q13, however this could not be confirmed in our series. In addition, 
in case 8, ophthalmic assessment showed myopia and salt-and-pepper retinal changes 
suggestive of retinitis pigmentosa. These eye anomalies, which have not been reported in the 
22q13 deletion syndrome before, are possibly attributable to the 2 Mb 22q13.31 duplication 
in this patient. Relationship between the deletion size and clinical features could not be 
observed. However, case 9 with the smallest 22q13 deletion (3.3 Mb), did not show any of the 
dysmorphic features commonly described in the 22q13 deletion syndrome. Facial dysmorphic 
features in this patient included upslanting palpebral fissures, a moderate hypertrophic nasal 
root, and thick lips.10 These findings underline the study of Wilson et al., in which no significant 
correlation with the size of the deletion could be demonstrated for most clinical features and 
support the idea that a gene in the 3.3 Mb minimal deleted region (notably SHANK3/ ProSAP2) 
may be the major candidate gene in the 22q13 deletion syndrome.3–6 
In conclusion, this study underscores the utility of array CGH for further characterization of the 
size and nature of subtelomeric deletions. In addition, these results confirm the considerable 
differences in deletion size observed in patients with the 22q13 deletion syndrome, regardless 
of the clinical phenotype. 
Acknowledgements
We thank the patients and their parents for their cooperation. David A Koolen, Joris A Veltman 
and Bert BA de Vries were supported by a grant from the Netherlands Organization for Health 
Research and Development.
opmaak koolen.indd   71 10-09-2008   10:12:01
72
Chapter 2
References
 1.  de Vries BB, Winter RM, Schinzel A, van Ravenswaaij CM. Telomeres: a diagnosis at the end of the chro-
mosomes. J Med Genet 2003;40:385-398.
 2.  Knight SJ, Flint J. Perfect endings: a review of subtelomeric probes and their use in clinical diagnosis. 
J Med Genet 2000;37:401-409.
 3.  Luciani JJ, de Mas P, Depetris D et al. Telomeric 22q13 deletions resulting from rings, simple deletions, 
and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. J Med Genet 
2003;40:690-696.
 4.  Manning MA, Cassidy SB, Clericuzio C et al. Terminal 22q deletion syndrome: a newly recognized cause 
of speech and language disability in the autism spectrum. Pediatrics 2004;114:451-457.
 5.  Phelan MC, Rogers RC, Saul RA et al. 22q13 deletion syndrome. Am J Med Genet 2001;101:91-99.
 6.  Wilson HL, Wong AC, Shaw SR et al. Molecular characterisation of the 22q13 deletion syndrome sup-
ports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med 
Genet 2003;40:575-584.
 7.  Veltman JA, Yntema HG, Lugtenberg D et al. High resolution profiling of X chromosomal aberrations 
by array comparative genomic hybridisation. J Med Genet 2004;41:425-432.
 8.  de Vries BB, Bitner-Glindzicz M, Knight SJ et al. A boy with a submicroscopic 22qter deletion, general 
overgrowth and features suggestive of FG syndrome. Clin Genet 2000;58:483-487.
 9.  Koolen DA, Nillesen WM, Versteeg MH et al. Screening for subtelomeric rearrangements in 210 pa-
tients with unexplained mental retardation using multiplex ligation dependent probe amplification 
(MLPA). J Med Genet 2004;41:892-899.
10.  Goizet C, Excoffier E, Taine L et al. Case with autistic syndrome and chromosome 22q13.3 deletion 
detected by FISH. Am J Med Genet 2000;96:839-844.
11.  Vissers LE, de Vries BB, Osoegawa K et al. Array-based comparative genomic hybridization for 
the genomewide detection of submicroscopic chromosomal abnormalities. Am J Hum Genet 
2003;73:1261-1270.
12.  Buckley PG, Mantripragada KK, Benetkiewicz M et al. A full-coverage, high-resolution human chromo-
some 22 genomic microarray for clinical and research applications. Hum Mol Genet 2002;11:3221-
3229.
13.  Anderlid BM, Schoumans J, Anneren G et al. FISH-mapping of a 100-kb terminal 22q13 deletion. Hum 
Genet 2002;110:439-443.
14.  Bonaglia MC, Giorda R, Borgatti R et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is 
associated with the 22q13.3 deletion syndrome. Am J Hum Genet 2001;69:261-268.
15.  Cotter PD, Kaffe S, Li L, Gershin IF, Hirschhorn K. Loss of subtelomeric sequence associated with a ter-
minal inversion duplication of the short arm of chromosome 4. Am J Med Genet 2001;102:76-80.
16.  Floridia G, Piantanida M, Minelli A et al. The same molecular mechanism at the maternal meiosis I 
produces mono- and dicentric 8p duplications. Am J Hum Genet 1996;58:785-796.
17.  Bonaglia MC, Giorda R, Poggi G et al. Inverted duplications are recurrent rearrangements always as-
sociated with a distal deletion: description of a new case involving 2q. Eur J Hum Genet 2000;8:597-
603.
18.  Ballif BC, Yu W, Shaw CA, Kashork CD, Shaffer LG. Monosomy 1p36 breakpoint junctions suggest pre-
meiotic breakage-fusion-bridge cycles are involved in generating terminal deletions. Hum Mol Genet 
2003;12:2153-2165.
19.  Giglio S, Broman KW, Matsumoto N et al. Olfactory receptor-gene clusters, genomic-inversion poly-
morphisms, and common chromosome rearrangements. Am J Hum Genet 2001;68:874-883.
opmaak koolen.indd   72 10-09-2008   10:12:01
73
Subtelomeric chromosome aberrations
20.  Shaw CJ, Lupski JR. Implications of human genome architecture for rearrangement-based disorders: 
the genomic basis of disease. Hum Mol Genet 2004;13 Spec No 1:R57-R64.
21.  Stankiewicz P, Lupski JR. Molecular-evolutionary mechanisms for genomic disorders. Curr Opin Genet 
Dev 2002;12:312-319.
22.  Sebat J, Lakshmi B, Troge J et al. Large-scale copy number polymorphism in the human genome. Sci-
ence 2004;305:525-528.
opmaak koolen.indd   73 10-09-2008   10:12:01
opmaak koolen.indd   74 10-09-2008   10:12:01
Chapter
Interstitial copy number variation 
in mental retardation
3.1  Genomic microarrays in mental retardation: a practical workflow for diagnostic 
applications.  
Hum Mutat (in press).
3.2  Identification of non-recurrent submicroscopic genome imbalances: the advantage of 
genome-wide microarrays over targeted approaches. 
    Eur J Hum Genet 2008;16:395-400.
3.3  A new chromosome 17q21.31 microdeletion syndrome associated with a common 
inversion polymorphism. 
    Nat Genet 2006;38:999-1001.
3.4  Clinical and molecular delineation of the 17q21.31 microdeletion syndrome.  
J Med Genet (in press).
opmaak koolen.indd   75 10-09-2008   10:12:02
opmaak koolen.indd   76 10-09-2008   10:12:02
Chapter 3.1
Genomic microarrays in mental 
retardation: a practical workflow for 
diagnostic applications 
Koolen DA1, Pfundt R1, de Leeuw N1, Hehir-Kwa JY1, Nillesen WM1, Neefs I1, Scheltinga I1, 
Sistermans E1,2, Smeets D1, Brunner HG1, Geurts van Kessel A1, Veltman JA1*, de Vries BB1*
1Department of Human Genetics, Nijmegen Center for Molecular Life Sciences, 
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 
2Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands
*equally contributed
Hum Mutat (in press).
opmaak koolen.indd   77 10-09-2008   10:12:02
78
Chapter 3
Abstract 
Microarray-based copy number analysis has found its way into routine clinical practice, 
predominantly for the diagnosis of patients with unexplained mental retardation. However, 
the clinical interpretation of submicroscopic copy number variants (CNVs) is complicated 
by the fact that many CNVs are also present in the general population. Here we introduce 
and discuss a workflow that can be used in routine diagnostics to assess the clinical significance 
of the CNVs identified. We applied this scheme to our cohort of 386 individuals with 
unexplained mental retardation tested by genome-wide tiling resolution DNA microarray and 
to 978 additional patients with mental retardation reported in 15 genome-wide microarray 
studies extracted from the literature. In our cohort of 386 patients we identified 25 clinically 
significant copy number losses (median size 2.6 Mb), 9 copy number gains (median size 2.0 Mb), 
and one mosaic numerical chromosome aberration. Accordingly, the overall diagnostic 
yield of clinically significant CNVs was 9.1%. Taken together, our cohort and the patients 
described in the literature include a total of 1,364 analyses of DNA copy number in which a 
total of 11.2% (71.9% losses, 19.6% gains, 8.5% complex) could be identified, reflecting the 
overall diagnostic yield of clinically significant CNVs in individuals with unexplained mental 
retardation.
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Introduction
Microarray technology was pioneered more than a decade ago and has now become a routine 
tool in basic and applied research. Five years ago, this technology was used for the first time 
in the field of clinical genetics, when we described microarray-based copy number analysis 
of all human telomeres in patients with mental retardation,1 a common disorder for which 
the genetic diagnosis is mostly lacking. At that time, we suggested that “the robustness and 
relative simplicity of this array-based telomere copy number screening makes it highly suited 
for introduction into the clinic as a rapid and sensitive automated diagnostic procedure.” Since 
then, microarrays have indeed found their way into the clinical setting, although the majority 
of applications now target not only the telomeres, but also other clinically relevant genomic 
regions,2-4 or the entire genome at varying resolution levels,5-7 for reviews see Menten et al.8 
and Veltman.9 The power of microarray technology is used to its fullest for unbiased whole 
genome copy number analysis. Initially, the clone-based genomic microarrays developed were 
only available to researchers with dedicated microarray facilities. These microarrays have now 
been largely replaced by commercially available microarrays using oligonucleotide probes 
that can easily be implemented in clinical diagnostic laboratories. The latter platforms provide 
higher genome coverage than most clone-based genomic microarrays, and can be produced 
in large quantities according to industrial quality standards. The latest microarrays achieve 
kilobase level resolution, a major leap forward as compared to the megabase level resolution 
for conventional chromosome analysis.
There appear to be no major technical shortcomings that preclude widespread implementation 
of this microarray-based copy number analysis in routine clinical settings. Clinical interpretation 
of the copy number changes identified, however, is still challenging and many questions 
remain.10 One of the major difficulties is the fact that genomes from apparently healthy 
individuals also show wide-scale genomic copy number variation,11-13 reviewed in Pinto et al.14 
Disease-causing copy number variants (CNVs) can be distinguished from variations without 
direct clinical significance by studying unaffected parents as well as large normal control 
cohorts. But what can we do if one or both parents are unavailable for testing inheritance? 
What are the chances of finding a rare inherited variant without clinical significance that is 
not present in the control cohort? How large does the control cohort have to be in order to 
exclude low frequency CNVs and can control data from multiple sources be used, as collected 
for example in the Database of Genomic Variation (http://projects.tcag.ca/variation/)?13 Most 
disease-associated CNVs identified so far appear to be unique and it is therefore difficult to 
predict long-term clinical outcome. Finally, independent validation of CNVs identified by 
microarrays is preferable, but often time-consuming, and it may be questioned whether it is 
still necessary for all cases. In this review we will present data from our own diagnostic cohort 
of 386 patients with unexplained mental retardation tested onto tiling resolution BAC arrays, 
as well as data on 978 patients extracted from the literature. We will discuss the ways by which 
different groups come to clinical interpretations and propose a practical workflow that can 
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be used in routine clinical diagnostics, independent of the microarray platform used and the 
prior experience. We will not discuss the use of different microarray platforms and their effect 
on CNV detection, as several genomic microarray platform comparison studies have recently 
been published.15-17 In addition, we will only focus on studies that reported on the application 
of genome-wide microarrays, as the clinical interpretation of CNVs identified in these studies 
is most challenging.
Microarray-based CNV analysis in mental retardation, description of 
studies included in this review
Our results are derived from genomic copy number profiling among a cohort of 386 individuals 
with unexplained mental retardation using tiling resolution 32k BAC array CGH (100 of which 
were previously reported).5 Microarray preparation, analysis and basic interpretation were 
performed as described elsewhere.5 CNVs were identified using a Hidden Markov Model, 
requiring a minimum of three adjacently mapped BACs to be present within a CNV for further 
follow-up. Based on the average insert size of ~170 kb and the clone cover size of 47 kb,18 the 
effective resolving power using this criterion is ~300 kb. The minimal number of adjacently 
located clones might lead to underestimation of smaller, but true CNVs, but minimizes the 
number of false positives. A total of 109 unaffected individuals, mostly parents of mentally 
retarded children, were analyzed on the same microarrays for establishing a control cohort. 
All CNVs that were considered to be clinically relevant were validated by multiplex ligation-
dependent probe amplification (MLPA) and/or fluorescence in situ hybridization (FISH) 
technology.5 MLPA and or FISH technology was also used to test DNA from the parents, if 
available.
Many other groups have now reported on the use of genomic microarrays in the clinical 
workup of mental retardation (listed in Table 3.1.1). While the majority has used microarrays 
consisting of collections of large-insert clones (mostly with an approximate coverage of one 
Figure 3.1.1: Clinical preselection of patients. 
A total of 120 unselected patients (dark gray) 
and 386 patients tested in the present study 
(light gray) were scored using a clinical scoring 
system.19,20 The mean score of the unselected 
group was 2.2 + 1.7 which was significantly less 
than the mean score (3.2 + 1.5) of the 386 pa-
tients tested in the current study (P < .0001 by 
Mann-Whitney U test), indicating that we are 
using a preselected cohort.
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clone per megabase), oligonucleotide based microarrays are becoming more widely used. The 
published microarray studies differ in various aspects. 
Firstly, different methods have been applied to reliably identify CNVs. In some studies every 
aberrant clone was followed-up, whereas in other studies a minimal number of adjacently 
located clones or oligonucleotides was used, or a minimal genomic size was considered as a 
threshold for further follow-up. 
Secondly, the majority of these studies can be regarded as proof-of-principle studies, since 
the number of patients included was often (far) below 100. These low numbers may reflect 
patient selection, which is likely to differ between these studies, although, unfortunately, most 
studies do not report on the use of standard clinical checklists. In the study by de Vries et 
al. we indicated that indeed our patient cohort was not representative for the overall referral 
of mentally retarded patients for cytogenetic analysis.5 This is changing now that microarrays 
are increasingly implemented in routine clinical diagnostic settings, although the currently 
included 386 patients still represent a preselected cohort (P < 0.001 by Mann-Whitney U test) 
(Figure 3.1.1). 
Thirdly, patients included have often undergone different cytogenetic and/or molecular tests 
prior to microarray analysis. Karyotyping was performed in all studies prior to microarray 
analysis, and often subtelomeric abnormalities were excluded, as well as known microdeletion 
or microduplication syndromes in selected cases.
Although, these different approaches hamper the comparison of the published studies in many 
ways, the basic workflow used to come to a clinical diagnosis is similar in the majority of cases. In 
all studies, if possible, parental samples were tested for testing de novo occurrence. In addition, 
efforts were made in almost all studies to compare the CNVs obtained, to collections of CNVs 
identified in unaffected control individuals, apart from the few studies which were published 
prior to the publication of widespread copy number variation in healthy individuals.7,21 Also, 
the fact that various genomic regions were known to be associated with well-known mental 
retardation syndromes was often used in the interpretation. Finally, various methods were 
used to validate microarray-based CNVs linked to mental retardation, ranging from FISH to 
qPCR to (a re-analysis of ) karyotyping. In Figure 3.1.2, we propose a workflow for the clinical 
interpretation of CNVs in individuals with mental retardation. On the basis of this workflow we 
classified all CNVs reported in the various studies listed in Table 3.1.1 either as (1) common 
CNVs not directly related to mental retardation, (2) rare CNVs related to mental retardation, or 
(3) CNVs of unknown clinical significance.
Common CNVs, not related to mental retardation
In order to differentiate between CNVs that are likely implicated in the etiology of mental 
retardation and CNVs that are not involved in the disease phenotype, it is essential to recognize 
common variation also identified in normal controls. It has been estimated that CNVs cover 
~12% of the human genome.12 Discriminating between common CNVs and rare CNVs is 
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a first step in the diagnostic process after having identified CNVs in a patient by microarray 
analysis. This first step is essential for all data obtained from microarray platforms with more 
than ~3,000 probes, as these platforms will reveal many common CNVs not related to disease. 
Although our current knowledge about the clinical implications of common CNVs is far from 
complete, it is unlikely that CNVs frequently found in normal controls are directly related to 
mental retardation. As yet, however, it cannot be excluded that they contribute to the severity 
of the phenotype.
CNVs identified in healthy controls have been documented in publicly available databases, such 
as the Database of Genomic Variants.13 It is important to realize that these databases have been 
created mainly for research purposes. Most CNVs are identified by high-resolution microarray 
Figure 3.1.2: Workflow for the decision making of CNVs in individuals with mental retardation
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or sequencing strategies. Only a minority of reported CNVs has been validated, and therefore, 
the percentage of false-positive CNVs is unknown. Moreover, it is often difficult to determine 
the size of a genomic region that is affected by CNV from these databases, especially when 
low-resolution microarray platforms have been used. The benign CNVs previously reported 
are often actually smaller than was previously thought, partly due to the older/low resolution 
microarrays used when they were discovered.22 With the advent of high-resolution microarray 
and sequencing platforms increasingly smaller CNVs are detected. In a study, using a two-stage 
high-resolution array CGH approach on 50 healthy males, the majority of CNVs was smaller 
than 20 kb.23 These results indicate that it will soon be difficult to find a megabase of genomic 
sequence that does not show CNVs in healthy controls. Therefore, one should be careful in 
comparing CNVs identified in patients to those in control databases by considering not only the 
presence or absence, but also the amount of overlap with CNVs identified in control cohorts.
As the interpretation of the publicly available datasets is challenging, we created an 
independent control cohort using the same microarray platform for analyzing patients and 
Figure 3.1.3: Rare CNVs versus common CNVs in healthy controls. Two examples of CNVs identified in patients 
with mental retardation that show overlap with CNVs in healthy controls. (a) Case 13, 3.21 Mb loss at 4q24 and 
(b) Case 21, 1.96 Mb gain at 12q24.21q24.23. Both CNVs do not overlap for more than 50% with CNVs in control 
datasets, and the non-overlapping (unique) genomic segment present in the patient CNVs is larger than 100 kb 
in size. Therefore, these CNVs are considered to be rare CNVs for which follow-up is needed to determine the 
clinical significance.
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controls. Ideally, such an internal dataset should contain copy number profiles from unrelated 
normal controls, but for practical and financial reasons we included data obtained from testing 
unaffected parents of individuals with mental retardation. This dataset consists of 109 samples 
analyzed by tiling resolution 32k BAC array, of which 98 were published by de Vries et al.5
We have used both the Database of Genomic Variants as well as our internal control dataset to 
determine whether a CNV identified in a patient is likely to be a common variant. For inclusion 
in this analysis we decided that a common CNV should be reported at least three times, 
preferably in different datasets, and that it should be reported in the same orientation (loss/
gain) as that observed in the patient. Furthermore, a CNV observed in the patient is considered 
to overlap significantly with known CNVs if this overlap exceeds 50% and the non-overlapping 
(unique) genomic segment is less than 100 kb in size (Figure 3.1.3). If we use the approach 
described above, the large majority of CNVs identified onto tiling resolution 32k BAC arrays 
fall into the class of common CNVs and, therefore, no validation is needed for these CNVs. This 
notion, significantly reduces the number of patients for which validation is required.
Most other groups have also started to report on the presence or absence of CNVs in healthy 
control cohorts, either as published separately or as deposited in the Database of Genomic 
Variation. Investigators sometimes prefer to look specifically at control data obtained on the 
same microarray platform because of the ease of comparison. The advantage of this approach is 
that a one-to-one comparison can be made as the same clones or oligonucleotides have been 
analyzed in both patients and controls, thus circumventing problems with comparing genomic 
sizes. Rosenberg et al. also compared the CNVs to an in-house dataset of 100 normal controls, 
encompassing a mix of data from unaffected individuals and data from normal chromosomes 
of cases with an abnormal karyotype.24 There are no generally accepted guidelines for dealing 
with overlap between CNVs in patients and CNVs present in control cohorts. Wagenstaller et al. 
for example state that “All regions that considerably overlapped with known CNVs provided by 
the Database of Genomic Variants had been excluded”,25 without defining what “considerably 
overlapped” means.
Rare CNVs of clinical significance 
Validation
After having excluded common CNVs, the remaining CNVs can be considered candidates for 
causing mental retardation. Before determining the clinical significance of such rare CNVs, we 
have validated the CNVs by an independent technology. For the present study, we have chosen 
to use MLPA, with specifically designed synthetic probe sets, and/or FISH on fixed metaphase 
spreads. Other published studies have also validated their results using a second independent 
technique, mostly FISH, MLPA, real-time PCR, qPCR, microsatellite analysis, or other microarray 
platforms (Table 3.1.1).
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From a technical point of view, and depending on the experience present in the diagnostic 
laboratory, validation of CNVs spanning more than ~50-100 targets may not be necessary, as it is 
unlikely that >50-100 adjacent targets show an abnormal copy number by chance. For example, 
for an oligonucleotide array containing 250,000 targets, this would mean that CNVs larger than 
~500 Kb in size require no validation by another technique. From a counseling perspective, 
however, follow-up FISH in the patient and the parents is valuable for the estimation of the 
recurrence risk, as it might reliably detect balanced rearrangements in healthy carriers.
De novo CNVs
The technique used for validation can also be applied for parental testing, which is often a 
crucial test to determine causality of an observed CNV, especially when the genomic region 
involved has not yet been reported to be associated with mental retardation. The use of control 
CNV data may provide a first clue about the possibility that a CNV is associated with disease, 
but does not provide a definite answer. Control CNV data are currently too limited to exclude 
the presence of uncommon CNVs without clinical significance. In addition, control CNV data 
are not available for all ethnic populations, while we know that there are many population-
specific CNVs.12,26 The clinical significance of a de novo event is stressed by the interrogation of 
CNVs among normal individuals. Of 12,060 biallelic CNV genotypes identified in the HapMap 
collection by Redon et al., only 0.2% exhibited Mendelian discordance, which according to the 
authors probably reflects the genotyping error rate rather than the rate of de novo events at 
these loci.12
Using the above criteria, in our diagnostic cohort of 386 individuals with mental retardation, 
de novo CNVs were identified in 29 patients (Table 3.1.2). In total, we found 21 de novo copy 
number losses (median size 1.57 Mb), seven de novo copy number gains (median size 2.60 Mb), 
including a complex duplication rearrangement27 and one mosaic numerical chromosome 
aberration. 
Also in most other published studies the clinical relevance of CNVs is determined mostly by 
establishing whether a CNV occurred de novo or is inherited from an unaffected parent. On 
average, de novo CNVs were found in 9.2% (126/1,364) of the patients (Table 3.1.1), varying 
from 4.2%28 up to 30%.29 This considerable variation can be explained by differences in 
microarray platform used, differences in patient inclusion criteria, as well as previous molecular/
cytogenetic tests performed, but also reflects the availability of parental samples, rather than 
the true diagnostic yield of the study.
CNVs overlapping critical regions of well-defined genomic disorders
In some cases, it is impossible to obtain DNA samples from both parents of a patient, hampering 
the clinical interpretation of rare CNVs. Parental samples are, however, not always needed to 
establish the clinical significance of a CNV. In the case of mental retardation, CNVs can be 
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considered pathogenic when they overlap with genomic regions known to cause well-defined 
mental retardation syndromes, as defined by the database of the Online Mendelian Inheritance 
in Man (OMIM) (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim). For diagnostic 
purposes, these CNVs should at least include the critical region of the syndrome and, if known, 
the causative gene(s). In addition, the clinical features of the patient should be consistent with 
the phenotype of the syndrome involved, although a wide variation in phenotypic expression 
should be considered. Even in case a CNV associated with a well known syndrome is found 
to be inherited from one of the parents, it does not rule out the pathogenicity of the CNV. 
Mosaicism in the parents, variable expression and incomplete penetrance have previously 
been described, for example in the DiGeorge/velocardiofacial syndrome (DGS/VCFS [MIM 
188400/192430]).36
In our study we observed eight cases in which a rare CNV overlapped with an OMIM mental 
retardation syndrome (Table 3.1.2). In all these cases, the critical disease region was included 
in the CNV and the phenotype matched, at least in part, with the syndrome associated with 
the genomic abnormality. Also, the other published studies considered a CNV pathogenic if it 
overlapped with that of a known clinical syndrome. In the combined studies, CNVs deposited 
in the OMIM database comprise 37.9% of the CNVs related to mental retardation (Table 3.1.3). 
Deletions of the 1p36 genomic segment (MIM 607872) and deletions of the 22q11.21 genomic 
segment, involved in DGS/VCFS (MIM 188400/192430) are the most frequent pathogenic 
Table 3.1.4: OMIM associated CNVs identified in combined microarray studies
Chr Syndrome OMIM Number
1 Monosomy 1p36 syndrome 607872 8
2 Brachydactyly mental retardation syndrome 600430 1
3 3q29 microdeletion syndrome 609425 2
4 Wolf-Hirschhorn Syndrome 194190 2
5 Sotos syndrome 117550 1
7 Williams-Beuren syndrome 194050 2
8 Nablus mask-like facial syndrome 608156 1
9 9q34 deletion syndrome 610253 2
15 Susceptibility to autism; AUTS4 608636 1
15 Prader-Willi/Angelman syndrome  176270/105830 2
17 Miller-Dieker syndrome 247200 1
17 17q21.31 microdeletion syndrome 610443 6
17 Potocki-Lupski syndrome 610883 5
17 Smith-Magenis syndrome 182290 1
18 18qter deletion syndrome 601808 1
18 Pitt-Hopkins syndrome 610954 1
22 22q13 microdeletion syndrome 606232 3
22 22q11.2 microduplication syndrome 608363 7
22 DiGeorge/velocardiofacial syndrome 188400/192430 7
X Leri-Weill dyschondrostosis 127300 1
X XLMR, MRGH 300123 1
X FG syndrome 5 300581 1
X XLMR. MRX3  309541 1
X Pelizaeus-Merzbacher disease 312080 1
X MECP2 duplication 312750 1
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CNVs. The reciprocal 22q11.21 duplication (MIM 608363) was also identified in multiple cases, 
as well as the recently identified 17q21.31 microdeletion syndrome.35,37,38 An overview of the 
CNVs associated with an OMIM mental retardation syndrome in all studies is provided in Table 
3.1.4.
Novel clinically recognizable recurrent CNVs
The application of genomic microarrays has resulted in the identification of several novel 
recurrent disease causing CNVs, not all of which have an OMIM entry yet. International 
databases, such as ECARUCA (www.ECARUCA.net) and DECIPHER (www.sanger.ac.uk/
PostGenomics/decipher/), capture cytogenetic and clinical information of patients with rare 
CNVs and are helpful in identifying overlapping copy number changes. However, these novel 
recurrent CNVs should be interpreted cautiously in a diagnostic setting, because the numbers 
are often small and in many cases no recurrent breakpoints have been identified, since the 
overlapping CNVs may differ in size. Moreover, the clinical features of many novel recurrent 
CNVs have not been studied in detail, which complicates the interpretation of the clinical 
significance of copy number changes in these regions. As a result, if no parental samples are 
available and the CNV does not overlap with that of a known genomic disorder, we consider 
a CNV to be clinically significant if it overlaps with the minimal critical region of at least two 
recurrent de novo CNVs identified in patients with mental retardation. Importantly, similar 
clinical features should support the pathogenicity of the aberrations.
In our study, we identified five CNVs overlapping with novel recurrent CNVs for which a 
phenotypic overlap has been described (1q44,39-41 2p15-16.1,31,42,43 3q29,44 10q22q23,45 and 
15q245,34,46). Also, recurrent CNVs that define novel clinically recognizable syndromes were 
identified in the combined studies, such as copy number losses at 6p25,47 8p23.1,48 12p14,49 
14q11.2,6,50 and 16p11.251 and it is to be expected that on the basis of genomic profiling, many 
other new syndromes will be defined in the near future.
CNVs of unknown clinical significance
The clinical significance of rare CNVs remains to be established in case DNA of one or both 
parents is unavailable and the CNV is not associated with a known mental retardation syndrome 
and/or does not overlap with a recurrent mental retardation region. In the present study, for 
14 rare CNVs (14/49= 28.6%), we were not able to define the clinical significance, which is 
comparable to the amount of genetic variants of uncertain significance or unclassified variants 
in BRCA1 and BRCA2 mutation analyses.52 In a recent study, variants of uncertain significance, 
even accounted for 67% of the mutations identified in DNA mismatch repair genes in a series 
of early onset colorectal cancer cases.53 Table 3.1.2 shows all CNVs with unknown clinical 
significance identified in our study and summarizes the clinical phenotype of the patients. 
One could speculate on the clinical significance of these CNVs by looking at the genomic size 
and the gene content of the genomic region involved, i.e., the larger a CNV, the more likely it 
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is that it would have been identified in normal control cohorts if it does not result in a clinical 
phenotype. Thus, with the rapid increase in control CNV data, it becomes more and more likely 
that a rare CNV spanning over 1 Mb is related to the disease phenotype. Similarly, rare CNVs 
encompassing numerous (protein-coding) genes are more likely to be causative than CNVs 
that do not span such genes, especially when these genes are known to be dosage-sensitive. 
In all cases, however, a straightforward clinical diagnosis cannot be reached by this approach 
before we know more about the biological pathways underlying mental retardation. 
CNVs on the X chromosome
CNVs on the X chromosome deserve special attention as the dosage effect obviously differs 
in males and females. Common CNVs on the X chromosome can be excluded and de novo 
occurrence, the involvement of regions associated with well-known syndromes or novel 
recurrent CNVs, are considered indicative for the pathogenicity of the CNV. The exception is 
that causal CNVs in a male patient can be inherited from a healthy mother. In our cohort, we 
identified rare CNVs on the X chromosome in three cases. A de novo 7.0 Mb gain at Xq13.2q21.1 
was considered to be causally related to the phenotype in the male patient. The other two gains, 
a 190 kb gain at Xq24q24 and a 4.7 Mb gain at Xq25q26.3, were found in male patients and 
also in their non-affected mothers. Although, these CNVs might contribute to the phenotype 
of the patients, we are unable to draw firm conclusions on their clinical significance. Overall, 
genome-wide microarray studies reported on 17 CNVs on the X chromosome, of which 10 
CNVs in male patients, were inherited from a normal mother. Rosenberg et al. stressed the 
clinical significance of an inherited CNV by showing segregation of the CNV with the disease in 
a family,24 whereas Wagenstaller et al. showed a non-random X-inactivation pattern in a healthy 
mother with the chromosome carrying the CNV being inactivated.25 However, segregation 
studies and X-chromosome inactivation analyses are not always feasible within a diagnostic 
setting. As a result, these rare CNVs on the X-chromosome should often be added to the group 
of CNVs with unknown clinical significance.
Conclusions
Developments in genomic microarray technology have revolutionized the study of human 
genomic copy number variation. Technological restrictions have been largely overcome and 
further enhancements in genomic microarray analysis will soon allow the reliable analysis 
of all CNVs throughout the genome at a kilobase or even single exon level. In recent years, 
microarray-based copy number analysis has found its way into routine clinical practice and 
will soon replace conventional karyotyping as the first test in the genetic diagnosis of patients 
with mental retardation. However, the interpretation of CNVs in routine clinical diagnostics 
is still a complex process, due to the presence of a high variability in relative large segments 
of the human genome, hampering the clinical interpretation of the CNVs identified. Here 
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we present a practical workflow that can be used in routine clinical diagnostics to assess the 
clinical significance of CNVs identified. This workflow discriminates between common CNVs 
and rare CNVs based upon publicly available databases collecting CNV in control cohorts 
and internal control datasets. Next, the rare CNVs are checked for de novo occurrence and 
the genomic regions involved are screened against a list of known microdeletion/duplication 
syndromes as well as novel recurrent CNVs associated with mental retardation. Based on this 
workflow, we reclassified all CNVs described in genome-wide microarray studies on mental 
Figure 3.1.4: Overview of all CNVs reported in genome-wide microarrays studies in mental retardation. CNVs 
are represented by colored bars. Copy number losses and copy number gains are depicted, respectively, on the 
left hand side and the right hand side of the chromosomes. Red bars, CNVs associated with a well-known OMIM 
syndromes. Orange bars, novel recurrent CNVs. Green bars, de novo CNVs not known to the previous categories 
and blue bars, CNVs of unknown clinical significance. For color figure see page 193.
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retardation. Figure 3.1.4 shows an overview of all rare CNVs related to mental retardation 
(either de novo, an OMIM mental retardation syndrome, or associated with a novel clinically 
recognizable syndrome) and CNVs of unknown clinical significance. The overall yield of 
clinically significant CNVs is 9.1% in our cohort of 386 patients (25 losses, median size 2.6 Mb; 9 
gains, median size 2.0 Mb, 1 mosaic trisomy 8), and 11.2% in the combined published genome-
wide microarray studies. Although comparison of the diagnostic yield of these studies is 
limited, the results emphasize the usefulness of genomic microarray technology in patients 
with mental retardation. The current frequency is likely to be an underestimate given the fact 
that most of the microarrays used only detect genomic rearrangements >100-300 kb in size. 
Novel oligonucleotide-based microarrays will allow the high-resolution detection of even 
intra-genic (exon) deletions and duplications and it is to be expected that the implementation 
of these platforms in a diagnostic setting will increase the frequency of clinically significant 
CNVs in patients with mental retardation. It is essential to further study these CNVs and their 
functional consequences as this will be instrumental for clinical diagnosis, the identification of 
the causative genes underlying the pathogenesis of mental retardation, and the identification 
of new mental retardation syndromes.
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Abstract
Genome-wide analysis of DNA copy-number changes using microarray-based technologies 
has enabled the detection of de novo cryptic chromosome imbalances in approximately 
10% of individuals with mental retardation. So far, the majority of these submicroscopic 
microdeletions/duplications appear to be unique, hampering clinical interpretation and 
genetic counseling. We hypothesized that the genomic regions involved in these de novo 
submicroscopic aberrations would be candidates for recurrent copy-number changes in 
individuals with mental retardation. To test this hypothesis, we used multiplex ligation 
dependent probe amplification (MLPA) to screen for copy number changes at eight genomic 
candidate regions in a European cohort of 710 individuals with idiopathic mental retardation. 
By doing so, we failed to detect additional submicroscopic rearrangements, indicating that 
the anomalies tested are non-recurrent in this cohort of patients. The break points flanking 
the candidate regions did not contain low copy repeats and/or sequence similarities, thus 
providing an explanation for its non-recurrent nature. On the basis of these data, we propose 
that the use of genome-wide microarrays is indicated when testing for copy-number changes 
in individuals with idiopathic mental retardation. 
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Introduction
Genome-scanning array technologies, such as microarray-based comparative genomic 
hybridization (array CGH), enable the detection of interstitial submicroscopic DNA copy-
number alterations in individuals with mental retardation (MR) of unknown etiology. De novo 
submicroscopic alterations have been identified in approximately 10% of individuals with 
MR using both bacterial artificial chromosome (BAC) microarrays1–8 and single-nucleotide 
polymorphism-based microarrays.9
Using genome-wide microarray strategies, novel recurrent interstitial submicroscopic 
aberrations have only been reported sparsely in individuals with MR.10–17 So far, the vast 
majority of the cryptic microdeletions/duplications identified appear to be unique, which 
hampers its clinical interpretation and counseling of the families. However, because these 
genomic imbalances are likely to harbor dosage sensitive genes related to the pathogenesis of 
MR, we hypothesized that the genomic regions involved in de novo submicroscopic aberrations 
are candidates for recurrent copy-number changes in individuals with idiopathic MR. To test 
this hypothesis, we subjected eight pre-selected regions to targeted copy-number analysis 
using multiplex ligation dependent probe amplification (MLPA) in a cohort of 710 individuals 
with idiopathic MR and compared the efficacy of our targeted MLPA-based approach to 
genomewide scanning strategies.
Materials and methods
Subjects
In total, 710 mentally retarded individuals with or without facial dysmorphisms or congenital 
malformations were included in this study. All individuals exhibited normal G-banded 
karyotypes at 550-band resolution. Genomic DNA was prepared from blood lymphocytes 
by standard procedures. The DNA samples were derived from Nijmegen, The Netherlands 
(n=200), Oxford, UK (n=200), Schwerzenbach, Switzerland (n=100), Stockholm, Sweden (n=80), 
Antwerp, Belgium (n=80), and Troina, Italy (n=50). 
Selection of novel submicroscopic aberrations and in silico LCR analysis
We selected eight de novo submicroscopic copy aberrations for testing among individuals with 
MR. The aberrations varied in size from 480 kb to 12.4 Mb and were dispersed throughout the 
genome (Table 3.2.1). The aberrations were previously identified in a cohort of 100 mentally 
retarded individuals using genome-wide tiling path resolution array CGH.1 The 2q23.1q23.2 
microdeletion partly overlapped with a microdeletion previously reported by our group.8,18
The flanking 400 kb break point regions of the eight candidate regions were screened for the 
presence of homologous low copy repeats (LCRs) using the Segmental Duplication Database 
(http://humanparalogy.gs.washington.edu) and BLAST2 (http://www.ncbi.nlm.nih.gov/blast/
bl2seq/ wblast2.cgi) analyses. The break points were defined by the average start and end 
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positions, respectively, of the first and last flanking BAC clone that identified the genome 
imbalance (based on NCBI, Build 35, May 2004).
Multiplex ligation-dependent probe amplification 
For the MLPA screening two to seven probes were designed within exonic sequences in the 
genomic regions of interest (Table 3.2.2) according to a protocol provided by MRC-Holland 
(http://www.mlpa.com/pages/support_desing_synthetic_ probespag.html). The same probes 
had also been used for the confirmation of the de novo aberrations, previously identified by 
genome-wide tiling resolution array CGH (Figure 3.2.1).1 The MLPA probes were combined 
in one MLPA assay in conjunction with four standard control probes in three different genes, 
VIPR2, MRPL41 and KIAA0056. MLPA reactions using 200 ng genomic DNA were performed as 
described previously.19,20 All MLPA reagents were obtained from MRC-Holland, Amsterdam, The 
Netherlands. Amplification products were identified and quantified by electrophoresis on a 
capillary sequencer (ABI 310, ABI 3100, ABI 3130 or ABI 3730), using GeneMapper software 
(Applied Biosystems, Foster City, USA). For copy-number quantification data were normalized 
by dividing each probe’s peak area by the average peak area of the control probes of the sample. 
The normalized peak patterns were divided by the average peak area of all the samples in the 
same experiment. For all DNA samples, we computed the coefficient of variation (c.v.) of the 
normalized signal strength over the controls. If a particular sample had a c.v. of more than 15, 
the result of the analysis for that particular sample was discarded. If a particular probe had a 
c.v. of more than 15 over all samples tested, the analysis was repeated. Copy-number change 
detection was based on thresholds for gains and losses of 1.30 and 0.70, respectively. The 
MLPA analyses were repeated for all samples in which an aberration was identified. For these 
confirmation experiments, DNA samples of healthy controls were used for the normalization. If 
available, DNA of positive controls were included in the MLPA assays
Results and discussion
We used MLPA to look for copy-number changes at eight pre-selected genomic regions in a 
European cohort comprising 710 individuals with idiopathic MR with or without associated 
Table 3.2.1: Candidate regions screened for DNA copy-number changes
 Location Start (Mb)a End (Mb)a Size (Mb)
1 1p34.3p34.2  39.2  43.1  3.85
2 2q23.1q23.2 149.2 150.1  0.92
3 3q27.1q29 184.3 196.7 12.42
4 5q35.1 170.5 171.5  0.97
5 9q31.1  99.7 102.6  2.85
6 9q33.1 115.3 115.8  0.48
7 11q14.1q14.2  77.8  85.1  7.28
8 12q24.21q24.23 114.9 116.9  1.98
a On the basis of 32k BAC microarray data (NCBI, Build 35, May 2004).6
opmaak koolen.indd   102 10-09-2008   10:12:10
103
Non-recurrent submicroscopic genome inbalances
Ta
bl
e 
3.
2.
2:
 M
LP
A
 p
ro
be
 in
fo
rm
at
io
n
G
en
e 
Ba
nd
 
Si
ze
 
5'
 h
yb
rid
iz
at
io
n 
se
qu
en
ce
a  
3'
 h
yb
rid
iz
at
io
n 
se
qu
en
ce
b
KC
N
Q
4 
1p
34
.2
 
10
0 
CA
G
G
G
CA
AC
AT
C
TT
CG
CC
AC
G
TC
CG
CG
C
T 
G
CG
CA
G
CA
TG
CG
C
TT
CC
TG
CA
G
AT
CC
TG
C
ED
N
2 
1p
34
.2
 
12
4 
G
CG
G
G
AG
CC
TC
G
G
TC
CA
CA
CA
TT
CC
AG
G
TG
G
AG
G
A
AG
AG
AT
 
AG
TG
TC
G
TG
AG
C
TG
G
AG
G
A
AC
AT
TG
G
G
A
AG
G
A
AG
CC
CG
CG
G
ZM
YN
D
12
 
1p
34
.2
 
12
8 
CC
AT
G
TT
TG
AC
CC
TT
AC
CG
G
CC
AC
TG
TA
CG
G
G
CC
TT
TC
TG
G
AC
 
TT
G
G
AC
TC
C
TT
G
G
G
AG
TC
G
TT
TC
TC
G
G
CC
AT
TT
G
AC
CC
G
TG
G
G
M
AC
F1
 
1p
34
.3
 
 9
2 
G
TG
G
A
AT
G
TT
TC
AC
TG
C
TC
CC
A
AG
G
 
AG
CG
G
G
TA
AT
G
AG
AG
TG
G
CA
C
TT
AG
M
BD
5 
2q
23
.1
 
 8
4 
CA
A
AG
AG
TG
TG
AC
G
G
AG
G
G
G
A
 
CA
AG
G
A
AG
G
AG
G
TC
TT
CC
AG
C
EP
C2
 
2q
23
.1
 
 9
2 
G
AG
G
TG
G
A
AG
G
TG
A
AG
TA
TT
TG
TT
T 
TC
AC
C
TG
G
TT
TT
TG
TT
TG
C
TA
TC
TG
M
BD
5 
2q
23
.1
 
10
0 
CA
C
TA
AC
AG
A
AG
G
TT
TG
G
A
AG
CC
TA
CA
G
C 
CG
TG
TC
CG
G
A
A
A
AG
G
A
AC
AG
A
A
AG
TA
AG
C
EP
C2
 
2q
23
.1
 
10
8 
CA
G
TT
AG
TT
CA
G
AT
G
CA
A
AG
G
CA
G
CA
AC
TT
G
CC
 
CA
G
C
TT
CA
G
CA
G
A
A
AC
AG
CA
AT
C
TC
AG
CA
TT
CC
KI
F5
C 
2q
23
.1
 
11
2 
CC
G
TG
TT
TG
TA
TT
TT
CG
CC
CA
C
TA
G
G
G
G
A
AG
C
TG
C 
AT
G
AC
CC
CC
AG
C
TC
AT
G
G
G
G
AT
CA
TC
CC
AC
G
A
AT
T
M
BD
5 
2q
23
.1
 
12
0 
CA
G
AG
TC
G
G
G
G
AT
TT
G
G
AG
AG
C
TG
C
TA
AG
CA
C
TG
CA
A
AG
 
CA
AG
AC
C
TG
G
TC
C
TA
G
AG
G
AG
CA
G
TC
TC
CA
AG
TT
CC
TC
A
M
BD
5 
2q
23
.1
 
12
4 
C
TA
A
AT
AC
CC
CA
AG
CA
G
TG
CA
G
C
TT
TT
CC
TA
C
TG
CA
TC
TG
C 
CG
G
A
AG
TA
G
TT
C
TG
TA
A
AG
AG
TC
AG
CC
TG
G
TT
TG
C
TG
G
G
A
A
M
A
P3
K1
3 
3q
27
.2
 
 8
4 
G
CA
CG
AT
G
G
CC
A
AC
TT
TC
AG
G
 
AG
CA
CC
TG
AG
C
TG
C
TC
C
TC
TT
LP
P 
3q
28
 
 8
8 
G
AC
G
C
TG
AG
AT
TG
AC
TC
C
TT
G
AC
 
CA
G
CA
TC
TT
G
G
C
TG
AC
C
TT
G
AG
T
TP
72
3L
 
3q
28
 
 9
2 
G
G
AG
A
AT
G
G
G
G
TG
AT
AT
TG
G
AG
A
AG
 
C
TG
CA
TG
AT
A
AG
AC
C
TG
TG
AC
C
TT
C
H
RA
SL
S 
3q
29
 
10
0 
CC
TT
TA
CA
AG
CG
CC
A
AG
TC
TG
TA
TT
CA
G
C 
AG
TA
AG
G
CC
C
TG
G
TG
A
A
A
AT
G
CA
G
C
TC
TT
FG
F1
8 
5q
35
.1
 
10
8 
CC
TC
AG
G
TC
CC
AC
TG
AC
CG
C
TT
C
TC
CA
TC
TG
TT
 
TC
CC
G
CA
G
G
TG
TT
TA
CA
C
TT
CC
TG
C
TG
C
TG
TG
C
ST
K1
0 
5q
35
.1
 
11
2 
C
TC
G
CC
C
TG
TG
CC
AC
CC
CA
AC
TG
TG
CC
TG
AT
AG
AC
 
C
TG
CC
CC
AG
CG
TT
CC
TG
AC
TT
C
TT
G
C
TG
G
CC
TG
TG
D
C-
U
bP
 
5q
35
.1
 
12
0 
C
TT
G
G
CA
CC
G
CC
A
AT
CA
AC
AT
G
AT
AG
AG
G
A
A
A
AG
AG
CG
A
 
CA
TA
G
AG
AC
TC
TG
G
AT
AT
TC
C
TG
AG
CC
AC
CA
CC
CA
AT
TC
ST
X1
7 
9q
31
.1
 
N
92
 
CA
G
G
TG
CA
C
TC
AT
CG
G
G
G
G
A
AT
G
G
T 
AG
G
G
G
G
TC
C
TA
TT
G
G
CC
TC
C
TT
G
CA
PR
G
-3
 
9q
31
.1
 
10
4 
CG
A
AT
G
CA
C
TG
AC
AC
TT
TT
CA
G
G
TG
CA
TA
TC
 
CA
AG
G
AT
TC
TT
C
TG
TC
AG
G
AC
G
G
AG
AC
TT
A
A
G
RI
N
3A
 
9q
31
.1
 
10
8 
G
CC
AC
AG
CC
AC
CA
TG
AT
CC
A
AC
CA
G
A
AC
TT
G
C
T 
C
TC
AT
TC
CC
AG
CA
CG
AT
G
A
AC
TG
CA
TG
G
AG
G
TG
C9
or
f2
7 
9q
33
.1
 
 9
2 
CA
A
AG
G
C
TC
TG
TG
TT
AG
TG
G
AT
TC
A
 
CA
AG
CA
AC
C
TG
TA
C
TC
C
TC
A
A
AG
A
A
C9
or
f2
7 
9q
33
.1
 
10
0 
G
TA
TG
CA
G
AC
TC
AT
CC
AT
CC
AT
G
A
AT
C
TA
 
G
AT
TG
CA
G
G
G
AT
G
TG
AC
C
TA
TG
TA
AT
G
A
A
G
A
B2
 
11
q1
4.
1 
 8
4 
C
TC
CA
G
CC
AG
CC
A
AC
TC
TG
TT
 
CA
CG
TT
TG
A
AC
CC
CC
TG
TG
TC
D
LG
2 
11
q1
4.
1 
11
2 
C
TG
AC
G
G
G
C
TT
TC
TG
CC
CA
AG
AG
AT
G
AG
AT
G
AG
AG
 
CC
TC
C
TC
AC
CC
CA
G
CA
G
AT
G
TC
CA
G
AG
C
TG
AT
TT
A
PI
CA
M
 
11
q1
4.
2 
12
0 
CA
CA
G
TG
TC
AC
CG
G
C
TC
TG
CC
G
TA
TC
CA
AG
AC
AG
TA
TG
C 
A
AG
G
CC
AC
G
AC
CC
AC
G
AG
AT
CA
TG
G
G
G
CC
CA
AG
A
A
A
A
AG
N
O
S1
 
12
q2
4.
22
 
11
2 
CA
CA
TG
TT
CG
G
TG
TT
CA
G
CA
A
AT
CC
AG
CC
CA
AT
G
T 
CA
TT
TC
TG
TT
CG
TC
TC
TT
CA
AG
CG
CA
A
AG
TT
G
G
G
G
KS
R2
 
12
q2
4.
23
 
12
0 
C
TG
G
C
TT
TC
TC
AT
G
G
C
TT
AC
CC
AT
TG
TC
TC
TG
C
TC
TT
C
T 
G
TT
CC
A
AC
TC
AG
G
AG
G
CA
AC
C
TT
TC
CA
A
AC
A
AG
AC
TG
G
A
a  T
he
 5
’ h
al
f-p
ro
be
 is
 p
re
ce
de
d 
by
 th
e 
5’
 u
ni
ve
rs
al
 p
rim
er
 ta
g.
b  T
he
 3
’ h
al
f-p
ro
be
 is
 p
re
ce
de
d 
by
 a
 5
’ p
ho
sp
ha
te
 g
ro
up
 a
nd
 fo
llo
w
ed
 b
y 
th
e 
3’
 u
ni
ve
rs
al
 p
rim
er
 ta
g.
opmaak koolen.indd   103 10-09-2008   10:12:10
104
Chapter 3
Figure 3.2.1: MLPA validation of submicroscopic genome imbalances. (a) Loss 1p34.3p34.2, (b) loss 2q23.1q23.2, 
(c) loss 3q27q29, (d) gain 5q35, (e) loss 9q31.1, (f) loss 9q33.1, (g) loss 11q14.1q14.2, (h) gain 12q24.21q24.23.
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dysmorphisms or congenital anomalies. Causative copy-number changes in these eight 
regions were previously described in single individuals with MR.1 The eight regions were based 
upon the unique and de novo aberrations that had been found in our initial study among a 
cohort of 100 MR patients using genome-wide tiling path resolution array CGH.1 Through the 
MLPA assay, we failed to detect additional submicroscopic rearrangements at all candidate 
regions in this patient cohort. Figure 3.2.2 shows an example of the data obtained by the 
MLPA copy-number screening of the candidate regions. The loss of the 11q14.1 segment is 
clearly demonstrated in the positive control sample, whereas in the remaining test samples in 
the assay, no copy-number changes are found. Subsequently, we screened the flanking break 
point regions of the preselected candidate regions for the presence of LCRs and/or sequence 
similarities that might predispose for the occurrence of non-allelic homologous recombination 
events leading to loss or gain of the intervening DNA sequence.21 
However, no significant LCRs and/or sequence similarities could be identified. The present study 
is the first report of a comprehensive screen for interstitial submicroscopic aberrations in a large 
cohort of individuals with MR using MLPA. Of course, the results might have been different if other 
regions, such as subtelomeric regions, had been analyzed in this cohort. Although copy-number 
changes in these latter regions are usually not mediated by LCRs, which is similar to our eight 
selected regions, they are in regions that have already been associated with recurrent aberrations. 
Others have employed a variety of microarray-based targeted approaches to detect recurrent 
submicroscopic aberrations. Sharp et al,15 for example, generated a segmental duplication 
BAC microarray targeted to 130 potential rearrangement hot spots in the human genome. By 
Figure 3.2.2: Copy-number screening at 11q14.1 using multiplex ligation-dependent probe amplification. x-axis, 
standard control probes and three probes hybridizing to 11q14.1 (for a complete list of probe sequences, see Table 
3.2.2). y-axis, normalized copy-number ratios. Copy-number change detection is based on thresholds for gains and 
losses of 1.30 and 0.70, respectively. The loss of the 11q14.1 segment is clearly demonstrated in the positive control 
sample, whereas in the remaining test samples in the same assay, no copy-number changes could be identified. 
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using this targeted approach, they tested 290 individuals with MR and identified 16 pathogenic 
rearrangements, including four microdeletions in 17q21.31.22 The phenotypic similarities 
between the individuals with an overlapping 17q21.31 deletion subsequently pointed to a new 
microdeletion syndrome.10,17,22 More recently, several other novel recurrent microdeletions that are 
mediated by flanking LCRs have been identified. These recurrent aberrations may give rise to new 
genomic disorders, such as the 15q24 microdeletion syndrome16 and the 10q22q23 microdeletion 
syndrome.23 Targeted microarrays have been developed with target sequences corresponding 
to genomic regions of known clinical significance, such as the chromosome subtelomeres and 
regions implicated in well-known human genomic disorders.24–27 Using these targeted microarrays, 
Shaffer et al28 found clinically relevant genomic alterations in 5.6% of 1500 consecutive cases 
referred to the clinic for a variety of developmental problems. Indeed, these targeted microarrays 
have some advantages over genome-wide microarray scanning technologies, especially in 
a diagnostic setting, as parental samples are not requisite for the clinical interpretation of the 
array CGH findings.29 In addition, in most cases there is ample information available about the 
clinical consequences of these submicroscopic copy-number alterations, thus facilitating the 
genetic counseling of families. However, most known microdeletion syndromes, will be clinically 
recognized by experienced clinical geneticists and can be confirmed by specifically designed 
FISH tests. Therefore, patients with a recognizable microdeletion syndrome will only rarely be 
sent in for microarray analysis. Moreover, in contrast to genome-wide microarray approaches, 
targeted approaches will miss sporadic DNA copy-number changes in MR, as these regions will 
not be represented on such microarrays.30 The latter might be overcome if the targeted array is 
up-dated, regularly, by including all newly and uniquely reported microaberrations. By doing so, 
one might eventually end up with a whole genome-wide array.
Our study indicates that de novo submicroscopic aberrations that are not flanked by genomic 
architectural features conferring susceptibility to rearrangements appear to be non-recurrent in a 
large cohort of patients. In the future it is conceivable that advanced technologies and results from 
large numbers of patient studies will help unravel the majority of genes involved in MR, thereby 
making targeted testing approaches more viable. However, in the meantime, we recommend the 
use of genome-wide microarrays when testing idiopathic MR patients for genome imbalance.
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Abstract
Submicroscopic genomic copy number changes have been identified only recently as 
an important cause of mental retardation. We describe the detection of three interstitial, 
overlapping 17q21.31 microdeletions in a cohort of 1,200 mentally retarded individuals 
associated with a clearly recognizable clinical phenotype of mental retardation, hypotonia and 
a characteristic face. The deletions encompass the MAPT and CRHR1 genes and are associated 
with a common inversion polymorphism. 
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Introduction
Mental retardation is the most common developmental disorder, affecting intellectual and 
adaptive functions with a frequency of approximately 2–3% in the general population. Whole-
genome scanning technologies such as array-based comparative genomic hybridization (array 
CGH)1 have enabled the detection of interstitial submicroscopic copy number alterations in 
~10% of individuals with mental retardation of unknown etiology.2
Material and methods
Individuals
We tested 360 mentally retarded individuals for copy number changes using our genome-wide 
tiling resolution microarray in a diagnostic setting.2 Previous routine chromosome analysis was 
normal and subtelomeric MLPA failed to reveal any anomalies (SALSA MLPA kit P036, MRC 
Holland, Amsterdam, the Netherlands) in all individuals. In addition, we tested a cohort of 
840 mentally retarded individuals for copy number changes in the 17q21.31 region by MLPA. 
DNA samples of these individuals were collected from centers in Oxford, UK (n=130), Antwerp, 
Belgium (n=130), Zurich, Switzerland (n=100), Troina, Italy (n=130), Stockholm, Sweden (n=70) 
and Nijmegen, The Netherlands (n=280). We obtained informed consent from the parents, 
including consent to publish photographs of all subjects described in this study.
Clinical description of individuals with the 17q21.31 deletion
Individual 1
The chromosomes of this 3 year-old-girl were analyzed prenatally and found to be normal. 
She was born at 35 2/7 weeks gestation with a birth weight of 2,078 g (10th centile) and head 
circumference of 30.4 cm (5th centile). She was severely hypotonic and her development 
was considerable delayed: sitting at 3 years and no words at 3 years and 1 month. Magnetic 
Resonance Imaging (MRI) of the brain at 1 year of age showed widened ventricles and 
periventricular white matter changes. Electromyography (EMG) was normal, but Brainstem 
Evoked Response Audiometry (BERA) was abnormal. At 3 months she was treated for a 
congenital hip dysplasia. Diagnostic testing including DNA analysis for myotonic dystrophy, 
Spinal Muscular Atrophy (SMA), Prader-Willi syndrome, metabolic screening in blood and urine 
revealed no abnormalities. 
On physical examination at the age of 3 years and 1 month, her height was 95 cm (40th centile), 
weight 12.5 kg (10th centile for height) and head circumference 49.5 cm (50th centile). She had a 
long hypotonic face with frontal bossing and bitemporal narrowing, ptosis, blepharophimosis, 
upward slanting palpebral fissures, epicanthal folds, large low set ears with hypoplastic crus 
superior, low nasal bridge, bulbous nasal tip, long columella, triangular nostrils, high palate with 
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broad gums and a broad chin (Figure 3.3.1a). Her broad thorax had wide-space nipples and a 
mild pectus excavatum. She had long fingers, narrow long feet with long toes and hyperlaxity 
of the joints (Beighton score of 6/10). She was good natured with normal eye contact. 
Individual 2
This 17-year-old, moderately mentally retarded woman was born at 38 weeks gestation in 
breech position with a caesarian section and she had a birth weight of 1,980 g (<3rd centile). 
In the first 3 weeks she received nasal catheter feeding because of low glucose levels and 
phototherapy because of hyperbilirubinaemia. She was hypotonic and started walking and 
speaking after the age of 2 years. She had an IQ of 48 points and attended special schooling. 
From the age of 1.5 to 3.5 years she had epileptic insults for which antiepileptic drugs were 
used. An MRI of the cerebrum showed wide ventricles, especially of the temporal horn of the 
lateral ventricles. In addition, routine chromosome analysis, metabolic screening in blood and 
urine and EMG, revealed no abnormalities. She developed a scoliosis at 13 years of age. She 
had normal hearing but mildly impaired vision (+4/+4). 
On physical examination at the age of 17 years, she had a low-normal height of 160.8 cm 
(10th centile). Her weight was 51.2 kg (50th centile for height) and head circumference 53 cm 
(10th centile). She had a long hypotonic face with ptosis, blepharophimosis, upward slanting 
palpebral fissures, large ears with hypoplastic crus superior, tubular pear-shaped nose with 
high nasal bridge and long columella, short philtrum, 2 missing upper teeth, everted lower lip 
and broad chin (Figure 3.3.1b). She had a thoracal scoliosis with a lumbar hyperlordosis. Her 
hands and fingers were long and slender with a simian crease in the left palm. Her feet had 
high arches with hallux valgus bilaterally and mild hammer toes. The lower part of the limbs 
were slender and there was a mild general decrease of strength. In addition, she had mild 
hyperlaxity of the finger joints (Beighton score of 2/10), and numerous moles on the skin. She 
had nasal speech and an amiable nature. 
Individual 3
This 26-year-old, moderately mentally retarded male was born after an uneventful pregnancy 
at term with a normal birth weight of 3,120 g (50th centile) but a large head circumference 
of 37.5 cm (>97th centile). He was notably hypotonic and computed tomography imaging 
of the brain at 4 months of age showed a communicating hydrocephaly without increased 
intracranial pressure. Both Somatosensory Sensory Evoked Potentials (SSEP) and BERA studies 
were abnormal at 6 months but normalized later in life. His development was retarded, walking 
at 3 years of age and he attended special school. He had an IQ of 40 points at the age of 18 
years. He was operated on inguinal hernia and cryptorchidism. A scoliosis developed at 13 
years of age. Diagnostic test including routine chromosome, FMR1 analysis and metabolic 
screening in blood and urine revealed no abnormalities. 
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On physical examination at the age of 26 years, he had a low-normal height of 173 cm (10th 
centile), and a large head circumference of 63 cm (>97th centile). His weight was 68 kg (70th 
centile for height). He had a long narrow face with a high, broad forehead, blepharophimosis, 
strabismus divergence, large ears with hypoplastic crus superior and large lobules, tubular 
pear-shaped nose with bulbous tip and long columella, high palate with broad gums and 
diastemia frontal upper teeth, and a large broad chin (Figure 3.3.1c). The thorax was flat and 
broad with wide-spaced nipples and a scoliosis. 
His hands and fingers were long and hyperlax (Beighton score of 4/10). His feet had high arches 
with hallux valgus bilaterally and his skin revealed numerous moles. He had nasal speech and 
a friendly nature. 
Array-based comparative hybridization
Microarray preparation, hybridization, and data analysis were performed as described 
previously.2 In brief, the array contains 32,447 BAC clones resulting in a complete coverage of 
the human genome.3 The array CGH profiles were established through co-hybridization of 500 
ng Cy3-dUTP labeled patient DNA and 500 ng sex-mismatched Cy5-dUTP labeled (Amersham 
Biosciences) reference DNA. After scanning, test-over-reference ratios were determined for 
each clone, log2-transformed and normalized by subtracting its local mean log2 test-over-
reference ratio obtained by a weighted median filter. The normalized ratios were analyzed for 
loss and gain regions by a standard hidden Markov model (HMM). 
Copy number screening of the 17q21.31 region by MLPA
We used MLPA4 to screen for copy number changes at 17q21.31 in the cohort of 840 mentally 
retarded individuals. A set of uniquely-sized MLPA probes, hybridizing to exon 3 and 13 of 
CRHR1, and to exon 2 of MAPT was used. The probes were designed according to a protocol 
Figure 3.3.1: Clinical characteristics of the 17q21.31 deletion syndrome. (a) Patient 1, at 3 years of age. (b) pa-
tient 2, at 17 years of age, and (c) patient 3, at 26 years of age. Note the characteristic facial features, a hypotonic 
face with ptosis, blepharophimosis, large low set ears, bulbous nasal tip, long collumella with hypoplasic alae 
nasi, and a broad chin. For color figure see page 194.
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provided by MRC-Holland (http://www.mlpa.com/index.htm). The three MLPA probes were 
combined in one MLPA assay in conjunction with three standard control probes (VIPR2, 
MRPL41, and KIAA0056). Probe sequences are provided in Table 3.3.1. Hybridization, ligation 
and amplification of the MLPA probes were performed as described before.4 Amplification 
products were identified and quantified by capillary electrophoresis on a genetic analyzer (ABI 
3730 or 3100), using GeneMapper software (Applied Biosystems). 
Data were normalized by dividing each probe’s signal strength by the average control probe 
signal strength of the sample. This normalized peak pattern was divided by the average peak 
height of all the samples in the same experiment. Copy number change detection was based 
on thresholds for gains and losses of 1.30 and 0.70 respectively (±3 SD). The MLPA analysis 
was repeated for all samples in which an aberration was identified. For these confirmation 
experiments, DNA samples of healthy controls were used for the normalization. 
FISH validation studies and de novo occurrence. 
The 17q21.31 deletions identified by array CGH and MLPA were validated and tested for de 
novo occurrence by fluorescence in situ hybridization (FISH) analysis on fixed metaphase 
spreads from the respective patients and their parents as described before.2 BAC clones in 
the aberrant 17q21.31 region were selected and used as probes in the FISH validation assay. 
In addition, parental DNA samples were tested using the same synthetic MLPA probe set 
described above. 
Genotyping for H1 and H2, and parent-of-origin analysis. 
The presence of an intronic 238-bp deletion in intron 9 of the MAPT gene, characteristic for 
the H2 background,5 was used to genotype individuals with the 17q21.31 deletion and the 
accompanying parental DNA 1 samples. The 238-bp deletion, if present, was determined by 
visualizing PCR product on an agarose gel. PCR reactions were performed using primer sequences 
GGAAGACGTTCTCACTGATCTG (sense) and AGGAGTCTGGCTTCAGTCTCTC (antisense) as 
described previously5 in a 25 μl reaction mixture containing 50 ng of template DNA, 10 pmol of 
each primer, 0.4 mM dNTPs, 1.6 mM MgCl2, and 1.25 U Amplitaq Gold Polymerase (Invitrogen). 
PCR conditions were as follows: 3 min 94°C followed by 5 cycles 94°C for 30s, 60°C for 30s, 72°C 
for 45 sec. Subsequently, a 10 cycle touchdown from 60°C to 50°C was performed, followed 
by 20 cycles 94°C for 30s, 50°C for 30s, 72°C for 45s, with a final extension 72°C for 10 min. 
The dinucleotide marker, DG17S142 in intron 9 of the MAPT gene, was used for independent 
validation of the H1/H2 genotyping. Two additional markers, D17S810 and D17S920, were used 
to study the parental origin of the deletions according to standard procedures
Computational analysis. 
The chromosome 17 H1 lineage sequence map, was reconstructed for the region of interest 
(40.5 Mb – 42.0 Mb) based on the finished human chromosome 17 sequence.5 Interspersed 
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repeat sequences within the reconstructed DNA sequence were eliminated by RepeatMasker 
(http://genome.ucsc.edu) and the repeat masked genomic sequence was analyzed using NCBI 
BLAST2 for the identification of LCRs (http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html). All 
LCRs identified on H1 were in concordance with the previous study of Stefansson et al.6 LCR 
structures for the H2 lineage were adapted from Stefansson et al.6 The H2 lineage differs from 
the H1 lineage by a common 900-kb inversion polymorphism, the presence of a 32-kb DNA 
sequence (LCR17qE) that is present in two copies on the H2 lineage whereas only once on the 
H1 lineage,6 and the absence of LCR17qC. 
Results and discussion
After obtaining informed consent, we tested 360 mentally retarded individuals within 
a diagnostic setting for copy number changes using our genome-wide tiling resolution 
microarray containing 32,477 BAC clones. In one individual, we identified a copy number 
loss with an approximate size of 600 kb at 17q21.31, encompassing eight BAC clones (Figure 
3.3.2a). Subsequently, we screened a cohort of 840 mentally retarded individuals for deletions 
in the 17q21.31 region using multiplex ligation-dependent probe amplification4 with probes 
hybridizing to unique sequences in two genes located within this region, MAPT and CRHR1. 
By doing so, we identified two additional individuals with microdeletions in 17q21.31 (Figure 
3.3.2b), with identical genomic sizes and deletion breakpoints at the BAC clone level. One of 
these breakpoints was identical to that of the index individual, whereas the other breakpoint 
was located ~100 kb distal to the first (Figure 3.3.4). For all individuals, we confirmed the 
presence of the 17q21.31 deletion by FISH and showed that it arose de novo (Figure 3.3.2c-k). 
In addition, the 17q21.31 deletion region has not been reported to show copy number variation 
in normal individuals (Database of Genomic Variants; http://projects. tcag.ca/variation/).
We identified the deletions at 17q21.31 in a 3-year-old, moderately mentally retarded girl 
(individual 1), a 17-year-old, moderately mentally retarded woman (individual 2) and a 
26-year-old, moderately mentally retarded male (individual 3). In all three individuals, severe 
hypotonia was present from birth onwards, leading to severely delayed motor development. 
None of the individuals could stand and/ or walk before the age of three years. Upon physical 
examination, we noted characteristic facial features. All showed a long hypotonic face with 
ptosis, blepharophimosis, large, low-set ears, tubular pear-shaped nose with bulbous nasal 
tip, long columella with hypoplastic alae nasi and a broad chin (Figure 3.3.1). In addition, 
they all had long fingers, nasal speech and displayed an amiable and friendly disposition. The 
individuals had wide ventricles, as assessed by magnetic resonance imaging before the age of 
1 year, whereas individual 1 had additional periventricular white matter abnormalities. Both 
individual 2 and individual 3 developed a hallux valgus, a pes cavus and, at 13 years of age, a 
thoracal scoliosis, probably due to marked hypotonia (Table 3.3.2).
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Figure 3.3.2: Analysis of individuals with the 17q21.31 microdeletion syndrome. (a) Chromosome 17 array CGH 
profile of individual 1 with a copy number loss of eight adjacent BAC clones on 17q21.31 (arrow). Clones are 
ordered on the x axis according to physical mapping positions; log2-transformed test-over-reference (T/R) in-
tensity ratios for each clone are given on the y axis. (b) Multiplex ligation-dependent probe amplification (MLPA) 
analysis, showing a deletion of two probes in CRHR1 and one probe in MAPT for both individual 2 (triangles) and 
individual 3 (squares). The circles represent the MLPA ratios of healthy controls. FISH validation of the 17q21.31 
deletion in individuals 1, 2 and 3 (c-e) and testing for de novo occurrence in the accompanying parents (f-k) 
using BAC clone RP11-656O14 (red) which is located within the deleted region. The centromere 17 probe was 
included for reference (green). All individuals show only one signal for RP11-6565O14 (arrow indicating aberrant 
chromosome 17). The de novo occurrence for the deletion was proven in all individuals. For color figure see page 
195.
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Notably, the deletions in 17q21.31 are all located within a genomic region that was recently 
reported to harbor a common 900-kb inversion polymorphism.6 For this region, two main 
and highly divergent haplotypes, designated H1 and H2, have been found. The H2 lineage, 
representing the 900-kb inversion polymorphism, is found at a frequency of 20% in Europeans 
and can be distinguished from the H1 lineage by genotyping of a dinucleotide marker 
(DG17S142) in intron nine of MAPT and by a characteristic 238-bp deletion in the same intron.6 
For all three individuals, one of the parents carried the H2 haplotype: the father of individual 
1 and the mother of individual 2 were heterozygous for this haplotype, and the mother of 
individual 3 was homozygous (Figure 3.3.3). Parent-of-origin analysis showed that the deletion 
occurred on the H2 haplotype in individual 1 and 3, whereas the results for individual 2 were 
inconclusive (Figure 3.3.3). Notably, the H2 haplotype differs from the H1 by a directly oriented 
low-copy repeat (LCR), LCR17qE (Figure 3.3.4) that immediately flanks the breakpoints in all 
three individuals. This suggests that these deletions have resulted from nonallelic homologous 
recombination5, mediated by this H2-specific LCR. Consequently, carriers of the H2 lineage are 
likely to be predisposed to nonallelic homologous recombination, similarly to predisposing 
Figure 3.3.3: Genotyping for H1 and H2 lineage and parent-of-origin analysis. (a) Genotyping for the H1 (483 
bp) and H2 (245 bp) lineages. Far left and far right: 100-bp marker lanes. Individual 3 carries the deletion on the 
H2 lineage and is of maternal origin. (b) Individual 1 and the parents were genotyped using D17S810, DG17S142 
and D17S920 to determine the parental origin of the deletion. The deletion was of paternal origin, and was pres-
ent on the H2 haplotype.  For color figure see page 196.
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inversion polymorphisms, which have been observed in other microdeletion syndromes such 
as Williams-Beuren syndrome, Angelman syndrome and Sotos syndrome.7
We detected the three individuals with a similar 17q21.31 microdeletion in an unselected 
European cohort of 1,200 individuals with mental retardation, resulting in an overall detection 
frequency of 0.3%. As mental retardation occurs in 2–3% of the general population, it can be 
estimated that the prevalence of this new syndrome is between 1 in 13,000 and 1 in 20,000. 
This makes it less common than the estimated population prevalence of the 22q11 deletion 
(DiGeorge-velocardiofacial syndrome) of 1 in 4,000,8 but similar in frequency to Williams-
Beuren syndrome, which has a frequency of 1 in 10,000 to 1 in 20,000.9 Notably, two other 
single cases have been reported.10,11
The 17q21.31 deletion encompasses two known genes, CRHR1 (NM_004382) and MAPT 
(NM_005910), and at least two putative genes, IMP5 (NM_175882) and STH (NM_001007532). 
Loss-of-function mutations have not been reported for any of these genes in humans. However, 
gain-of-function mutations in MAPT, encoding the microtubule-associated protein TAU, cause 
autosomal dominant forms of frontotemporal dementia and parkinsonism.12,13 Abnormal 
filamentous TAU deposits have been reported as a pathological characteristic in several other 
neurodegenerative diseases.13 Haploinsufficiency for the microtubule-associated protein TAU 
may affect axonal elongation and neuronal migration, thereby explaining the major clinical 
features observed in the 17q21.31 microdeletion-positive individuals (that is, severe hypotonia 
and moderate mental retardation). In support of this, tau-deficient mice showed muscle 
weakness and memory disturbance.14,15 
Table 3.3.2: Clinical data from individuals with a 17q21.31 deletion
 Individual 1 Individual 2 Individual 3
Level of MR Moderate Moderate Moderate
Hypotonia +++ ++ +++
Characteristic face   
Long + + +
Blepharophimosis + + +
Ptosis + + +
Tubular pear-shaped nose + + +
Long columella/ hypoplasic alae nasi + + +
Broad nasal tip + + +
Large ears + + +
Broad chin + + +
Friendly/amiable behavior + + +
Brain anomalies WV, PWM WV WV
MR: mental retardation; +: present; -: absent. Hypotonia: +: mild; ++: moderate; +++: severe. Brain anomalies: WV: 
wide ventricles; PWM: periventricular white matter.
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In conclusion, we report a previously unknown, clinically recognizable syndrome defined by a 
17q21.31 microdeletion that includes MAPT. The deletion is flanked by LCRs and is associated 
with a common inversion polymorphism. This observation underscores the relevance of 
genomic architectural features as the main determinant for the de novo occurrence of recurrent 
segmental aneuploidies.
Acknowledgements
We are thankful to all individuals and parents who participated in this study. In addition, we 
want to thank I. Scheltinga, I. Neefs, I. Janssen, W. van der Vliet, H. Mieloo, H. Venselaar, G. 
Schobers and W. Nillesen for expert technical assistance and C. van Ravenswaaij-Arts, M. Ruiter, 
J. de Bruin and K. Ultee for referral of individuals and clinical analysis. This work was supported 
by grants from the Netherlands Organisation for Health Research and Development (ZON-
MW) (D.A.K., J.A.V., H.G.B. and B.B.A.d.V.), Hersenstichting Nederland (B.B.A.d.V.), The Health 
Foundation (S.J.L.K.) and The Swedish Research Council (J.S. and B.M.A.).
Figure 3.3.4: Transcript map and genomic architecture for the H1 and H2 lineage of the 17q21.31 region. (Dot-
ted) black lines represent the deleted 17q21.31 region identified in the three individuals. Genes located within 
this region are depicted by black arrows. The H1 and H2 lineage LCR17q structures are depicted as rectangles 
with colors signifying shared homology and horizontal arrows showing relative orientation (LCR17qA, red; 
LCR17qB, green; LCR17qC, purple; LCR17qD, blue; LCR17qE, yellow). Note the different genomic orientation of 
H2, the absence of LCR17qC and presence of LCR17qE. Cen, centromeric; Tel, telomeric. For color figure see page 
196.
opmaak koolen.indd   120 10-09-2008   10:12:19
121
Identification of the 17q21,31 microdeletion syndrome
References
 1.  Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using com-
parative genomic hybridization to microarrays. Nat Genet 1998;20:207-211.
 2.  de Vries BB, Pfundt R, Leisink M et al. Diagnostic genome profiling in mental retardation. Am J Hum 
Genet 2005;77:606-616.
 3.  Ishkanian AS, Malloff CA, Watson SK et al. A tiling resolution DNA microarray with complete coverage 
of the human genome. Nat Genet 2004;36:299-303.
 4.  Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 
40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 
2002;30:e57.
 5.  Baker M, Litvan I, Houlden H et al. Association of an extended haplotype in the tau gene with progres-
sive supranuclear palsy. Hum Mol Genet 1999;8:711-715.
 6.  Stefansson H, Helgason A, Thorleifsson G et al. A common inversion under selection in Europeans. Nat 
Genet 2005;37:129-137.
 7.  Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006;7:85-
97.
 8.  Lindsay EA. Chromosomal microdeletions: dissecting del22q11 syndrome. Nat Rev Genet 2001;2:858-
868.
 9.  Donnai D, Karmiloff-Smith A. Williams syndrome: from genotype through to the cognitive phenotype. 
Am J Med Genet 2000;97:164-171.
10.  Shaw-Smith C, Redon R, Rickman L et al. Microarray based comparative genomic hybridisation (array-
CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disa-
bility/mental retardation and dysmorphic features. J Med Genet 2004;41:241-248.
11.  Varela MC, Krepischi-Santos AC, Paz JA et al. A 17q21.31 microdeletion encompassing the MAPT gene 
in a mentally impaired patient. Cytogenet Genome Res 2006;114:89-92.
12.  Hutton M, Lendon CL, Rizzu P et al. Association of missense and 5’-splice-site mutations in tau with the 
inherited dementia FTDP-17. Nature 1998;393:702-705.
13.  Rademakers R, Cruts M, van BC. The role of tau (MAPT) in frontotemporal dementia and related tauo-
pathies. Hum Mutat 2004;24:277-295.
14.  Takei Y, Teng J, Harada A, Hirokawa N. Defects in axonal elongation and neuronal migration in mice 
with disrupted tau and map1b genes. J Cell Biol 2000;150:989-1000.
15.  Ikegami S, Harada A, Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditio-
ning in tau-deficient mice. Neurosci Lett 2000;279:129-132.
opmaak koolen.indd   121 10-09-2008   10:12:20
opmaak koolen.indd   122 10-09-2008   10:12:20
Chapter 3.4
Clinical and molecular delineation of the 
17q21.31 microdeletion syndrome 
Koolen DA1, Sharp AJ2,3, Hurst JA4, Firth HV5, Knight SJ6, Goldenberg A7, Saugier-Veber P7, 
Pfundt R1, Vissers LE1, Destrée A8, Grisart B8, Rooms L9, Van der Aa N10, Field M11, Hackett A11, 
Bell K12, Nowaczyk MJ13, Mancini GM14, Poddighe PJ14,  Schwartz CE15, Rossi E16,  
De Gregori M16, Antonacci-Fulton LL18, McLellan II MD18, Garrett JM18, Wiechert MA18,  
Miner TL18, Crosby S18, Ciccone R16, Willatt L5, Rauch A19, Zenker M19, Aradhya S20,  
Manning MA21, Strom TM22, Wagenstaller J22, Krepischi-Santos AC23, Vianna-Morgante AM23, 
Rosenberg C23, Price SM4, Stewart H4, Shaw-Smith C5, Brunner HG1, Wilkie AO24, Veltman JA1, 
Zuffardi O16,17, Eichler EE2,25, de Vries BB1
1Department of Human Genetics, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical 
Center, Nijmegen, The Netherlands. 2Department of Genome Sciences, University of Washington School of Medicine, 
Seattle, USA. 3Department of Genetic Medicine and Development, University of Geneva Medical School CMU, Geneva, 
Switzerland. 4Department of Clinical Genetics, Oxford Radcliffe Hospitals National Health Service (NHS) Trust, Churchill 
Hospital, Oxford, UK. 5Department of Medical Genetics, Addenbrooke’s Hospital, Cambridge, UK. 6Oxford Genetics 
Knowledge Park, The Wellcome Trust Centre for Human Genetics, Churchill Hospital, Oxford, UK. 7Department of 
Genetics, Rouen University Hospital, & Inserm U614, Institute for Biomedical research, University of Rouen, Rouen, 
France. 8Centre de Génétique Humaine, Institut de Pathologie et de Génétique, Gosselies, Belgium. 9Department of 
Medical Genetics, University of Antwerp, Antwerp, Belgium. 10Antwerp University Hospital, Antwerp, Belgium. 11Hunter 
Genetics, Hunter New England Area Health Service, Newcastle, NSW, Australia. 12Genetic Services, McMaster University 
Medical Centre, Hamilton, Canada. 13Department of Pathology and Molecular Medicine, McMaster University, 
Hamilton, Ontario, Canada. 14Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands. 
15JC Self Research Institute, Greenwood Genetic Center, Greenwood, USA. 16Biologia Generale e Genetica Medica, 
Università di Pavia, Pavia, Italy. 17Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 18Genome Sequencing Center, 
Washington University School of Medicine, St. Louis, MO, USA. 19Institute of Human Genetics, University Hospital 
Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. 20Department of Pathology, 
Stanford University School of Medicine, Stanford, California, USA. 21Division of Medical Genetics, Department of 
Pediatrics, Stanford University School of Medicine, Stanford, California, USA. 22Institute of Human Genetics, GSF 
National Research Center for Environment and Health, Munich-Neuherberg, Germany. 23Department of Genetics 
and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, Brasil. 24Weatherall Institute 
of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK. 25Howard Hughes Medical Institute, 
Seattle, USA.
J Med Genet (in press).
opmaak koolen.indd   123 10-09-2008   10:12:20
124
Chapter 3
Abstract
The chromosome 17q21.31 microdeletion syndrome is a novel genomic disorder that has 
originally been identified using high-resolution genome analyses in patients with unexplained 
mental retardation. Here we report the molecular and/or clinical characterization of 22 
individuals with the 17q21.31 microdeletion syndrome. We estimate the prevalence of the 
syndrome to be 1 in 16,000 and show that it is highly underdiagnosed. Extensive clinical 
examination reveals that developmental delay, hypotonia, facial dysmorphisms including 
a long face, a tubular or pear-shaped nose and a bulbous nasal tip, and a friendly/amiable 
behaviour are the most characteristic features. Other clinically important features include 
epilepsy, heart defects (ASD, VSD) and kidney/ urologic anomalies. Using high-resolution 
oligonucleotide arrays we narrow the 17q21.31 critical region to a 424-kb genomic segment 
(chr17: 41046729-41470954, hg17) encompassing at least six genes, among which the gene 
encoding microtubule-associated protein tau (MAPT). Mutation screening of MAPT in 122 
individuals with a phenotype suggestive of 17q21.31 deletion carriers, but who do not carry 
the recurrent deletion, failed to identify any disease-associated variants. In five deletion carriers 
we identify a <500-bp rearrangement hotspot at the proximal breakpoint contained within 
an L2 LINE motif and show that in every case examined the parent originating the deletion 
carries a common 900-kb 17q21.31 inversion polymorphism, indicating that this inversion is a 
necessary factor for deletion to occur (p<10-5). Our data establish the 17q21.31 microdeletion 
syndrome as a clinically and molecularly well recognizable genomic disorder.
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Introduction
Microdeletion syndromes, such as Prader-Willi syndrome, Williams-Beuren syndrome and 
velocardiofacial syndrome, were initially clinically described before the underlying causative 
genomic copy number rearrangement was identified. The introduction of microarray-based 
technology enabled genome profiling in large cohorts of individuals with mental retardation, 
resulting in the detection of recurrent microdeletions prior to their clinical description. The 
chromosome 17q21.31 microdeletion syndrome [Mendelian Inheritance in Man (MIM) 
#610443] is such a new genomic disorder, characterized by a recurrent 500-650 kb deletion 
involving chromosome 17q21.31.1-3 The recurrent microdeletion was first identified after 
screening of large heterogeneous cohorts of individuals with mental retardation using high-
resolution microarray screening technologies.1-3 
So far, fourteen 17q21.31 deletions were reported in the medical literature,1-8 but for the 
majority of these cases only limited clinical and molecular data was presented. Further cases 
and extensive clinical descriptions and molecular studies are needed in order to define the 
phenotype and genotype of the syndrome.
In all 17q21.31 deletions studied to date the breakpoints map to large clusters of flanking low-
copy repeats (LCRs) suggesting that the deletions are stimulated by non-allelic homologous 
recombination (NAHR),9 which is further supported by the identification of the reciprocal 
duplication in a girl with severe psychomotor developmental delay and dysmorphic craniofacial 
features.10
We previously estimated the minimal critical region that is recurrently deleted in individuals 
with the 17q21.31 microdeletion syndrome to a 478-kb region,2 encompassing six genes, 
including the corticotropin-releasing hormone receptor 1 gene (CRHR1) (MIM #122561) and 
the microtubule-associated protein tau gene (MAPT) (MIM #157140). The deletion interval 
is also the site of a common ~900 kb inversion polymorphism, associated with two highly 
divergent haplotypes designated H1 and H2.11 The H2 lineage, representing the 900 kb 
inversion polymorphism, is found at a frequency of 20% in the European population.11 So far, 
the parents of eight affected individuals have been tested and in all cases at least one of the 
parents carried the H2 haplotype.1-3 Therefore, it has been suggested that the offspring of 
carriers of the H2 lineage are likely to be predisposed to deletion,12 a phenomenon which has 
also been described in other microdeletion syndromes, such as Williams-Beuren syndrome, 
Angelman syndrome, Sotos syndrome,13 and the recently defined 15q13.3 microdeletion 
syndrome.14
Here we report a collection of 22 individuals with the 17q21.31 microdeletion syndrome. We 
determine the size of each deletion, allowing detailed delineation of the critical region. We 
also present the H1/H2 genotypes of the parents, further consolidating the involvement of 
the H2 haplotype in the deletion. Importantly, based on detailed clinical information of all 
deletion carriers, the clinical phenotype of the syndrome is characterized and an estimate of 
the prevalence of the 17q21.31 microdeletion syndrome is obtained.
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Materials and methods
Study Subjects
Twenty-two individuals (13 males and 9 females) with a 17q21.31 deletion were included in 
this study. In three cases the 17q21.31 deletion was suspected, prior to molecular studies, 
based on the clinical features of the patient. All 19 other cases had been included in broader 
cohorts of patients with mental retardation screened for genomic copy number changes. The 
identification of the 17q21.31 deletion in 11 individuals has previously been reported.1-8 The 
other cases were identified later using different molecular techniques: multiplex ligation-
dependent probe amplification (MLPA),15,16 1 Mb resolution BAC array CGH,6,7 quantitative 
multiplex PCR of short fluorescent fragments (QMPSF),17 fluorescence in situ hybridization 
(FISH), segmental duplication BAC microarray (SD array),18 chromosomal microarray analysis 
(CMA) version V6.0 (Baylor),19 whole-genome oligonucleotide array CGH (Agilent Human 
Genome CGH Microarray Kit 44A and 244A, Agilent Technologies, Santa Clara, CA),20 and 
single nucleotide polymorphism (SNP) micoarray (GeneChip Human Mapping 100K, Array Set, 
Affymetrix, Inc., Santa Clara, CA.)21 Clinical information and facial photographs were obtained 
from the referring clinicians. All legal representatives of the patients gave informed consent for 
the molecular studies and publication of clinical data.
In total 122 individuals (66 males and 56 females) with learning and/or speech and language 
delay who had a phenotype suggestive of the 17q21.3 microdeletion syndrome, based on facial 
characteristics and hypotonia, but who did not carry the recurrent deletion, were included in 
the study for sequencing of the MAPT gene. Microdeletion of 22q11.2  had been excluded 
previously in 48 patients.
This study was approved by the Medical Ethics Committee of the Radboud University Nijmegen 
Medical Center.
Deletion mapping by high-resolution microarray
The 17q21.31 deletions that had not been ascertained by a high-resolution microarray platform 
and for which genomic DNA was available were further characterized. For this study, 8 cases 
were tested using a Nsp1 250K SNP array, which contained 262,264 25-mer oligonucleotides. 
All SNP array experiments were performed according to manufacturer’s protocols (Affymetrix, 
Inc., Santa Clara, CA). Copy number estimates were determined using the CNAG software 
package (v2.0).22
In order to fine-map deletion breakpoints we used an ultra-high density custom oligonucleotide 
array (NimbleGen Systems, Madison, WI). This array consisted of 385,000 isothermal 45-75mer 
probes covering six genomic regions, including 121,041 probes specifically targeted to two 300-
kb intervals (chr17:40800000-41100000 and chr17:41550000-41850000, hg17), corresponding 
to the putative breakpoints of the 17q21.31 microdeletion (mean density, one probe per 5.2-
bp). Hybridizations were performed as described previously.18,23
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Genotyping for H1 and H2, and parent-of-origin analysis 
The presence of a 238-bp deletion in intron 9 of the MAPT gene, characteristic for the H2 
background,11,24,25 and the dinucleotide marker DG17S142 in intron 9 of the MAPT gene11 were 
used to genotype individuals with the 17q21.31 deletion and the accompanying parental DNA 
samples. The 238-bp deletion was determined through visualizing by gel electrophoresis. PCR 
reactions were performed using primer sequences GGAAGACGTTCTCACTGATCTG (sense) and 
AGGAGTCTGGCTTCAGTCTCTC (antisense) as described previously.24 The dinucleotide marker 
DG17S142, four additional variable number tandem repeats (VNTR) inside the deletion interval, 
and two flanking short tandem repeats D17S810 and D17S920, were used to study the parental 
origin of the deletions. All marker analyses were performed according to standard procedures and 
the size of the peaks were calculated with GeneMapper (v3.7) software (Applied Biosystems).
Mutation screening of MAPT
122 patients who presented with features potentially indicative of a deletion of 17q21.31 
were identified from clinical records. Each patient was first tested by MLPA (n=15) or array 
CGH using a custom segmental duplication BAC microarray (n=107),2 and found not to carry 
the recurrent 17q21.31 deletion. A further seven patients with known deletions of 17q21.311,2 
were also selected. Primers targeting all exons and splice sites of the MAPT gene were designed 
and whole genome amplification of genomic DNA (REPLI-g Kit, Qiagen Inc., Valencia, CA) 
performed to yield sufficient quantities of DNA for sequencing. High-throughput bidirectional 
dideoxynucleotide sequencing of PCR-amplified gene products was performed (http://genome.
wustl.edu/activity/med_seq/protocols.cgi) at the Genome Sequencing Center (Washington 
University, St. Louis, USA) and Department of Human Genetics Nijmegen (RUNMC, Nijmegen, 
the Netherlands) using standard protocols. PolyPhred,26 and PolyScan27 software were used 
to generate an automated report of sequence variations by comparison against reference 
sequences listed in the NCBI (RefSeq) database. Chromatograms were visually inspected for 
confirmation of non-synonymous sequence variations.
Results
Identification of novel 17q21.31 deletions
The individuals in whom a 17q21.31 deletion was identified were ordered by age at diagnosis, 
ranging from 10 months in case 1 to 26 years in case 22 (mean age at diagnosis 9 years). The 
identification of the 17q21.31 deletion in case 3, case 5-6, 8, 10, 12, 16-17, and case 20-22 had 
previously been reported.1-8 In addition, eleven previously unreported 17q21.31 deletions were 
ascertained: four novel deletions were found using targeted techniques (MLPA, n=2; QMPSF, 
n=1; FISH, n=1), two deletions by semi-targeted techniques (SD array, n=1; CMA V6.0, n=1), and 
five deletions were identified using whole-genome screening technologies (1 Mb resolution 
BAC array, n=1; 100K SNP array, n=2; Agilent whole-genome oligonucleotide array, n=2). Results 
of the FISH, MLPA, and QMPSF analyses, and an example of a chromosome 17 profile obtained 
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using whole-genome microarray technology are shown in Figure 3.4.1. Parental samples were 
available for 21 patients, and showed that in each case the deletion had arisen de novo.
Deletion mapping by high-resolution microarray analysis
Refinement of the 17q21.31 deletion intervals was conducted using 250K SNP array on DNA 
samples from eight patients (case 4, 6, 7, 10, 13-15, 19) and using ultra-high density custom 
oligonucleotide array targeted to the 17q21.31 region in five cases (cases 5, 8, 17, 21, 22). All 
cases had an overlapping deletion of the 17q21.31 interval. 
The SNP array analyses revealed a 458-kb region (chr17:41012856-41470954, hg17) that is recurrently 
deleted in the eight affected individuals but for which aneuploidy has not been reported in a 
control cohort of 240 individuals using similar arrays (unpublished results). The proximal breakpoint 
resided within a 100 kb region in all cases, whereas the distal breakpoint showed more variation. 
Note worthily, the distal breakpoint is also a site of frequent copy number variation in controls, most 
likely confounding the mapping and interpretation of this deletion breakpoint.
Figure 3.4.1: Identification of the 17q21.31 deletions. (a) Chromosome 17 plot of Case 1 obtained by whole-
genome oligonucleotide array (Agilent Human Genome CGH Microarray Kit 244A, Agilent Technologies). Chro-
mosome 17 is represented by 5,881 coding and noncoding human sequences (indicated by circles representing 
the log2-transformed and
 normalized test : reference intensity ratios [(Log2(T/R)], ordered from pter to qter
 for 
chromosome 17, in hg17 (NCBI build 35, May 2004). The arrow indicates the presence of a copy number loss at 
17q21.31. (b) FISH analysis on metaphase spreads of Case 7, using the BAC clones CTD-2324N3 (red) and RP11-
413P22 (green) which are both located within the deleted 17q21.31 region. The patient shows only one signal for 
CTD-2324N3 and RP11-413P22, indicating an aberrant chromosome 17 (arrow). (c) Detection of a heterozygous 
MAPT deletion in Case 4 using the microdeletion/ microduplication QMPSF assay. The electropherogram of the 
patient (in red) was superimposed on that of a normal female control (in blue) by adjusting to the same level 
the peaks obtained for the control amplicon. The Y-axis displays fluorescence intensity, and the X-axis indicates 
the genes tested. The heterozygous deletion is detected by a 50% reduction of the MAPT peak compared to the 
normal control (arrow). (d) MLPA results for Case 19 (triangles) and two healthy controls (rectangles), showing 
a deletion of all 13 probes in the CRHR1, IMP5, MAPT, and STH genes within the 17q21.31 genomic interval. For 
color figure see page 197.
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Figure 3.4.2: Ultra-high resolution oligonucleotide array analysis. Results of ultra-high resolution oligonucleo-
tide array analysis of the 17q21.31 microdeletion proximal breakpoint (mean probe density 1 probe/5.2 bp). (a) 
Data from a 50-kb region (chr17:41025000-41075000, hg17) in five unrelated 17q21.31 deletion patients and one 
control. In each deletion, the proximal breakpoint occured in a segmental duplication of length, 34.2 kb, identity 
98.7% (chr17:41026709-41060948). (b) Zoomed view showing a 5-kb region (chr17:41044500-41049500). All five 
patients have breakpoints which are indistinguishable, mapping to within an interval of <500 bp contained wit-
hin an L2 LINE motif. The highly variable dynamic response of certain probes in this region to report the deletion 
is likely a result of their different sequence properties.38 For each individual, deviations of probe log2-ratios from 
zero are depicted by gray/black bars, with those exceeding a threshold of 1.5 standard deviations from the mean 
probe ratio colored green and red to represent relative gains and losses, respectively. Tracks above each plot 
indicate segmental duplications (gray/yellow bars represent duplicons with 90–98%/98–99% sequence identity, 
respectively). For color figure see page 198.
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To further define the breakpoints we characterized the deletion in five different patients using 
an ultra-high density custom oligonucleotide array targeted to the 17q21.31 region, with 
a mean density of one probe per 5.2 bp. These data show that all five patients have proximal 
deletion breakpoints that map within an interval of <500-bp (chr17:41046729-41047168, hg17), 
contained within a single L2 LINE motif (Figure 3.4.2). Testing of nine control subjects (including 
carriers of both the H1 and H2 haplotypes) showed that this hybridization signature was specific 
to deletion patients and does not represent a copy number variation. In contrast, we were unable 
to identify a deletion signature at the distal breakpoint which was specific to deletion carriers. 
On the basis of the location of the L2 LINE element at the proximal side and the copy number 
variation identified in 240 normal controls at the distal side we refined the critical region to an 
424-kb genomic interval (chr17:41046729-41470954, hg17), relative to the H1 lineage.
Genotyping
We performed genotyping of the H1 and H2 haplotypes using a dinucleotide marker (DG17S142) 
in intron nine of MAPT and a characteristic 238-bp deletion in the same intron.11,24,25 In all 
parents tested (n= 42) at least one of the parents carried the H2 inversion and seven parents 
were homozygous for the H2 inversion. Genotyping of D17S810, DG17S142 and D17S920 and 
four polymorphic loci, designed in the deleted region, showed that the parent-of-origin carried 
the H2 inversion polymorphism (Table 3.4.1 and Figure 3.4.3). In total, eight deletions were of 
maternal origin and 12 were of paternal origin, whereas in two cases marker analysis could not 
distinguish between the parental chromosomes.
Figure 3.4.3: Genotyping H1 and H2 on 17q21.31 and parent-of-origin analysis. Genotyping results in the family 
of Case 4. (a) PCR results of a 238-bp deletion in intron 9 of MAPT indicative for the H2 lineage. Both parents are 
H1/H2 heterozygotes. Far left and far right: 100-bp marker lanes. (b) PCR results of a VNTR (chr17: 41,224,986-
41,225,022) within the deleted 17q21.31 region excluding a paternal origin. (c) Reconstruction of genomic 
markers located within and outside the deleted 17q21.31 segment shows the maternal origin of the deletion. 
Dinucleotide marker DG17S142 is indicative for the H2 lineage.11 
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Mutation screening of MAPT
Two novel non-synonymous mutations in MAPT were identified among the 122 non-deletion 
patients tested: (i) an identical heterozygous G>A transition at hg17 position chr17:41443588, 
resulting in the replacement of valine with isoleucine in an alternatively-spliced exon was 
detected in two unrelated patients; (ii) a heterozygous G>A transition at hg17 position 
chr17:41457221, resulting in the replacement of glycine with arginine. Screening of seven 
17q21.31 deletion patients did not identify any novel variants.
Clinical Details of the Study Subjects
The clinical features of the patients with a 17q21.31 deletion are listed in Table 3.4.2. A 
summary of the 22 patients is given below.
In the majority of cases (82%) the pregnancy was uneventful. In Case 2 however, the pregnancy 
was characterized by a placental abruption at seven weeks of gestation, and in Case 9 and 21, 
the pregnancy was complicated by intrauterine growth retardation. Low birth weight (<3rd 
centile) was noted in six (27%) individuals. Other birth measurements were within the normal 
range, although in Case 9 microcephaly was noted, and Case 3 and 14 were small for gestational 
age. Short stature (<3rd centile) was present in four patients (18%). Case 19 was investigated 
Table 3.4.1: Genotyping results
Case Father Mother Parent-of-origin
1 H1/H2 H1/H2 maternal
2 H1/H1 H1/H2 maternal
3 H1/H2 H1/H1 paternal
4 H1/H2 H1/H2 maternal
5 H1/H2 H1/H1 paternal
6 H2/H2 H1/H1 paternal
7 H1/H2 H1/H2 paternal
8 H2/H2 H1/H1 paternal
9 H1/H2 H1/H2 paternal
10 H1/H2 H1/H2 maternal
11 H2/H2 H1/H1 paternal
12 H2/H2 H1/H2 –
13 H1/H1 H1/H2 maternal
14 H1/H2 H1/H1 paternal
15 H1/H2 NA paternal
16 H1/H2 H1/H1 paternal
17 H1/H2 H1/H1 paternal
18 NA H1/H2 –
19 H1/H1 H2/H2 maternal
20 H1/H2 H2/H2 paternal
21 H1/H1 H1/H2 maternal
22 H1/H1 H2/H2 maternal
Note.The parent-of-origin was determined by genotyping for H1/H2 status as well as by other polymorphic 
markers in the region. For Cases 6, 8, 11, and 16 the parent-of-origin was inferred by SNP array data and 
extrapolation from child and parental alleles. NA: DNA sample not available. -: marker analyses could not 
distinguish between the paternal or maternal origin of the deletion.
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for short stature at 11 years of age, with a borderline low growth hormone measurement on 
provocation testing.
In all patients global psychomotor developmental delay was noted from an early age. The level 
of developmental delay varied significantly and was estimated from the mild to severe range. 
For example, in Case 17 the early motor milestones were delayed, but she started to walk at 
19 months, whereas Case 10 did not start walking before the age of four years. Eleven patients 
did not have any words before three years of age. The speech and language development of 
Case 17 were particularly affected. She did not achieve two-three word sentences until age six. 
Case 16 communicated primarily with gestures at six years of age, while Case 10 showed no 
understandable speech during the investigation at the age of six years and two months. 
Hypotonia with poor sucking and slow feeding was evident in the neonatal period and during 
childhood in all but one. In at least six patients feeding difficulties required hospitalization 
and/or nasogastric tube feeding in the neonatal period.
A history of epilepsy was noted in 50% of the cases. Generalized seizures were present in eight 
cases (36%). In Case 4 unilateral clonic seizures and hypotonia were observed 48 hours after birth. 
A parieto-occipital haemorrhagic infarction on the left side with bilateral ventricular haemorrhage 
was diagnosed and a large thrombus was identified in the terminal portion of the aorta. 
Dysmorphic craniofacial features present in more than half of the individuals included a high/
broad forehead, long face, upward slanting palpebral fissures, epicanthic folds, an abnormally 
formed nose (either “tubular” or “pear”-shaped), bulbous nasal tip, large prominent ears, everted 
lower lip and in addition, abnormal hair pigmentation and texture was observed in 12 individuals 
(55%). The nose can have a high nasal bridge, a broad nasal root, long columella, hypoplastic 
and/or thick alae nasi. Ophthalmological evaluation showed strabismus in 45% of patients and 
hypermetropia was present in 8 cases (36%). Facial photographs of 20 individuals are provided 
in figure 4. Facial photographs at different ages, spanning a significant period of time, could be 
obtained for five individuals (Figure 3.4.5). The facial characteristics of the patients change with 
age. In infancy the facial gestalt is mostly characterized by the hypotonia of the face with an open 
mouth appearance. However, with increasing age there is elongation of the face and broadening 
of the chin and also the “tubular” or “pear”-shape form of the nose becomes more pronounced.
Slender long fingers were reported in 61% of the patients. In addition, hypoplasia of the hand muscles 
was described in multiple patients (29%) as well as slender lower limbs (41%), dislocation of the 
hip(s) (27%), and positional deformities of the feet (27%). Case 13 had in-turned feet with significant 
pronation and had been fitted with an ankle-foot orthosis. He had progressive contractures in his 
wrists and ankles and bilateral ulnar deviation of his wrists and deviation of his toes.
Septal heart defects, both atrial septal defects (ASD) and ventricular septal defects (VSD), were 
found in 6 cases (27%). Kidney and urologic anomalies were found in 7 cases (32%). The latter 
included vesicoureteric reflux, hydronephrosis, right sided pyelectasis, and a duplex renal system. 
In Case 6 pyelonephritis and bilateral vesicoureteric reflux grade II was detected. In Case 14 a 
renal ultrasound at the age of five months showed left hydronephrosis due to a primary pelvi-
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Figure 3.4.4: Facial photographs of individuals with a 17q21.31 deletion. Facial photographs of Case 1, at age 10 
months; Case 2, at age 1 year; Case 3, at age 2 years; Case 4, at age 3 years; Case 5, at age 3 years; Case 6, at age 3 
years 5 months; Case 7, at age 3 years 8 months; Case 8, at age 3 years; Case 9, at age 5 years 8 months; Case 10 
at age 5 years; Case 11, at age 3 years 9 months; Case 12, at age 8 years 6 months; Case 14, at age 13 years; Case 
15, at age 14 years; Case 16, at 14 years; Case 18, at 16 years; Case 19, at 13 years; Case 20, at age 18 years; Case 
21, at 17 years and Case 22, at age 26 years. Informed consent was obtained for publication of photographs. For 
color figure see page 199.
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ureteric junction stenosis. Cryptorchidism was reported in seven out of nine male patients (78%) 
and deformity of the spine requiring treatment was present in eight patients (36%). The spine 
anomalies mostly included scoliosis, but lordosis and kyphosis were also reported. In Case 13 the 
scoliosis was progressing rapidly. A brace was required and an X-ray suggested that he might be 
suffering from a mild degree of restrictive lung disease. Magnetic resonance imaging of the spine 
showed a compression of the upper cervical spinal cord, due to developmental anomaly in the 
craniocervical junction and upper cervical canal. Imaging of the spine in Case 19 showed fusion 
of the C4/5 vertebrae and two small syringes in the thoracic cord.
Figure 3.4.5: Facial photographs at different ages. Facial photographs at different ages (<1, 1-4, 5-6, 7-12, and 
>12 years of age). Note that the facial characteristics of the patients change with age. With increasing age there 
is elongation of the face and broadening of the chin and also the “tubular” or “pear”-shape form of the nose 
becomes more pronounced. For color figure see page 200.
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In the vast majority of the patients (89%) the behavior was described as friendly, amiable 
and co-operative with or without frequent laughing. In contrast to this general pattern, the 
attention span of Case 7 was very short, his interaction with people limited, and he had temper 
tantrums. Additionally, Case 15 showed behavior problems including hyperactivity alternating 
with introspection, bad humor, and difficult interaction with other children.
Discussion
The 17q21.31 microdeletion syndrome is a new mental retardation syndrome.1-3 We performed 
an extensive clinical and molecular characterization of 22 patients. In the majority of cases 
the microdeletion was identified after microarray-based genomic copy number profiling 
of large heterogeneous cohorts of individuals with mental retardation. In only three cases 
the 17q21.31 deletion was suspected based on the clinical features of the patient (cases 
7, 8, 18). The remaining 19 cases had been included in broader cohorts including a total of 
2,978 patients with mental retardation. Therefore, the prevalence can be estimated to be 
in the order of 0.64% (95% CI, 0.35-0.93%) of the individuals with unexplained mental retardation. 
Mental retardation occurs in approximately 2-3% of the general population,28,29 of which in 
approximately 50% a diagnosis cannot be made.30 Therefore, we estimate the prevalence 
of the 17q21.31 deletion syndrome as approximately 1 in 16,000 individuals. For example, 
for the Netherlands, this implies that ~12 affected individuals are born each year. So far, 
only a total of four cases from the Netherlands have been reported, indicating that the 
17q21.31 deletion syndrome in individuals with mental retardation is currently highly 
underdiagnosed.
The 17q21.31 region contains multiple CNVs that are also found in the general population 
(http://projects.tcag.ca/variation/), complicating the definition of the precise deletion 
breakpoints. Based on 250K SNP array analyses we could delineate a minimal 424-kb 
critical region (41046729-41470954 Mb, hg17) that is recurrently deleted in patients, but 
not in controls. Further refinement of five deletions using an ultra-high density oligonucleotide 
arrays (mean density, one probe per 5.2 bp) revealed that the proximal breakpoint in all 
five tested patients is contained within an interval of <500-bp within an L2 LINE motif, representing 
a possible hotspot for NAHR. Even with the ultra-high density oligonucleotide arrays it is not 
possible to ascertain the distal breakpoint accurately. The deletion seems to extend more distally 
in some patients tested, although this might reflect the extreme copy number polymorphism at 
the distal side, rather than variation in the breakpoints. Future deep sequencing unraveling the 
H2-sequence and a putative common distal breakpoint, which is currently unknown, will be of 
major importance to prove NAHR as the underlying mechanism.
The 424 kb critical region encompasses at least six genes, C17orf69, CRHR1 (MIM #122561), IMP5 
(MIM #608284), MAPT (MIM #157140), STH (MIM #607067), and KIAA1267. Haploinsufficiency 
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of one or more of these genes might underlie the phenotype seen in the 17q21.31 deletion 
syndrome. The MAPT is of particular interest as the gene is highly expressed in brain and is 
involved in several neurodegenerative diseases, such as frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17),31,32 progressive supranuclear palsy,33 and 
corticobasal degeneration and Alzheimer’s disease.25 Therefore we performed mutation analysis 
of the entire coding sequence of the MAPT (MIM #157140) gene in 122 patients targeted for 
testing on the basis of clinical features but lacking the characteristic deletion. 
Two non-synonymous mutations of uncertain significance were found in this cohort. The first 
of these, resulting in the replacement of valine with isoleucine, was identified in two unrelated 
patients. Although not previously reported, the presence of this same variant in two unrelated 
individuals suggests that this it likely represents a rare polymorphism. Furthermore, the amino 
acids valine and isoleucine are structurally and biochemically quite similar, suggesting that this 
substitution is unlikely to significantly affect protein structure. The second variant identified 
results in the replacement of glycine with arginine at amino acid 389. This same amino acid 
variant has been previously reported in two families with Pick’s disease (frontotemporal 
dementia, MIM #172700).34,35 However, this variant only has mild effects on MAPT function 
and in neither of these reports did the mutation segregate with the neurological phenotype, 
suggesting that this may also represent a rare polymorphism. Although our extensive efforts 
to identify pathogenic mutations in MAPT did not uncover any variants that seem likely to 
be responsible for the phenotype, no firm conclusions can be made, because parental 
DNA samples were unavailable for further testing. These data suggest that the 17q21.31 
microdeletion syndrome is not caused solely by haploinsufficiency of MAPT, although single 
exon deletions could have been missed in our analyses. We speculate that the phenotype of 
the 17q21.31 deletion syndrome instead results from haploinsufficiency for one or more other 
elements within the critical region, perhaps representing a contiguous gene syndrome. This 
is in contrast to some other genomic disorders in which the associated phenotypes largely or 
completely result from haploinsufficiency for single genes, e.g. the RAI1 gene in Smith–Magenis 
syndrome,36 and the UBE3A gene in Angelman syndrome.37
The 17q21.31 genomic interval contains a common 900 kb inversion polymorphism, resulting 
in a haplotype block with two highly divergent haplotypes designated H1 and H2.11 
Genotyping the parents with respect to the H1/H2 lineage showed that in each trio tested the 
parent originating the deleted chromosome 17 carries at least one H2 chromosome, which is 
significantly different from the ~20% frequency of the inversion in the European population 
reported by Stefansson et al.11 (p<10-5, Pearson’s Chi square test). In total, eight deletions 
were of maternal origin and 12 were of paternal origin, indicating that there is no significant 
bias for parental origin of the deletion. The H2 haplotype results in a genomic structure with 
directly oriented LCR subunits that can undergo a deletion rearrangement via NAHR,38 which 
suggests that the inversion found in all parents of origin may be a necessary factor for the 
deletion to occur. Although the H2 allele is a risk factor, the frequency of de novo 17q21.31 
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microdeletions in carriers of the H2 inversion is low, therefore other as yet poorly understood 
factors are likely to be important in the generation of the deletion. Moreover, all deletions 
detected to date are sporadic. Therefore, assuming the H2 allele is requisite for the deletion, 
based on current knowledge, the occurrence risk for the 17q21.31 deletion in a carrier of the 
H2 inversion polymorphism might be considered to be in the order of 1/3,200 in European 
populations. However, from a genetic counseling perspective, the recurrence risk in a family of 
an affected individual could be higher, because of other factors such as germline mosaicism.
Our analysis of 22 patients with the 17q21.31 deletion syndrome shows a clinically recognizable 
phenotype. Common features present in more than 50% of the patients that should prompt 
consideration of this diagnosis include developmental delay, childhood hypotonia, abnormal 
hair color/texture, high/broad forehead, long face, upward slanting palpebral fissures, 
epicanthal folds, tubular or pear-shaped nose, bulbous nasal tip, large/prominent ears, slender/
long fingers, cryptorchidism, and a friendly/amiable behavior. Other common features that 
need special medical attention are epilepsy, hypermetropia, pectus excavatum, congenital 
heart defects (VSD/ASD), kidney and urologic anomalies, dislocation of the hip(s), positional 
deformities of the feet, and spinal deformities. Hypotonia of the face is most obvious in infancy 
with an open-mouth appearance, everted lower lip, and a protruding tongue. The typical nose 
and other facial characteristics can be observed from birth. However, with increasing age, there 
is a change in phenotype, which is also seen in other mental retardation syndromes, such as 
Mowat-Wilson syndrome,39 Noonan syndrome,40 and Williams-Beuren syndrome.41
In conclusion, the molecular and/or clinical characterization of 22 individuals with the 17q21.31 
microdeletion syndrome defines the phenotypic features associated with this novel syndrome 
and provides further insight into the critical region and rearrangement hotspot. Our data 
further support the hypothesis that the common 17q21.31 inversion polymorphism in the 
parent-of-origin is a necessary factor for the deletion to occur.
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4.1 Frequency of copy number variation in mental retardation
The identification of submicroscopic structural variation in the human genome has 
revolutionized the diagnostic process of patients with mental retardation. Through the 
development and implementation of novel methodologies the technical divide between 
molecular genetic and cytogenetic testing has been bridged and, by doing so, it has been 
emphasized that submicroscopic structural variants, notably copy number variations (CNVs), 
are an important cause of mental retardation. At the onset of the work described in this 
thesis the investigation of subtelomeric regions, mainly by FISH, had already revealed that 
cryptic subtelomeric CNVs are an important cause of otherwise unexplained cases of mental 
retardation.1,2 Subsequent high-throughput FISH-based methods enabled the detection of 
subtelomeric aberrations in a routine fashion,3,4 but these methods remained relatively labor 
intensive and expensive. Therefore, quantitative PCR-based technologies such as MAPH,5 
Q-PCR6 and MLPA7 were developed for a more rapid and comprehensive identification of these 
CNVs. We performed subtelomeric DNA copy number analyses using MLPA in individuals 
with unexplained mental retardation and identified clinically relevant CNVs in 4.3% of them, 
demonstrating that MLPA serves as a robust high-throughput method for the detection of 
subtelomeric rearrangements (Chapter 2.1). Moreover, clinical scoring8 of the patients revealed 
that subtelomeric screening may be offered to all mentally retarded patients, irrespective of the 
level of mental retardation. In a total of 33 different studies, encompassing ~3,800 subtelomeric 
copy number analyses, rearrangements were identified in 5-6% of cases with unexplained 
mental retardation.9 However, it should be noted that most of these reports represent proof-
of-concept studies employing pre-selected patient cohorts. This notion is underlined by the 
lower diagnostic yield of 2.5% obtained in two subtelomere studies of almost 19,000 unselected 
individuals with mental retardation.10,11 The majority of these patients (~12,000) were tested 
by FISH, implicating that in tandem microduplications could have been missed. Subtelomeric 
microduplications, however, appear to be a rare cause of mental retardation. Ballif et al. failed 
to encounter pathogenic microduplications in almost 7,000 patients analyzed by array CGH,10 
and we found pathogenic in tandem microduplications at the subtelomeres in only 0.5% of 
patients with mental retardation.12
In order to establish the frequency of interstitial CNVs in mental retardation, we studied 386 
patients using array CGH in conjunction with whole-genome tiling resolution BAC arrays 
(Chapter 3.1). The overall diagnostic yield of clinically significant CNVs in this patient cohort 
was 9.1%, thus emphasizing the diagnostic importance of genome-wide copy number 
profiling in patients with unexplained mental retardation. The overall yield of pathogenic 
CNVs in 1,364 patients reported in the literature was 11.2%. It should be taken into account, 
however, that similar to the initial subtelomeric studies, these studies are not representative 
for all patients with unexplained mental retardation. Clinical pre-selection for high resolution 
screening will become less rigorous in the near future as microarrays are increasingly being 
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implemented in routine clinical diagnostic settings. Using a clinical scoring system, we showed 
that the detection rate of 9.1% in our sample set partly reflected clinical pre-selection bias 
based on phenotypes with additional dysmorphic features and/or growth abnormalities. 
Clinical characterization of unselected patients with mental retardation using the same clinical 
scoring system allowed us to extrapolate the diagnostic yield, resulting in an expected yield 
of interstitial submicroscopic alterations over the genome within an unselected population of 
mentally retarded patients of ~8%.
Taken together, it has amply been shown now, by us and others, that submicroscopic copy 
number variation is an important cause of mental retardation. Cryptic subtelomeric and 
interstitial CNVs larger than 100-300 kb can be detected in ~3.0% and ~8.0% of the patients with 
unexplained mental retardation, respectively. Accordingly, submicroscopic CNVs account for 
~11% of previously unexplained cases of mental retardation, i.e., ~5% of the overall population 
of patients with mental retardation. This current frequency is likely to be an underestimate 
given the fact that most of the microarrays used only detect genomic rearrangements larger 
then 100-300 kb in size. The development of novel SNP-based microarrays (see below) allows 
high-resolution detection of even intra-genic (exon) deletions and duplications and, thus, will 
further increase the frequency of CNV detection in patients with mental retardation. Modeling 
of structural variants, including CNVs, strongly suggested that smaller structural variants are 
much more common in the genome than larger structural variants.13 Moreover, validation and 
refinement of the location of 1,695 structural variants across nine diploid human genomes 
showed that indeed the majority of the CNVs is 5-10 kb in size or less, and that for several 
sites (15%) the current reference human genome sequence represents the minor allele.14 The 
clinical significance of these small CNVs has still to be elucidated, but it is expected that only 
a minority will have a direct role in the etiology of mental retardation. However, since they far 
outnumber CNVs larger than 100-300 kb in size, the absolute contribution of these variants may 
still be significant (Figure 4.1). Consequently, we speculate that CNVs of 1 to 100 kb in size may 
account for at least another 5% of the causes of mental retardation. Obviously, further testing 
using high-resolution microarray and/or next-generation sequencing (see below) platforms is 
required to firmly establish the true frequency of this category of structural variants.
4.2  Clinical interpretation of copy number variation in mental 
retardation
The major challenge in studying CNVs and other forms of structural genomic variation is to 
identify the variants that have clinical consequences. Differentiation of CNVs identified by 
microarray platforms with a dosage-dependent phenotypic effect from those without such an 
effect is still complicated, mainly since the genomes of normal control individuals also show 
large-scale copy number variation.15,22,23 Redon et al. identified a total of 1,447 copy number 
variable regions covering ~12% of the human genome.15 Given the limited set of reference 
opmaak koolen.indd   146 10-09-2008   10:12:33
147
Discussion and future prospects
samples assayed, however, the CNVs reported by Redon et al. are probably just a tip of the 
iceberg. New tiling oligonucleotide-based microarrays are expected to reveal ~20 times more 
CNVs, i.e., 825-1500 CNVs per individual (Matt Hurles, the Wellcome Trust Sanger Institute, 
personal communication). The Database of Genomic Variants (hg17v2)22 suggests copy-
number variation in ~ 25% of the human genome. As yet, the clinical implications of these 
CNVs are far from understood. Moreover, many CNVs are population-specific and control CNV 
data are not available yet for all ethnic populations.15,24,25 
In Chapter 3.1, we propose a practical workflow for the diagnostic interpretation of CNVs. 
In order to understand the variations discovered by high-resolution microarray and/or next-
generation sequencing platforms (see below), thorough clinical characterization of patients 
and controls is a prerequisite. Currently, publicly available databases documenting CNVs 
identified in controls are used to discern common CNVs from rare CNVs. These databases, 
however, have mainly been created for research purposes and only a minority of the reported 
CNVs has actually been validated. Moreover, it has been shown that the CNVs listed in these 
databases are often smaller than previously thought, which may partly be attributed to the fact 
that the data were obtained using relatively low-resolution microarray platforms.14,26,27 In order 
to determine whether a CNV identified in a patient is a common variant, we used both publicly 
available and internal control datasets using the same microarray platform for analyzing both 
patients and controls (Chapter 3.1). It is anticipated that in the end every megabase of the 
human genome will show CNV in normal controls and, therefore, not only the presence or 
Figure 4.1: Frequency plot of CNV sizes in patient and control cohorts. Black bars, CNVs obtained through a 
study of 270 individuals from four populations with ancestry in Europe, Africa or Asia (the HapMap collection) 
using clone-based array CGH.15 Grey bars, CNVs causally related to mental retardation identified using microar-
ray platforms with similar resolution (n= 757).16-21
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absence, but also the amount of overlap with CNVs identified in control cohorts should be 
considered. By using high quality control data sets, the number of patients for which validation 
is required may be reduced significantly. From a genetic counseling perspective, however, 
follow-up studies of patients and parents remain important as they also allow the detection of 
balanced rearrangements in the parents, which is crucial for estimation of the recurrence risk.
Parental testing is also imperative when the genomic region involved has not yet been 
reported before as being associated with mental retardation. The clinical significance of de 
novo events is stressed by the low estimated de novo locus-specific mutation rates in normal 
controls (~1.7 x 10-6).28 Parental samples are, however, not always required to establish the 
clinical significance of a CNV. For example, CNVs that overlap with genomic regions known 
to cause mental retardation syndromes, as e.g. defined by the database of Online Mendelian 
Inheritance in Man (OMIM), can be considered pathogenic. Again, similar to the overlap of 
CNVs identified in controls, it is important to quantify and qualify the extent of overlap. The 
CNVs should at least include the critical region of the syndrome and, if known, the causative 
gene(s). Moreover, the clinical features of the patient have to be consistent with the phenotypic 
characteristics of the syndrome involved.
In reverse, the identification of a rare CNV in a patient and one of his/her parents does not 
automatically rule out its pathogenicity. The latter is illustrated by the recurrent microdeletions 
of 1q21.1 that are associated with a variable spectrum of phenotypic abnormalities and are 
also identified in apparently unaffected parents.29 This phenotypic diversity and incomplete 
penetrance may be explained by multiple CNVs that act in concert or by mutant alleles that 
exert their effects only within specific genetic backgrounds and/or under specific environmental 
conditions. Moreover, (i) the parents can be mosaic for the CNV, (ii) an inherited deletion may 
uncover a recessive mutation in the other allele, (iii) the effect of a CNV may be allele-specific, 
and (iv) the phenotypic effect of a given CNV may vary depending on the exact copy number, 
which is difficult to establish accurately with currently available methods.
The current clinical interpretation of CNVs is still limited and for some rare CNVs the clinical 
significance will remain unclear due to the fact that (i) one or both parents may not be available 
for further testing and (ii) the CNV has not been associated with a known clinical syndrome. The 
size of the genomic region involved and its gene content, however, may provide clues for its 
clinical significance, but obviously more knowledge about the biological pathways underlying 
mental retardation has to be gained before a straightforward clinical diagnosis can be reached 
by this approach alone. Therefore, alternative strategies need to be developed to predict the 
phenotypic consequences of CNVs and to identify putative dosage sensitive genes within 
CNV regions causing mental retardation and/or additional clinical features. In order to obtain 
a probabilistic model that predicts the phenotypic effects of CNVs, in-depth bioinformatic 
analyses are required (see below), which may result in a ‘CNV classifier’ that can be used for a 
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clinical interpretation in routine diagnostics and for the identification novel dosage sensitive 
genes as candidates for mental retardation.
4.3  Identification of syndromes: the 17q21.31 microdeletion 
syndrome
The application of genomic microarrays has resulted in the identification of several recurrent 
disease causing CNVs. The number of overlapping CNVs, however, is still limited and in many 
cases no recurrent breakpoints have been identified. Moreover, the corresponding clinical 
description of the patients in the literature is often incomplete, thus complicating the 
delineation of a common phenotype. Now that microarrays become widely implemented in 
the diagnostic process of mental retardation it is to be expected that, based on genetic data, 
novel syndromes will increasingly be defined. The identification of overlapping CNVs and the 
delineation of clinical syndromes will be facilitated by international databases that capture 
cytogenetic and clinical information from patients with rare CNVs, such as ECARUCA (www.
ecaruca.net) and DECIPHER (https://decipher.sanger.ac.uk/). These databases are of major 
importance and, as the number of cases increases, they will significantly accelerate the clinical 
interpretation of microarray data.
The implementation of microarray technologies has already resulted in the identification 
of several microdeletion and microduplication syndromes (Chapter 1.3), such as the 3q29 
microdeletion syndrome,30 the 15q13.3 microdeletion syndrome,31 the 15q24 microdeletion 
syndrome,32 and the Xq28 microduplication syndrome.33 In addition, using array CGH and 
targeted DNA copy number analyses in a large cohort of patients with mental retardation, we 
and others identified overlapping submicroscopic deletions at 17q21.31 in patients displaying 
consistently similar phenotypic features and, thus, defined a novel microdeletion syndrome 
(Chapter 3.3).34-36
Using subsequent high-resolution oligonucleotide-based microarray analyses, we narrowed 
down the critical region of this novel 17q21.31 microdeletion syndrome to a 424 kb genomic 
segment encompassing at least six genes. It is most likely that one or more of these genes is 
responsible for the disease phenotype. Mutation screening of one of these genes, MAPT, in a 
cohort of 122 individuals with phenotypes reminiscent to that of 17q21.31 deletion carriers, 
but without the deletion, failed to identify any disease-associated variants (Chapter 3.4). This 
may be due to the relative small size of the cohort tested or, alternatively, to an inadequate 
clinical selection of the patients. Now that the phenotype of the 17q21.31 microdeletion 
syndrome is better defined (Chapter 3.4) the pre-selection will be facilitated and, therefore, 
more clinically well characterized patients can studied. However, the 17q21.31 microdeletion 
syndrome may also very well represent a contiguous gene syndrome. As such, a mouse model 
carrying a hemizygous chromosomal deletion that spans a region syntenic to the human 
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17q21.31 microdeletion region could provide valuable information on the molecular and 
cellular consequences of dosage alterations in this region. It has previously been shown that 
through chromosome engineering defined rearrangements can be introduced into the mouse 
genome.37 The critical region of the 17q21.31 microdeletion syndrome in human is syntenic to a 
400 kb region of mouse chromosome 11qE1, with the order, number, and orientation of the genes 
being highly conserved, thus making it feasible to establish such a mouse model. Previously such 
models have been generated for other human genomic disorders such as DGS/VCFS, SMS and 
PWS (reviewed by van der Weyden and Bradley37). Through a model carrying a microdeletion 
syntenic to the 1.5 Mb human 22q11.2 DGS/VCFS-associated microdeletion, alterations in the 
brain transcriptome were detected, thus providing evidence that microRNA biogenesis may 
contribute to the phenotypic deficits in this model.38 Similarly, in a 17q21.31 microdeletion 
mouse model, genome-wide expression profiling may allow the identification of differentially 
expressed genes which, in turn, may provide clues for the underlying biological mechanisms. 
Alternatively, altered regulation of one or more flanking genes due to a position effect may 
contribute to the 17q21.31 microdeletion phenotype. This has for example been observed in WBS, 
where gene expression analyses in patients suggested that not only the aneuploid genes, but 
also flanking genes that map several megabases away from the genomic rearrangement should 
be considered as possible contributors to the WBS phenotype.39 Likewise, altered expression 
of the PGRN gene, located 1.2 Mb centromeric of the recurrent 17q21.31 microdeletion, may 
contribute to the characteristic phenotype of the patients. PGRN encodes the multifunctional 
growth factor progranulin and loss-of-function mutations in the gene have been identified in 
patients with the neurodegenerative disorder FTLD-U.40-42. Interestingly, haploinsufficiency of 
progranulin due to a 1.1 Mb microdeletion in the 17q21.31 region was encountered in a girl 
with mental retardation, poor language, growth hormone deficiency and dysmorphic features 
(Corrado Romano, personal communication). Preliminary genome-wide expression analyses 
using EBV-transformed cells derived from 17q21.31 deletion carriers and their parents, however, 
failed to reveal differential expression for the PGRN gene (unpublished data). Ideally, however, 
this global gene expression profiling should be conducted in brain tissue, as was previously 
done in both histopathologically affected and unaffected areas of human FTLD-U brains. This 
revealed 414 upregulated and 210 down-regulated genes in the frontal cortex.43 Since such brain 
tissue is not available from 17q21.31 microdeletion carriers, a 17q21.31 deletion mouse model 
may provide the tool to interrogate the effect of the 17q21.31 deletion on the expression of its 
associated (flanking) genes. Such a model has already successfully been used for the Potocki-
Lupski syndrome (PTLS), which is associated with a microduplication of the 17p11.2 region. In 
a PTLS mouse model, Dp(11)17/+, direct assessment of the relative transcription levels of genes 
within and oudside the 17p11.2 genomic interval revealed that not only duplicated genes, but 
also normal copy number genes that flank the engineered interval may serve as candidates.44
Detailed genomic analyses of recurrent 17q21.31 microdeletions has shown that in all these 
deletions the breakpoints cluster to LCRs or segmental duplications, suggesting that they are 
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mediated by non-allelic homologous recombination (NAHR) events.45 This notion is supported 
by the identification of a reciprocal duplication within this region in a girl with severe 
psychomotor developmental delay and craniofacial dysmorphisms.46 In order to provide 
evidence that NAHR indeed mediates the rearrangements, patient-specific junction fragments 
should be characterized in detail in order to determine whether there is a recombination 
hotspot and, if so, whether a homologous recombination event has taken place, possibly 
accompanied by gene conversions and/or other events that would be consistent with a double 
strand break repair homologous recombination event.
So far, at least one of the parents of the 17q21.31 microdeletion patients carried the H2 
inversion polymorphism haplotype (Chapters 3.3 and 3.4). The inversion results in a genomic 
structure with directly oriented LCR subunits which can undergo a deletion rearrangement via 
NAHR.28 This observation indicates that the inversion may be a prerequisite for the deletion to 
occur. There are increasing indications for a link between common inversion polymorphisms 
and genomic disorders.14 For several loci that undergo NAHR it has been shown that deletions 
in the patients are linked to an inversion in one of the parents, for example in WBS,47 Angelman 
syndrome48 and Sotos syndrome49. In addition, inversions were found to be involved in a 
recurrent t(4;8)(p16;p23) translocation giving rise to WHS with a relatively mild spectrum of 
dysmorphic features.50,51 Detailed analyses of 17q21.31 rearrangement rates using sperm-
based assays may underscore the hypothesis that the H2-lineage is a prerequisite for the 
deletion to occur. Turner et al. developed such a sperm-based assay to dissect the relative 
rates of NAHR between different pairs of duplicated sequences and showed that deletions 
via these sequences are generated at a higher rate than their reciprocal duplications in the 
male germline.52 To test the hypothesis that the H2-lineage is a prerequisite for the generation 
of the 17q21.31 microdeletion, germline rates of de novo meiotic deletions and duplications 
at 17q21.31 in sperm samples of donors homozygous for either the H1 or H2 lineage, and of 
donors heterozygous for the inversion polymorphisms, should be compared.
4.4 Identification of novel mental retardation genes
To date ~300 different genes are known to give rise to mental retardation when mutated, 
but their total number may run into the thousands (reviewed by Ropers 2006).53 Genes 
linked to mental retardation and cognitive function have predominantly been found on 
the X chromosome, mainly due to the ease to identify families with an X-linked inheritance 
pattern.54,55 To date, mutations in more than 80 genes on the X chromosome have been found 
to underlie mental retardation.55 The majority of autosomal mental retardation genes, however, 
still awaits identification.
Genome-wide genomic profiling of patients with unexplained mental retardation represents a 
powerful strategy for the identification of novel mental retardation genes. Screening for CNVs 
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using microarray-based technologies already disclosed the causative genes for several known 
syndromic and previously elusive mental retardation disorders. The first syndrome for which the 
causative gene was identified using microarrays was CHARGE syndrome (MIM #214800).56 Array 
CGH revealed microdeletions in 8q12 in two patients with CHARGE syndrome. Subsequently, 
several mutations in the CHD7 gene, located within the deleted region, were detected in 
patients with CHARGE syndrome without a 8q12 deletion.56 Since then, CHD7 mutations have 
been identified in the majority of cases with CHARGE syndrome.57 Similarly, mutations in the 
TCF4 gene (18q21.2) were identified in Pitt-Hopkins syndrome (MIM #610954)58,59 and in the 
ZNF674 gene (Xp11.3) in individuals with X-linked mental retardation.60 Another example of 
a causative gene that has been identified using a targeted approach based on phenotypic 
characteristics is EHMT1, a gene that underlies the 9q34 microdeletion syndrome (MIM 
#610253).61 Similarly, biallelic truncating mutations in the B3GALTL gene were identified in 
patients with Peters-Plus syndrome (MIM #261540) after the detection of a microdeletion in 
the region 13q12.3q13.1.62 
The identification of causative genes in known mental retardation syndromes emphasizes the 
potential of microarray-based mapping strategies to pinpoint candidate autosomal mental 
retardation genes. The subsequent identification of causative gene mutations is performed in 
patients selected on the basis of phenotype. The success of this strategy relies on the clinical 
recognition of a syndrome and the availability of patients with similar overlapping clinical 
features.
For the identification of recessive mental retardation genes, strategies have been aimed at 
homozygosity mapping of polymorphic markers in consanguineous families. Here too, 
technological improvements have been instrumental. Notably, SNP analysis has replaced 
microsatellite marker analysis, allowing more efficient and more complete homozygosity 
scans.63-65 This strategy has e.g. successfully been used for the identification of the autosomal 
recessive mental retardation gene CC2D2A.66 A major problem with homozygosity mapping 
in consanguineous families, however, is that it usually reveals large regions encompassing 
up to 200 genes. Therefore, the identification of genes causing recessive mental retardation 
by homozygosity mapping in consanguineous families has had limited success. One could 
speculate that even in outbred populations many patients will be homozygous for a single 
mutation. The obvious explanation for this assumption lies in the paucity of disease alleles at 
the population level. Therefore, it is anticipated that high-density SNP arrays can successfully 
be used for the mapping of autosomal recessive mental retardation genes.
Prioritization of candidate genes for high-throughput sequencing
In general, the CNV regions detected in routine analyses of individuals with unexplained 
mental retardation serve as candidate regions harboring mental retardation-related genes. 
Subsequently, sequencing of large patient cohorts with a similar phenotype (‘phenocopies’) 
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may result in gene identification through mutation detection. Novel sequencing technologies 
(‘next-generation sequencing’) will facilitate the efficient detection of causative mutations 
and additionally, it will allow the screening of entire genes, including the introns, UTRs and 
promoter regions. However, throughput in medical (re-)sequencing of hundreds of candidate 
regions, harboring thousands of candidate genes will still be rate-limiting in the coming years. 
Therefore, candidate genes and/or other functional elements within these regions should be 
prioritized for high-throughput sequencing. In-depth bio-informatic analyses can be used to 
select dosage sensitive genes. Several additional strategies can be applied to further prioritize 
candidate genes within these regions, such as their specific and restricted expression patterns 
in brain and their known roles in human neurodegeneration-related pathways. In addition, 
genes whose mouse orthologues, when disrupted, result in recognizable phenotypes may be 
enriched in mental retardation-associated CNVs (Figure 4.2a).
Also, physical interactions between proteins may be relevant for the prediction of disease-
causing genes.67 When protein A encoded by a gene located in a disease-associated region 
has been shown to interact with protein B known to be involved in that disease, the likelihood 
that protein A is also involved is increased by a factor 10.67 Similarly, if a disease is genetically 
heterogeneous it becomes more likely that the proteins involved may interact. For several 
genetically heterogenous disorders, such as Fanconi anemia and limb-girdle muscular 
dystrophy, it has already been shown that proteins with previously unknown function may 
actually participate in the same complexes.68,69 Similarly, genes causing mental retardation 
have been connected to specific pathways, e.g. the RhoGTPase pathway, or to the formation of 
specific neuronal complexes such as the postsynaptic density (PSD) complex, which comprises 
over 1,100 proteins.70,71 Interestingly, learning and/or memory were affected in 75% of mice 
with mutations inactivating individual PSD proteins.72
Figure 4.2: Prioritization schemes of candidate genes. (a) Genes whose mouse orthologues, when disrupted, 
result in abnormal phenotypes may be enriched in mental retardation-associated CNVs. (b) Interaction network 
based on protein-protein interactions or gene-gene interactions culled from different databases may reveal no-
vel mental retardation-associated genes. 
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The protein products of genes within CNVs related to mental retardation can also be linked in 
silico to known protein-protein interaction networks. The genes that, in this way, link disease 
causing CNVs may serve as interesting candidates for mental retardation (Figure 4.2b).
Moreover, evolutionary conserved gene co-expression patterns may be used to prioritize 
candidate genes.73 Genes within CNVs causing mental retardation are thought to be dosage 
sensitive and, therefore, to show a tight regulation of expression in the developing and adult 
brains of normal individuals. Also, co-expression of genes in different species may indicate that 
they are part of the same pathway.74 Together, these features may facilitate the identification of 
new genes involved in mental retardation.
Several disease-gene prediction programs have already been developed, such as Prioritizer75 
and Endeavour.76 These programs are based on different data sources, such the Kyoto 
Encyclopedia of Genes and Genomes (KEGG), the Biomolecular Interaction Network Database 
(BIND), Reactome, the Human Protein Reference Database (HPRD), the Gene Ontology (GO) 
database, predicted protein-protein interactions, human yeast two-hybrid interactions and 
microarray-based co-expression patterns. The efficacy of these and other bio-informatic tools 
are likely to improve in the near future, as data from different sources can be integrated and 
more information will be available on the structures and functions of genes and the biological 
pathways in which they operate.
4.5 Future diagnostics in mental retardation
In recent years, genomic microarray-based profiling technologies have increasingly been 
implemented in the routine diagnostic workup of individuals with mental retardation. The initial 
clone-based genomic microarray platforms have already largely been replaced by commercially 
available oligonucleotide-based platforms. Current high-density oligonucleotide microarrays 
encompass large numbers of short DNA targets (oligonucleotides) targeting random genomic 
sequences77-79 or single nucleotide polymorphisms (SNPs).18,80-83 The advantages of these 
platforms are numerous: (i) they provide a higher genome coverage than most clone-based 
genomic microarrays, (ii) they can be produced in large quantities according to industrial 
quality standards, (iii) they are available to all investigators, including those without dedicated 
microarray production facilities, and (iv) they are widely used and thus generate large data 
sets that facilitate comparison and integration. Most technological restrictions of the initial 
microarray platforms have been overcome and the resolution of the technology has increased 
towards the kilobase level (currently: 3-10 kb), which is a major step forward as compared to 
the ~5-10 Mb level.
It is anticipated that microarray-based genomic profiling technologies will continue to replace 
conventional karyotyping. Through these technologies also subtelomeric CNVs can be detected 
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and, therefore, there will no longer be a need for the exclusion of subtelomeric abnormalities 
e.g. by MLPA prior to whole genome profiling. Obviously, genomic microarrays do not allow 
for the detection of balanced aberrations, although these aberrations may include cryptic 
imbalances and/or complex rearrangements.84,85 With the advent of microarray and next-
generation sequencing technologies, more and more cryptic changes at the breakpoints of 
rearrangements will be identified. It should also be noted that conventional techniques such 
as karyotyping and FISH may still be valuable for the elucidation of e.g. complex structural 
chromosome rearrangements, especially when there is a family history positive for mental 
retardation.
Targeted microarray approaches may have advantages over genome-wide approaches, 
especially in a diagnostic setting, as parental samples are not required for the clinical 
interpretation of targeted microarray data. However, through these targeted approaches 
sporadic DNA copy number changes will be missed, as the corresponding regions will not 
be represented on such microarrays (Chapter 3.2). Moreover, although the interpretation of 
genome-wide microarray data is not as straightforward as that of targeted microarrays, the 
results obtained will be helpful for the identification of new syndromes and mechanisms.86 
Targeted (re-)sequencing may efficiently be applied to genes associated with genetically 
heterogeneous disorders such as Bardet-Biedl (MIM #209900), and clinically related 
developmental disorders that e.g. have been linked to mutations in the RAS/MEK/ERK signaling 
pathway such as Cardio-facio-cutaneous syndrome (MIM #115150), Noonan syndrome (MIM 
#163950) and Costello syndrome (MIM #218040).87
Eventually, targeted or genome-wide (re-)sequencing may replace microarray-based profiling 
technologies as the main molecular tool in the genetic diagnostic process of mental retardation. 
Major advances in DNA sequencing technologies have recently resulted in the publication of 
the first two individual human whole-genome sequences.88,89 The genome of James Watson, 
co-discoverer of the structure of DNA, was the first genome to be sequenced by a so called 
next-generation technology.88 The next-generation sequencing strategies currently in use 
require a DNA amplification step, which may introduce a bias as some strands of DNA amplify 
more easily than others. The latest revolution in the field of genome sequencing is single-
molecule sequencing and recently Harris et al. reported the sequence of a whole viral genome 
using this approach.90 Reading the sequence of a single fragment of DNA further simplifies 
the sequencing process, which ultimately may bring personalized genome sequencing within 
reach. This, in turn, will allow the comparison of total genomes from patients and parents and 
the concomitant detection of de novo mutational events associated with disease. By using 
these novel sequencing methodologies, it is anticipated that the majority of single gene 
disorders associated with mental retardation will be elucidated at the molecular level at an 
increasingly rapid pace. Sequencing of multiple whole genomes will allow the delineation of 
the frequency of de novo CNVs in humans, and genome-wide SNP and CNV association studies 
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in large cohorts of fully sequenced individuals with mental retardation is expected to provide 
new insight into the pathogenesis of mental retardation and other common diseases.
Obviously, there are ample related ethical, legal and social issues that should be addressed 
within this context.91 Major considerations are the circumstances under which research results 
are disclosed to research participants, the obligations that are owed to participant’s close 
genetic relatives and how the future use of patient samples and data obtained by whole-
genome sequencing will be dealt with.91 Ultimately, however, it is anticipated that whole 
genome sequencing will become part of routine clinical care and an integral part of medical 
records, facilitating the identification of sequences that are associated with disease such as 
mental retardation, but also predicting the response to specific medication. 
4.6 Concluding remarks
The increasing resolution of genomic analyses tools such as microarray and/or (re-)sequencing 
platforms will in the near future increase CNV detection in patients with mental retardation. 
Comprehensive phenotyping and bioinformatic analyses will be imperative for the clinical 
interpretation of CNVs, including the role of causative mutations, genetic risk factors and 
modifiers influencing the disease severity. Improvements in our understanding of the role of 
CNVs in health and disease will lead to a decrease in the number of so called unclassified CNVs. 
Eventually, up to 25% of all cases of mental retardation may be explained by copy number-
dependent gene dosage variations. Moreover, high-throughput (re-)sequencing of candidate 
genes and other functional elements in large patient cohorts may reveal causative mutations 
in another 10 to 20% of cases. The identification of overlapping CNVs in patients with similar 
clinical features will be essential for confirmation of the causal role of these CNVs. Therefore, the 
continued collection of disease-causing CNVs and their associated phenotypes in databases 
such as ECARUCA and DECIPHER will be of major importance, not only for the confirmation of 
pathogenicity, but also for the proper counseling of patients and their families.
Moreover, increased insight into genomic abnormalities and mechanistic pathways underlying 
mental retardation may result in the development of specifically targeted therapies. In fact, 
already several strategies are currently being developed. The reduction in metabotropic 
glutamate receptor (mGluR5) signaling, for example, has been shown to reverse the clinical 
features of Fragile X syndrome (MIM #300624), thus providing a compelling rationale for the 
use of mGluR5 antagonists in the treatment of Fragile X syndrome and related disorders.92 
Similarly, discoveries regarding the genetics and pathogenesis of spinal muscular atrophy 
have revealed potential targets for pharmacotherapy,93 and the testing of potential therapeutic 
agents in a mouse model for tuberous sclerosis (TSC, MIM #191100) has suggested that these 
agents may be used to treat TSC-related brain disease, including infantile spasms.94 These 
encouraging results underline the notion that further insight into the pathways affected in 
mental retardation may pave the way for the development of novel treatment strategies.
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Mental retardation, a condition that includes limitations in intellectual functioning and lack 
of skills necessary for daily living, is estimated to affect 2–3% of the population. An etiologic 
diagnosis, however, can be established in only 50% of all patients. The elucidation of the 
underlying cause is of importance as it improves the clinical management of patients and 
allows the disclosure of relevant information to family members. Genetic abnormalities are 
the most common identifiable cause of mental retardation. Three main categories of genetic 
disorders associated with mental retardation can be recognized: multifactorial disorders, 
single-gene disorders and chromosome disorders. Chromosome disorders larger than 5-10 
Mb in size can be detected by conventional karyotyping. Other techniques, notably high 
resolution chromosome banding and fluorescence in situ hybridization (FISH), but also 
amplification methods such as multiplex ligation dependent probe amplification (MLPA), allow 
the detection of chromosome aberrations below the resolution of conventional karyotyping, 
so-called submicroscopic aberrations. The introduction of array-based comparative genomic 
hybridization (array CGH) enabled genome-wide screening for submicroscopic chromosome 
imbalances, bridging the technical divide between single-gene defects and microscopically 
visible chromosome aberrations. Array CGH revealed that submicroscopic DNA copy number 
variation (CNV) is a significant cause of mental retardation. CNV is a type of variation that refers 
to segments of DNA that are present in variable copies in comparison to a reference genome and 
may include deletions, duplications and insertions. This thesis aims to provide understanding of 
the contribution of submicroscopic CNVs in mental retardation by determining the frequency 
of CNVs in patients with mental retardation and by the identification of mental retardation 
syndromes.
In Chapter 2.1 subtelomeric DNA copy number analyses using MLPA in 210 individuals with 
unexplained mental retardation is described. Clinically relevant CNVs were identified in 4.3% 
of the patients, confirming the diagnostic value of subtelomeric screening in individuals 
with mental retardation and demonstrating that MLPA serves as a robust high-throughput 
technique for the detection of subtelomeric rearrangements.
The implementation of subtelomeric DNA copy number analysis in the diagnostic workup of 
patients with mental retardation resulted in the recognition of several previously unrecognized 
clinical syndromes. One of the first distinct syndromes caused by a submicroscopic 
subtelomeric CNV identified among unselected individuals with idiopathic mental retardation 
was the subtelomeric 22q13.3 microdeletion syndrome. In Chapter 2.2 the size and nature 
of several 22q13.3 microdeletions is studied using high-resolution chromosome-specific array 
CGH. Moreover, the relationship between clinical features and deletion sizes is investigated. 
Global developmental delay and absent speech or severely delayed speech development 
were constant features in all patients. Considerable variability in the size of the 22q13.3 
microdeletions was shown without correlations between the genotype and the phenotype.
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In Chapter 3.1 the results from a genome-wide array CGH analysis of a cohort of 386 patients 
is integrated with those from 15 similar genome-wide studies on 978 patients, reported by 
other groups. The overall diagnostic yield of clinically significant CNVs in our patient cohort 
was 9.1% and in combination with data from the literature a collective yield of pathogenic 
CNVs of 11.2% was assessed. These data strongly underscore the importance of array CGH as a 
genomic profiling tool for the detection of submicroscopic CNVs in patients with unexplained 
mental retardation.
Using a clinical scoring system, it was found that the detection rates of subtelomeric CNVs 
and interstitial CNVs partly reflect clinical pre-selection biases, based on phenotypes with 
additional dysmorphic features and/or growth abnormalities. After correction for this clinical 
preselection, a yield of clinically significant CNVs among patients with mental retardation of 
~8% was determined. In addition, the challenge of characterizing and classifying genomic 
CNVs in order to assess their putative implications in mental retardation was addressed and 
a practical workflow that can be used in a diagnostic setting for the interpretation of CNVs 
related to mental retardation was proposed.
In Chapter 3.2 the hypothesis that genomic regions involved in de novo submicroscopic 
aberrations may serve as candidates for recurrent CNVs in individuals with mental retardation 
is tested. MLPA was used to screen for copy number changes in eight selected candidate 
regions in a European cohort of 710 individuals with idiopathic mental retardation. No 
additional submicroscopic rearrangements were determined, indicating that the candidate 
regions tested were non-recurrently affected in this cohort of patients. These results support 
the notion that genome-wide analyses are indicated when testing for copy number changes 
in individuals with idiopathic mental retardation.
In Chapter 3.3 the identification of a previously unknown microdeletion syndrome involving 
chromosome region 17q21.31 is reported. Three overlapping 17q21.31 microdeletions were 
uncovered in a cohort of 1,200 mentally retarded individuals using array CGH and targeted 
DNA copy number analyses. The presence of low copy repeat sequences flanking the deletion 
breakpoints suggested that, most likely, nonallelic homologous recombination acts as the 
underlying mechanism. Subsequent clinical comparison of the patients revealed marked 
phenotypic similarities, indicating that this novel recurrent genomic anomaly causes a 
previously unrecognized microdeletion syndrome.
In Chapter 3.4 the 17q21.31 microdeletion syndrome is further delineated as a clinically and 
molecularly well-recognizable disorder. Twenty-two individuals with the 17q21.31 microdeletion 
syndrome were studied. Clinical examination revealed that developmental delay, hypotonia, 
facial dysmorphisms including a long face, a tubular or pear-shaped nose, a bulbous nasal tip, 
and a friendly/amiable behavior were the most characteristic features. Other clinically relevant 
features included epilepsy, heart defects and kidney/ urologic anomalies. The prevalence of 
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the syndrome was estimated to be 1 in 16,000 and using high-resolution oligonucleotide 
microarrays the 17q21.31 critical region was narrowed down to a 424 kb genomic segment 
encompassing the MAPT gene. Mutation screening of MAPT in 122 individuals with a ‘17q21.31 
deletion-like’ phenotype failed to identify any disease-associated variants. In addition, further 
evidence was provided that a common 900 kb 17q21.31 inversion polymorphism in one of the 
parents is a necessary factor for the deletion to occur.
In Chapter 4 the most important results of this thesis are discussed in relation to both 
molecular genetic and clinical genetic relevance. The increasing resolution of genomic analysis 
tools will inevitably increase CNV detection in patients with mental retardation in the near 
future. Comprehensive phenotyping and bioinformatic analyses will be required for the clinical 
interpretation of these CNVs. The concomitant elucidation of novel genetic causes of mental 
retardation will provide further insight in its occurrence and its associated clinical features, 
facilitating a better clinical management of the patient and a better genetic counseling of the 
family.
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Mentale retardatie gaat gepaard met een verstandelijke handicap en beperkingen in het 
dagelijks leven en komt bij ongeveer 2-3% van de populatie voor. De precieze oorzaak is 
echter in ongeveer 50% van de patiënten onbekend. De opheldering van de onderliggende 
oorzaak is van belang, omdat het mogelijkheden geeft tot verbetering van de begeleiding van 
de patiënt en gerichte counseling van de betrokken familieleden mogelijk maakt. Genetische 
aandoeningen zijn de meest voorkomende oorzaak van mentale retardatie. Er bestaan drie 
belangrijke groepen genetische aandoeningen die samengaan met mentale retardatie: 
aandoeningen ten gevolge van een combinatie van genetische factoren en omgevingsfactoren 
(multifactorieel), afwijkingen (=mutaties) in afzonderlijke genen en aandoeningen ten gevolge 
van chromosoom afwijkingen. Chromosoom afwijkingen groter dan 5-10 miljoen basenparen 
(Mb) kunnen worden vastgesteld met conventionele karyotypering. Andere technieken, met 
name chromosoom bandering met hoge resolutie en fluorescence in situ hybridization (FISH), 
maar ook amplificatie methoden zoals multiplex ligation dependent probe amplification 
(MLPA), maken het mogelijk chromosoom afwijkingen te vinden die kleiner zijn dan de 
resolutie van conventionele karyotypering, zogenaamde submicroscopische afwijkingen. 
Met de introductie van array-based comparative genomic hybridization (array CGH) werd het 
mogelijk om het gehele genoom te screenen op submicroscopische afwijkingen. Hiermee 
werd een brug geslagen tussen de kloof tussen gen-defecten en microscopisch zichtbare 
chromosoom afwijkingen. Door de toepassing van array CGH bleken submicroscopische DNA 
kopie nummer veranderingen een belangrijke oorzaak voor mentale retardatie te vormen. 
Deze veranderingen hebben betrekking tot delen van het DNA die in vergelijking met een 
referentie genoom een afwijkend kopie aantal hebben. Dit kunnen zowel deleties, duplicaties 
als inserties zijn. Dit proefschrift richt zich op het vergroten van het inzicht in de rol van 
kopie nummer veranderingen in mentale retardatie door het bepalen van de frequentie van 
submicroscopische kopie nummer veranderingen in patiënten met mentale retardatie en door 
nieuwe mentale retardatie syndromen te identificeren.
Hoofdstuk 2 beschrijft het onderzoek van de uiteinden van de chromosomen (de subtelomeren) 
middels MLPA bij 210 personen met onverklaarde mentale retardatie. Klinisch relevante 
veranderingen werden gevonden in 4,3% van de patiënten, waarmee het diagnostische 
belang van screening van de subtelomeren bij personen met mentale retardatie bevestigd 
werd en tevens werd aangetoond dat MLPA een robuuste techniek is voor de detectie van 
subtelomeer veranderingen.
De invoering van subtelomeer DNA kopie nummer analyse in het diagnostische proces 
van patiënten met mentale retardatie heeft geleid tot het vinden van verschillende nieuwe 
klinische syndromen. Een van de eerste goed omschreven syndromen veroorzaakt door 
een submicroscopische subtelomeer afwijking die gevonden werd in een ongeselecteerde 
groep patiënten met onbegrepen mentale retardatie is het 22q13.3 microdeletie syndroom. 
Hoofdstuk 2.2 beschrijft het onderzoek van de grootte en de aard van verschillende 22q13.3 
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submicroscopische deleties (microdeleties) door middel van chromosoom specifieke array 
CGH. Daarnaast werd de relatie onderzocht tussen de klinische kenmerken en de grootte 
van de deleties. Algemene ontwikkelingsachterstand en afwezige- of sterk vertraagde spraak 
ontwikkeling waren aanwezig bij alle geteste patiënten. Er bleek echter een aanzienlijk verschil 
is in de grootte van de 22q13.3 microdeleties, zonder een duidelijke relatie met de klinische 
kenmerken.
Hoofdstuk 3.1 beschrijft de resultaten van genoomwijde array CGH analyse van een groep 
van 386 patiënten met mentale retardatie in combinatie met de resultaten van 15 in de 
literatuur beschreven vergelijkbare genoomwijde studies van in totaal 978 patiënten. In onze 
groep patiënten werden klinisch significante kopie nummer veranderingen gevonden bij 9,1% 
van de patiënten en in combinatie met de andere studies leidde dit tot ziekteveroorzakende 
DNA kopie nummer veranderingen in 11,2% van de geanalyseerde personen. Deze data 
onderschrijven de waarde van array CGH in de detectie van submicroscopische kopie nummer 
veranderingen bij patiënten met onverklaarde mentale retardatie. 
Door middel van een klinisch scoringssysteem werd aangetoond dat het aantal DNA kopie 
nummer veranderingen van de subtelomeren en elders in het genoom (interstitieel) voor een 
deel afhangt van klinische voorselectie van patiënten met bijkomende dysmorfe kenmerken 
en/of groeistoornissen. Na correctie voor deze klinische voorselectie kon een frequentie van 
klinisch belangrijke veranderingen bij mensen met een verstandelijke handicap worden 
vastgesteld van ~8%. Een voorstel voor een klinisch toepasbare diagnostische workflow voor 
de interpretatie van kopie nummer veranderingen gerelateerd aan mentale retardatie wordt 
voorgesteld.
In Hoofdstuk 3.2 wordt de hypothese getoetst of bepaalde regio’s betrokken bij de 
novo submicroscopische afwijkingen kandidaat regio’s kunnen zijn voor kopie nummer 
veranderingen die ook bij andere personen met mentale retardatie gevonden kunnen worden. 
Om hier uitspraken over te kunnen doen werd MLPA gebruikt voor het screenen op kopie 
nummer veranderingen van 8 geselecteerde kandidaat regio’s in een Europees cohort van 710 
personen met onverklaarde mentale retardatie. Er werden geen nieuwe submicroscopische 
veranderingen in ons cohort patiënten gevonden, hetgeen betekent dat genoomwijde 
analyse aangewezen is voor het testen op kopie nummer veranderingen bij personen met 
onbegrepen mentale retardatie.
In Hoofdstuk 3.3 wordt de identificatie van een nieuw microdeletie syndroom in de 
chromosoom 17q21.31 regio beschreven. In een groep van 1200 personen met mentale 
retardatie werden drie overlappende 17q21.31 microdeleties vastgesteld middels array CGH 
en gerichte DNA kopie nummer analyse. De aanwezigheid van low copy number repeat 
sequenties aan weerszijde van de breukpunten van de deletie maken het waarschijnlijk 
dat nonallelic homologous recombination het onderliggende mechanisme is. Klinische 
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vergelijking van de patiënten liet vervolgens zien dat zij naast de mentale retardatie duidelijke 
kenmerken overeenkomstig hebben wat betekent dat deze nieuwe afwijking de basis vormt 
voor een nieuw microdeletie syndroom.
In Hoofdstuk 3.4 wordt het 17q21.31 microdeletie syndroom verder uitgewerkt tot een 
klinisch en moleculair goed gedefinieerde en herkenbare aandoening. Hiertoe werden 22 
personen met het 17q21.31 microdeletie syndroom beschreven. Klinisch onderzoek toonde 
aan dat de meest uitgesproken kenmerken van het syndroom een ontwikkelingsachterstand, 
hypotonie, faciale dysmorfieën, waaronder een lang gezicht, een ‘buis- of peervormige’ neus, 
een bolvormige neuspunt en een vriendelijk voorkomen betreffen. Andere klinisch relevante 
kenmerken waren epilepsie, hartafwijkingen en nier/ urinewegafwijkingen. De prevalentie 
van het syndroom wordt geschat op 1 op 16000. Met oligonucleotide microarrays met hoge 
resolutie werd de kritische 17q21.31 regio terug gebracht tot een segment van 424 duizend 
basenparen (kb). Deze regio omvat het MAPT-gen, maar screening op mutaties in MAPT bij 
122 personen met ‘17q21.31 deletie-achtige’ kenmerken leidde niet tot veranderingen 
die met ziekte in verband konden worden gebracht. Wel werd aangetoond dat een veel 
voorkomend polymorfismeeen 900 kb grote inversie op 17q21.31bij één van de ouders, 
een noodzakelijke factor is voor het krijgen van een kind met de 17q21.31 deletie.
In Hoofdstuk 4 worden de meest belangrijke resultaten van dit proefschrift besproken in relatie 
tot hun moleculair- en klinisch genetische relevantie. Hogere resolutie van genomische analyse 
zal ontegenzeggelijk leiden tot een toename in het aantal kopie nummer veranderingen in 
patiënten met mentale retardatie. Een goede klinische beschrijving en bioinformatica analyses 
zullen nodig zijn voor de uiteindelijke klinische interpretatie van deze deleties en duplicaties. 
De opheldering van nieuwe genetische oorzaken van mentale retardatie die hieruit voortkomt 
zal verder inzicht verschaffen in de klinische kenmerken en een betere klinische begeleiding 
van de patiënt en counseling van de familieleden mogelijk maken.
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Wat een heerlijk moment; het dankwoord… dat kenmerkt dat de eindstreep van dit proefschrift 
nu echt nabij is! Een eindsprint van een lange bergetappe. Een die, net als in de wielersport, 
pieken en dalen kende en soms alles overheerste. Dit deed me op sommige momenten zelfs 
uit het oog verliezen wat ik hier nou zo leuk aan vond. Gelukkig gaf het op andere momenten 
ook veel tevredenheid en voldoening. Deze wetenschappelijke tocht heb ik natuurlijk niet 
alleen volbracht. Ik wil hier dan ook graag een aantal mensen bedanken voor hun bijdrage als 
‘coach’,  ‘toeschouwer’ en ‘medesporter’.
Bert: voor je visie, voor je snelle correcties, je vertrouwen, je betrokkenheid, je optimisme en 
je talent het totale plaatje te blijven zien, maar ook voor je gastvrijheid, zoals maar weer bleek 
tijdens de laatste fase waarin ik nog in je vakantie bij jullie thuis de laatste dingen met je door 
kon nemen en en passant mee kon eten (ook Jolijn dank daarvoor).
Ad: voor je precisie, nauwgezetheid en met name ook je cytogenetische input terwijl je tevens 
oog hield voor mijn ‘doktersperspectief’.
Ben en Nine: voor de mogelijkheid als arts onderzoek te doen in een tamelijk biologisch 
veld en dit te combineren met de opleiding tot klinisch geneticus. Met name het laatste jaar 
trokken promotie en opleiding soms in tegengestelde richting en moest ik me soms bijna 
splitsen.  Ook mijn andere collega’s van de kliniek wil ik hierbij bedanken voor de gezelligheid 
en betrokkenheid.
Joris: voor je ideeën en  vooruitziende blik, je ambitie en voor de mogelijkheid op je lab te 
werken. Je schrijftalent is inspirerend. Het was steeds prettig met je samen te werken en als er 
iemand ook letterlijk met me mee heeft gefietst was jij het wel! 
Ik wil natuurlijk iedereen bedanken van de microarray faciliteit, maar met name Lisenka. Je 
hebt me veel geleerd over de vereiste labtechnieken en hebt me wegwijs gemaakt in de 
wereld van BACs, vortex en Milli-Q. Ook Irene en Simon hebben me daar veel bij geholpen. 
Zonder het harde werk van de microarray diagnostiek groep was mijn onderzoek bovendien 
niet zo ver gekomen. Bedankt.
Aan de andere kant van het gebouw heb ik ook veel steun gehad. Met name van de groep van 
Erik. Willy, ik kon je altijd wat vragen en je hebt me ontzettend vaak geholpen als ik een sample 
niet kon vinden of als een (van de vele) MLPA-reacties niet deed wat ik voor ogen had. Martina, 
Gaby en Jelmer, heel erg bedankt!
Mijn paranimfen: Bregje, het is een beetje alsof ik het ‘stokje’ aan jou overdraag, ondanks 
dat je alweer een tijd bij ‘groep de Vries’ hoort. Ik vind het hartstikke leuk dat je mij ook hier 
terzijde staat. Arnt: op de fiets, op vakantie en nu zelfs in een apenpakje hier; soms wat actiever, 
soms wat minder; soms de een voorop, soms de ander, maar al vanaf dag één van de studie 
geneeskunde vind ik het prettig om met je op te trekken. Dankjewel.
Mijn ouders: Henk en Henny, met hele andere keuzen, een heel ander pad in het leven, kun je 
toch zoveel overeenkomsten hebben en elkaar nabij zijn. Dank voor jullie vertrouwen. Vanaf 
nu is Breda ook weer echt dichterbij.
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Mijn verdere familie, schoonfamilie en vrienden: net iets te vaak kwam ik de laatste tijd even 
beneden een glaasje meedrinken om vervolgens weer achter de computer te verdwijnen. Met 
de verhoudingen weer in perspectief heb ik weer meer tijd om met jullie door te brengen.
Lieve Nadja: je hebt me altijd gesteund en me naast werk veel andere leuke dingen laten zien. 
Trouwen en verhuizen hebben we er even tussendoor gedaan, maar ons eerste kindje verdient 
straks de volle aandacht.
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beton en staal ging hij in 1996 Geneeskunde studeren aan de Radboud Universiteit Nijmegen 
(voorheen Katholieke Universiteit Nijmegen). Tijdens zijn studie deed hij onderzoek op de 
afdeling Medische Oncologie onder begeleiding van Prof. dr. C.J.A. Punt. Daarnaast liep hij 
stage in het Mount Sinai Hospital, Toronto, Canada, in het laboratorium van Prof. dr. I.G. Fantus 
waar hij onderzoek deed naar de expressie van PTEN in insuline resistente vetcellen. Hiervoor 
ontving hij een subsidie van de Stichting Diabetes Fonds Nederland. Hij legde in november 
2002 het artsexamen met goed gevolg af. Hierna werkte hij tot juli 2003 als arts-assistent 
op de afdeling Interne Geneeskunde van het Canisius Wilhelmina Ziekenhuis in Nijmegen 
om vervolgens de overstap naar de klinische genetica te maken. Als junioronderzoeker op 
de afdeling Antropogenetica van het Universitair Medisch Centrum St. Radboud, Nijmegen 
werkte hij mee aan het opzetten van een Europese database voor cytogenetische en klinische 
informatie over chromosomale afwijkingen (ECARUCA). In die tijd werd ook een start gemaakt 
met het promotieonderzoek dat heeft geleid tot dit proefschrift (Promotor: Prof. dr. A. Geurts 
van Kessel, Copromotor: Dr. B.B.A. de Vries). Sinds december 2004 combineert hij als assistent-
geneeskundige in opleiding tot klinisch onderzoeker (AGIKO) zijn promotieonderzoek met de 
opleiding tot klinisch geneticus (Opleiders: Prof. dr. B.C.J. Hamel en Prof. dr. N.V. van Slobbe-
Knoers). Hij is getrouwd met Nadja Joosen.
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Figure 1.3: The principle of array CGH. Equal amounts of isolated and fragmented genomic test DNA and re-
ference DNA are differentially labeled using fluorescent dyes. Subsequently, test (patient DNA; left panel) and 
reference samples (reference DNA; right panel) are mixed with Cot-1 DNA, co-precipitated, and resuspended 
in a hybridization solution. After denaturation the DNA mix is hybridized to the DNA on the array. After several 
washing steps, images of the fluorescent signals are captured and the ratio of test over reference signals is quan-
tified computationally and plotted for each probe on the array.  
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Figure 1.5: Clinical photographs of patients with subtelomere deletions. (a) 1pter deletion (b) 4pter deletion (c) 
9qter deletion (d) 22qter deletion. Informed consent was obtained for publication of photographs. 
Figure 1.6: Patients with newly recognized interstitial microdeletion syndromes. (a) 2p15p16.1 microdeletion, 
(b) 3q29 microdeletion (c) 17q21.31 microdeletion (d) distal 22q11 microdeletion. Informed consent was ob-
tained for publication of photographs.
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Figure 2.2.1: Patients with 22q13 deletion syndrome. Note the known facial features of the 22q13 deletion 
syndrome, prominent dysplastic ears (visible in cases 1, 2, 4 and 5), and a prominent/ pointed chin (cases 1 and 
4– 7). 
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Figure 3.1.4: Overview of all CNVs reported in genome-wide microarrays studies in mental retardation. CNVs 
are represented by colored bars. Copy number losses and copy number gains are depicted, respectively, on the 
left hand side and the right hand side of the chromosomes. Red bars, CNVs associated with a well-known OMIM 
syndromes. Orange bars, novel recurrent CNVs. Green bars, de novo CNVs not known to the previous categories 
and blue bars, CNVs of unknown clinical significance.
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Figure 3.3.1: Clinical characteristics of the 17q21.31 deletion syndrome. (a) Patient 1, at 3 years of age. (b) pa-
tient 2, at 17 years of age, and (c) patient 3, at 26 years of age. Note the characteristic facial features, a hypotonic 
face with ptosis, blepharophimosis, large low set ears, bulbous nasal tip, long collumella with hypoplasic alae 
nasi, and a broad chin. 
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Figure 3.3.2: Analysis of individuals with the 17q21.31 microdeletion syndrome. (a) Chromosome 17 array CGH 
profile of individual 1 with a copy number loss of eight adjacent BAC clones on 17q21.31 (arrow). Clones are 
ordered on the x axis according to physical mapping positions; log2-transformed test-over-reference (T/R) in-
tensity ratios for each clone are given on the y axis. (b) Multiplex ligation-dependent probe amplification (MLPA) 
analysis, showing a deletion of two probes in CRHR1 and one probe in MAPT for both individual 2 (triangles) and 
individual 3 (squares). The circles represent the MLPA ratios of healthy controls. FISH validation of the 17q21.31 
deletion in individuals 1, 2 and 3 (c-e) and testing for de novo occurrence in the accompanying parents (f-k) 
using BAC clone RP11-656O14 (red) which is located within the deleted region. The centromere 17 probe was 
included for reference (green). All individuals show only one signal for RP11-6565O14 (arrow indicating aberrant 
chromosome 17). The de novo occurrence for the deletion was proven in all individuals.
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Figure 3.3.3: Genotyping for H1 and H2 lineage and parent-of-origin analysis. (a) Genotyping for the H1 (483 
bp) and H2 (245 bp) lineages. Far left and far right: 100-bp marker lanes. Individual 3 carries the deletion on the 
H2 lineage and is of maternal origin. (b) Individual 1 and the parents were genotyped using D17S810, DG17S142 
and D17S920 to determine the parental origin of the deletion. The deletion was of paternal origin, and was pres-
ent on the H2 haplotype. 
Figure 3.3.4: Transcript map and genomic architecture for the H1 and H2 lineage of the 17q21.31 region. (Dot-
ted) black lines represent the deleted 17q21.31 region identified in the three individuals. Genes located within 
this region are depicted by black arrows. The H1 and H2 lineage LCR17q structures are depicted as rectangles 
with colors signifying shared homology and horizontal arrows showing relative orientation (LCR17qA, red; 
LCR17qB, green; LCR17qC, purple; LCR17qD, blue; LCR17qE, yellow). Note the different genomic orientation of 
H2, the absence of LCR17qC and presence of LCR17qE. Cen, centromeric; Tel, telomeric. 
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Figure 3.4.1: Identification of the 17q21.31 deletions. (a) Chromosome 17 plot of Case 1 obtained by whole-
genome oligonucleotide array (Agilent Human Genome CGH Microarray Kit 244A, Agilent Technologies). Chro-
mosome 17 is represented by 5,881 coding and noncoding human sequences (indicated by circles representing 
the log2-transformed and
 normalized test : reference intensity ratios [(Log2(T/R)], ordered from pter to qter
 for 
chromosome 17, in hg17 (NCBI build 35, May 2004). The arrow indicates the presence of a copy number loss at 
17q21.31. (b) FISH analysis on metaphase spreads of Case 7, using the BAC clones CTD-2324N3 (red) and RP11-
413P22 (green) which are both located within the deleted 17q21.31 region. The patient shows only one signal for 
CTD-2324N3 and RP11-413P22, indicating an aberrant chromosome 17 (arrow). (c) Detection of a heterozygous 
MAPT deletion in Case 4 using the microdeletion/ microduplication QMPSF assay. The electropherogram of the 
patient (in red) was superimposed on that of a normal female control (in blue) by adjusting to the same level 
the peaks obtained for the control amplicon. The Y-axis displays fluorescence intensity, and the X-axis indicates 
the genes tested. The heterozygous deletion is detected by a 50% reduction of the MAPT peak compared to the 
normal control (arrow). (d) MLPA results for Case 19 (triangles) and two healthy controls (rectangles), showing a 
deletion of all 13 probes in the CRHR1, IMP5, MAPT, and STH genes within the 17q21.31 genomic interval. 
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Figure 3.4.2: Ultra-high resolution oligonucleotide array analysis. Results of ultra-high resolution oligonucleo-
tide array analysis of the 17q21.31 microdeletion proximal breakpoint (mean probe density 1 probe/5.2 bp). (a) 
Data from a 50-kb region (chr17:41025000-41075000, hg17) in five unrelated 17q21.31 deletion patients and one 
control. In each deletion, the proximal breakpoint occured in a segmental duplication of length, 34.2 kb, identity 
98.7% (chr17:41026709-41060948). (b) Zoomed view showing a 5-kb region (chr17:41044500-41049500). All five 
patients have breakpoints which are indistinguishable, mapping to within an interval of <500 bp contained wit-
hin an L2 LINE motif. The highly variable dynamic response of certain probes in this region to report the deletion 
is likely a result of their different sequence properties.38 For each individual, deviations of probe log2-ratios from 
zero are depicted by gray/black bars, with those exceeding a threshold of 1.5 standard deviations from the mean 
probe ratio colored green and red to represent relative gains and losses, respectively. Tracks above each plot 
indicate segmental duplications (gray/yellow bars represent duplicons with 90–98%/98–99% sequence identity, 
respectively).
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Figure 3.4.4: Facial photographs of individuals with a 17q21.31 deletion. Facial photographs of Case 1, at age 10 
months; Case 2, at age 1 year; Case 3, at age 2 years; Case 4, at age 3 years; Case 5, at age 3 years; Case 6, at age 3 
years 5 months; Case 7, at age 3 years 8 months; Case 8, at age 3 years; Case 9, at age 5 years 8 months; Case 10 at 
age 5 years; Case 11, at age 3 years 9 months; Case 12, at age 8 years 6 months; Case 14, at age 13 years; Case 15, 
at age 14 years; Case 16, at 14 years; Case 18, at 16 years; Case 19, at 13 years; Case 20, at age 18 years; Case 21, at 
17 years and Case 22, at age 26 years. Informed consent was obtained for publication of photographs.
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Figure 3.4.5: Facial photographs at different ages. Facial photographs at different ages (<1, 1-4, 5-6, 7-12, and 
>12 years of age). Note that the facial characteristics of the patients change with age. With increasing age there 
is elongation of the face and broadening of the chin and also the “tubular” or “pear”-shape form of the nose 
becomes more pronounced. 
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